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The need for efficient and reproducible cell culture is necessary for the development 
of novel biological applications. Traditional two-dimensional cell culture is 
traditionally done using monolayer cultures on tissue culture plastic. Such surfaces 
however, do not mimic the natural three-dimensional (3D) in vivo setting in which 
cells reside, namely the complex 3D extracellular matrix (ECM), which is composed 
of multiple components, including proteins, polysaccharides and proteoglycans. 
Clearly monolayer cell culture is unable to recapitulate this environment and 
consequently results in altered gene expression profiles, changes to cell metabolism, 
signalling and morphology when compared to cells grown in 3D.   
 
Therefore, there is a need to develop 3D matrices that can support in vitro cell culture. 
Commonly used 3D matrices tend to be based on animal-derived products that are 
subject to batch-to-batch variations with variable compositions. With this in mind, 
using synthetically defined and tuneable synthetic materials for 3D cell culture would 
be advantageous offering a higher level of material control, and understanding of cell 
behaviour in response to the material. Hydrogels are highly hydrated networks that 
exhibit promising properties as ECM-mimics, and can be generated from various 
sources including polymers, proteins, and peptides or mixtures thereof and have been 
used for a range of cell-based applications. A limiting factor in the development of any 
biomaterial is the time-consuming nature of its discovery and optimisation. As such, a 
high-throughput approach where multiple materials of variable compositions are 
fabricated and screened in parallel offers a powerful approach to the discovery of 
optimal materials for a specific cell type or application. 
  
In this thesis I present the development and fabrication of a dynamic 3D hydrogel 
array, based on imine cross-linked polymers and peptides printed using a drop-on-
demand inkjet-printer. 250 different hydrogels were initially screened as novel cell 
matrices. Hits from the array screen were scaled-up for studies with endothelial cells 
and showed that these dynamic hydrogels had the ability to maintain the endothelial 
cell phenotype, promote proliferation and allow the generation of 3D cell clusters. 
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Furthermore, a mild and enzyme-free passaging system was developed that allowed 
for the degradation of the hydrogels and cell release by addition of Vitamin B6 
derivatives that compete for the imine-linkage. Thus a 3D cell culture matrix allowing 
for long-term culture and promoting the formation of 3D cell constructs with the 
capacity to passage in a mild and cell compatible manner was realised.  
 
As a second project a collaborative effort with Tokyo Medical and Dental University 
aimed to identify novel polymeric substrates that supported pancreatic cancer stem 
cells and recapitulated the niche environment. Using a polymer microarray of 382 
different polyacrylates/acrylamides and polyurethanes, substrates were identified that 
fulfilled these rules. Subsequently a novel peptide-containing polymer microarray was 
developed and screened with hits identified that upon scale-up were found to 






The ability to grow cells in the lab in a controllable, robust and scalable manner is 
necessary for researchers to be able to make new biomedical discoveries such as 
identifying new therapeutic targets. Traditionally, cells are grown on 2D plastic 
surfaces, which although being a straightforward way to grow cells, is a poor model 
of the actual cell environment within our bodies. Cells grow and reside in a complex 
3D environment, known as the extracellular matrix (ECM), which not only provides 
a support in which cells grow and multiply, but also provides signals and cues that 
alter cell behaviour. To be able to grow cells in the lab on substrates that can mimic 
this complex environment would therefore be greatly beneficial. Current materials 
that offer this to researchers have some serious drawbacks and are poorly defined. 
Therefore, reproducibility of cell behaviour with these materials is limited.  
 
To address these challenges, the work in this thesis sets out to create new synthetically 
defined and reproducible materials that can mimic the natural ECM environment. 
Additionally, the use of an inkjet printing system (similar to the ones used as home) 





Table of Contents  
Abstract ........................................................................................................................................... i 
Lay Summary ............................................................................................................................... iii 
Table of Contents ......................................................................................................................... iv 
Declaration of Authorship .......................................................................................................... vi 
Acknowledgements .................................................................................................................. viii 
Abbreviations ................................................................................................................................ x 
Chapter 1. Introduction ............................................................................................................... 1 
1.1 Recapitulating the ECM for Cell Culture Applications ................................................ 1 
1.2 Hydrogels for 3D cell culture ......................................................................................... 13 
1.3 High-throughput synthesis, screening and microarrays ........................................... 39 
Aims .............................................................................................................................................. 47 
Chapter 2: Development of a high-throughput screening platform of imine cross-linked 
hydrogels ..................................................................................................................................... 48 
2.1. Introduction ..................................................................................................................... 48 
2.2 Hydrogel Library Development .................................................................................... 50 
2.3 Hydrogel Array Fabrication ........................................................................................... 55 
2.4 Discussion ......................................................................................................................... 76 
2.5 Conclusions ....................................................................................................................... 80 
2.6 Materials and Methods .................................................................................................... 80 
Chapter 3: Identification and scale-up of an imine cross-linked hydrogel that supports 
endothelial cell maintenance and proliferation ...................................................................... 89 
3.1. Introduction ..................................................................................................................... 89 
3.2 Choosing hydrogels for scale-up ................................................................................... 90 
3.3 Scanning electron microscopy analysis ........................................................................ 92 
3.4 Optimising the hydrogel scale-up platform ................................................................. 94 
3.5 Investigating cell viability in HG15 ............................................................................... 96 
3.6 Protein expression analysis in HG15 ............................................................................. 97 
v 
 
3.7 Gene expression analysis in HG15 .............................................................................. 102 
3.8 Mechanical properties of HG15 ................................................................................... 104 
3.9 Discussion ....................................................................................................................... 105 
3.10 Conclusions ................................................................................................................... 109 
3.11 Materials and Methods ................................................................................................ 109 
Chapter 4: Development of an enzyme-free hydrogel passaging system for cells ......... 116 
4.1. Introduction ................................................................................................................... 116 
4.2 pH and cytotoxicity of Vitamin B6 and its derivatives ............................................ 118 
4.3 Developing a passaging protocol ................................................................................ 120 
4.4 3D cell culture and passaging in HG15 ....................................................................... 123 
4.5 Discussion ....................................................................................................................... 127 
4.6 Conclusions ..................................................................................................................... 129 
4.7 Materials and Methods .................................................................................................. 129 
Chapter 5: Identifying a defined substrate for niche mimicking and trapping of pancreatic 
cancer stem cells‡ ...................................................................................................................... 134 
5.1. Introduction ................................................................................................................... 134 
5.2 CSC niche mimicking polymer identification ............................................................ 138 
5.3 CSC trapping polymer identification .......................................................................... 145 
5.4 Screening of a peptide-containing polymer microarray .......................................... 147 
5.5 Discussion ....................................................................................................................... 156 
5.6 Conclusions ..................................................................................................................... 157 
5.7 Materials and Methods .................................................................................................. 158 
References .................................................................................................................................. 166 
Appendix ................................................................................................................................... 177 
A.1 Appendix for Chapter 2 ............................................................................................... 177 
A.2 Appendix for Chapter 3 ............................................................................................... 205 




Declaration of Authorship 
 
The research detailed within this thesis has been accumulated by the author in the 
duration of her PhD scholarship between the dates of October 2014 and September 
2018 under the supervision of Professor Mark Bradley, School of Chemistry, 
University of Edinburgh. 
 
The work, data and interpretation presented in here is that of the author unless there 
was a significant collaborative contribution, in which case it has been clearly 
recognised.  
 
This work has not been submitted for any other degrees of professional qualifications.  
 
Where published work has been consulted or quotations made, the source has been 
clearly cited.  
 
The work detailed in this thesis has been presented at the following conferences and 
meetings: 
• Bioinspired Materials GRC and GRS, Les Diablerets, 2018 
• Biomaterials International, Fukuoka, 2017 
• Stem Cell Research in Europe: Status and Prospective, Amsterdam, 2017  
• RSC Chemical Biology and Bio-Organic Group Postgraduate Symposium, 
Glasgow, 2017  
• Joseph Black Conference, Edinburgh, 2016 and 2017  
• HumEn consortia meeting, Max Planck Institute Bad Nauheim, 2016 
• Bioprinting and 3D Printing in the Life Sciences, Cambridge, 2016  
• Lab on a chip and microfluidics, Munich, 2016  
• Warwick Polymer Conference, University of Warwick, 2016 
• RSC Innovations in Encapsulation, Edinburgh, 2016 
• Hydra XI Stem Cell School, Hydra, 2015 
 


















First and foremost, I must thank Professor Mark Bradley for taking me on as a PhD 
student and for providing me with such an exciting project. Thank you for all your 
support and guidance for the past four years, and for the many opportunities you 
have given me regarding collaborations, visits to other labs and supporting my 
attendance at international conferences.  
 
Dr Annamaria Lilienkampf – Nanna – I am forever grateful for everything you have 
done for me during my PhD and the excellent support you have provided with 
regards to my research, career and everything else. I would also like to thank all other 
Bradley group members, past and present, for their support and help during my time 
in the group.  
 
I want to extend a special thanks to Dr Matthew Owens, whom I am sure knows that 
I consider myself a very lucky gal to have him as a friend and colleague. The past four 
years would have been significantly less fun and rewarding without you as my 
intelligent and hilarious partner in crime. 
 
Two former Bradley group members, Dr Jessica Clavadetscher and Dr Andrea 
Venturato have also been hugely important for me during my PhD and I want to 
thank them both for their help and friendship. Jess, it was a pleasure to share a fume 
hood with you and I sure learnt a lot from your professionalism and work ethic in the 
lab. Andrea, our HumEn trips and discussions about polymers, collaborations and 
more made me both think, laugh and develop as a researcher. I also want to 
acknowledge a newer Bradley group member, Sonia Rehman, who is stronger than 
most, and funnier too. You say I am your spirit animal, but really you are mine.  
 
Also thanks to the student’s that I have been fortunate enough to supervise during 
my PhD, Sarah, Ross, Zuzanna and Charlotte, who have helped with various aspects 




I must also thank my collaborators at the Tokyo Medical and Dental University for 
working with me on an exciting project and making the process of working across 
continents effortless. I particularly want to thank Dr Yoshitaka Murota, it was a 
pleasure to work with you, both from Tokyo, but particularly during your visit to the 
Bradley group.  
 
The various support staff that I have worked with during the years – Steve at the SEM 
facility, Melanie, Lyndsey and Mike at the histology and immunohistochemistry 
service and Elena who helped me with the rheology measurements – were all 
immensely helpful and supportive.   
 
On a more personal note, I must thank my parents, Cristina Glad and Olle Schmidt, 
and brother, Fredrik Schmidt, who always believed in me and was there during both 
the happy and sad times. Particularly thanks to my mother, I hope you know that you 
are my role model and the one who inspired me to become a scientist in the first place. 
I also want to thank my lovely girls, Alex Amon and Anna Brand. Without our chats, 
laughs, tears, brunches and just generally excellent times together I am not sure where 
I would be today.  
 
Finally, thanks to David Edwards, the person who makes every day worthwhile. You 
helped me push through to the end and your actions remind me every day that what 
we have together is very special. The love we share is just amazing and I cannot wait 










Ahx 6-aminohexanoic acid 
AIBN Azobisisobutyronitrile 
ALP Alkaline phosphatase 
APTES (3-aminopropyl)triethoxysilane 
BF Bright-field 
BSA Bovine serum albumin 
CD31 Cluster of differentiation 31 
cDNA Complimentary deoxyribonucleic acid 








DMEM Dulbecco’s Modified Eagle Medium 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
ECM Extracellular matrix 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EGF Epidermal growth factor 
ELP Elastin-like polypeptide/protein 
ESA Epithelial-specific antigen 
FACIT Fibril associated collagens with interrupted triple helices 
FACS Fluorescence assisted cell sorting  
FAK Focal adhesion kinases 
FBS Foetal bovine serum 




FGF Fibroblast growth factor 
FITC Fluorescein isothiocyanate 
Fmoc Fluorenylmethoxycarbonyl 
FXIIIa Transglutaminase factor XIIIa 
GAG Glycosaminoglycan 
GF Growth factor 
GPC Gel permeation chromatography 
GSPG Chondroitin sulphate proteoglycan 
H&E Haemotoxylin and Eosin  
HA Hyaluronic acid 
HEK293 Human embryonic kidney cells 293 
hESC Human embryonic stem cell 
HRMS High resolution mass spectrometry 
HSPG Heparan sulphate proteoglycan 
HTSS High-throughput synthesis and screening 
HUVEC Human umbilical vein endothelial cell 
IHC Immunohistological 
iPSC Induced pluripotent stem cells 
KOSR Knock-out serum replacement 
MAPK Mitogen-activated protein kinase 
mESC Mouse embryonic stem cells 
MMP Matrix metalloproteases 
mRNA Messenger ribonucleic acid 
MSC Mesenchymal stem cell 
NHS N-hydroxysuccinimide 
NMP N-Methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance 
ODC Ornithine decarboxylase 
PCL Poly(ε-caprolactone) 
PDI Polydispersity index 
PEG Poly(ethylene glycol) 
PEGDA Poly(ethylene glycol) diacrylate 




PFOA Perfluorooctanoic acid 
PHEMA poly(2-hydroxyethyl methacrylate) 
pHUVEC Primary human umbilical vein endothelial cell 
PI Propidium iodide 
PLA Poly(lactic acid) 
PLGA Poly(lactic-co-glycolic acid)  
PLP Pyridoxal 5’-phosphate 
PMMA Poly(methyl methacrylate) 
PNIPAAm Poly(N-isopropylacrylamide) 
PS Polystyrene 
PVA  Poly(vinyl alcohol) 
PyrAm Pyridoxamine dihydrochloride 
PyrHCl Pyridoxal hydrochloride 
qPCR Quantitative polymerase chain reaction 
RGD Arginine-Glycine-Aspartic acid 
RNA Ribonucleic acid  
RP-HPLC Reverse phase high-performance liquid chromatography 
SD Standard deviation 
s.e.m Standard error of mean 
SEM Scanning electron microscopy 
SPAAC Strain-promoted azide-alkyne cycloaddition 
SPPS Solid phase peptide synthesis 
TCPS Tissue culture plastic polystyrene 
TFA Trifluoroacetic acid 
TGF-b Transforming growth factor b 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
VEGF Vascular endothelial growth factor 
vWf von Willebrand factor 




Chapter 1. Introduction 
 
1.1 Recapitulating the ECM for Cell Culture 
Applications 
 
1.1.1 From tissue culture to in vitro virus culture 
Before cell culture was developed as we know it today, scientists developed methods 
for culturing pieces of tissue in vitro. The field of tissue culture developed from the 
early 1900’s onwards, notably by Harrison who developed the first tissue culture 
technique by growing frog nerve fibres embedded in plasma on a coverslip, which 
then was inverted to let the plasma form a hanging drop in which the tissue was 
maintained.1 Methods similar to this hanging drop technique are used nowadays in 
spheroid and organoid cultures.2  
 
Thereafter Carrell and Burrows demonstrated the growth of tissue from chickens and 
various mammals, by culturing them in plasma and transferring them to new flasks 
following sufficient growth (known as passaging).3,4 Claims were made that cells 
from a chick embryo heart were passaged over 100 times and kept alive over the span 
of 33 years, although today it is questioned whether this actually was the original 
culture or a contaminated version.5,6 In parallel with the development of these 
techniques, Carrell also emphasised the necessity of sterile techniques and work 
environments when working with biological samples, and was a key player in 
developing the composition of growth media used for cell culture. Notably, he 
introduced the use of serum, solving the issue of plasma clotting.6 Another key player 
in these early days was the aviator Lindbergh, who together with Carrell in the 1920’s 
developed the Corning Pyrex® tissue culture flasks that due to their heat resistance 
could be sterilised by autoclaving.6,7 
 
Developments in virus growth in vitro was a key driving force for cell culture. It was 
shown that viruses could be replicated in vitro by adding them to chick embryonic 
tissue and incubating for 24 h with virus activity maintained after 2 weeks storage at 
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– 20 °C. Viruses including polio, influenza and chickenpox were cultured using this 
technique, thus beginning in vitro culture of viruses and vaccination strategies.6,8 The 
plaque assay was subsequently developed, allowing for virus quantification.9 
Moreover, during these early days, several components ubiquitous to today’s cell 
culture were discovered, including the use of antibiotics and fungicides to cell culture 
medium to prevent contamination, and the use of the protease trypsin to dissociate 
tissues and allow single cell isolation.6  
 
1.1.2 Establishment of continuous mammalian cell lines  
Even with the development of techniques for tissue culture, the ability to culture 
human cells in vitro was unsuccessful, despite many attempts. It was not until 1951 
that the first human cell line was established with the isolation of cells from a cervical 
cancer tumour.10 The tumour cells came from a woman named Henrietta Lacks, hence 
the naming of the cell line as HeL. The culture was established in the lab of professor 
Gay, where they identified cells that grew very rapidly, with seemingly endless 
proliferation. Gay sent cell samples to scientists around the world and HeLa cells 
quickly spread and became the staple cell line for cell culture. The success of HeLa 
was not just in their rapid and aggressive growth, which allowed studies for cell 
reproduction and division, but also importantly their ability to support the growth of 
viruses for vaccine production that previously had not been possible to culture in 
vitro.6   
 
With the identification of HeLa, several other cells were identified that could grow 
independently in vitro, causing a rapid expansion of the cell culture field. Among 
these was the development of the mouse fibroblast cell line L292,11 and of the CHO 
cell line isolated from Chinese hamsters.12 CHO cells have been particularly useful to 
study genetics, due to their near normal chromosome set.6  
 
In the 1970’s Milstein and Köhler established hybrid cell cultures and the production 
of monoclonal antibodies.13 By mixing cultures of myeloma cells (fast growing 
tumour cells) and antibody-producing B-cells isolated from spleens, hybrids (termed 
hybridomas) were formed that grew as rapidly as the myeloma cells, but also 
produced antibodies like the B-cells. In the 1980’s further discoveries into growth 
factors present in serum that could support the culture of lymphocytes and isolation 
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of stem cells paved the way for the establishment of immune cell culture and stem 
cell culture.6 This brings us to cell culture as we know it today, where despite the 
constant introduction of new discoveries and establishment of more complex cell 
models, many of the techniques used in the lab today still resemble those established 
more than 50 years ago.  
 
Despite the numerous developments made with traditional cell culture methods, 
there are several limitations. Firstly, culturing cells on hard plastic or glass surfaces 
as a monolayer, although facile, is very different from the natural in vivo environment 
where cells reside in and are part of a complex and dynamic 3D environment called 
the ECM.14–16 The function of the ECM is not only to provide a structural support for 
the cells residing within it, but to organise cells into tissue-specific shapes and provide 
them with spatially and temporally controlled chemical and mechanical signals. In 
this environment, a dynamic interplay of cell-cell and cell-matrix interactions as well 
as the secretion of soluble signals e.g. growth factors and cytokines and metabolic 
signals, e.g. hormones and ions, direct cell behaviour such as proliferation, 
differentiation, adhesion, spreading, and survival while maintaining tissue 
homeostasis (the maintenance of tissue structure and function).14–19 Cell behaviour 
and signalling affects the composition of the ECM, which is produced by cells 
themselves, with its formation and degradation dictated by the surrounding and 
infiltrating cells.20 This reciprocal relationship between the ECM and cells result in a 
dynamic environment where spatial and temporal control over its composition and 
remodelling directs tissue formation and function. 
 
Culturing cells as a monolayer means that important aspects of the natural 
environment are lost, including 3D cell-cell and cell-matrix interactions, mechanical 
cues from the ECM to cells and vice versa, as well as the interplay between different 
cell types within a tissue.15 The lack of these aspects leads to dramatically altered cell 
behaviour with 2D culture of cells leading to cell flattening, rearrangement of the 
actin cytoskeleton and a flattened nucleus. It also leads to numerous changes in gene 
expression and subsequent protein expression levels that alter cell behaviour and give 
rise to a different phenotypes.21,22 Thus conclusions from in vitro experiments do not 
reflect the real in vivo environment which they are supposed to model. As such cells 
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in a monolayer culture respond very differently to drugs compared to those in a 3D 
environment, representing a great challenge for preclinical drug discovery.22 
 
Thus, recent years have seen an increased attention paid to the development and use 
of 3D cell culture models, wherein crucial cell-cell and cell-matrix interactions are 
maintained or at the very least mimicked based on their natural in vivo setting.15,16 The 
use of 3D cell culture and matrices promises to bridge the gap between 2D cell culture 
and animal models,16 but before detailing the usefulness and options for 3D cell 
culture it is important to understand the composition and attributes of the natural 
ECM. 
 
1.1.3 The composition and function of the ECM 
 
i) Components of the ECM 
Two main types of macromolecules, in combination with water, make up the ECM: 
fibrous proteins such as collagen, elastin, fibronectin and laminin and glycoproteins 
such as proteoglycans and hyaluronic acid.17,23 The major structural elements of the 
ECM are collagen, proteoglycans and hyaluronic acid that provide cells with  a 
structural framework, while proteins like laminin and fibronectin aid in connecting 




Collagen is the most abundant protein of the ECM, with over 20 different types found 
in humans. It is composed of trimeric polypeptides (α-chains) assembled into helices, 
with the repeating Gly-X-Y motif, where X and Y can be any amino acid, but 
frequently are proline or hydroxyproline as they aid in helical stability.23 The trimeric 
assembly of the α-chains results in different types of collagen with one of the most 
common being fibrillary collagen or Collagen type I, whose assembly consist of four 
main steps (Figure 1.1). Propeptides are first intracellularly synthesised and 
assembled into triple helices initiated by the C-terminal domain, followed by removal 
of N- and C-termin, resulting in collagen formation.23 The enzyme lysyl oxidase 
subsequently catalyses oxidative deamination of lysine residues to form inter- and 
intramolecular cross-links between the chains. Fibrillar collagen is found in multiple 
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Figure 1.1: Structure and folding of collagen e.g. Type I. Collagen fibrils are composed of three 
α chains, characterised by Gly-X-Y repeats (where X and Y are frequently proline or 
hydroxyproline) flanked by N- and C-terminal propeptides, and undergo folding into 
procollagen triple helices. The so-called called N- and C-terminal propeptides are 
enzymatically cleaved to form mature collagen that self-assembles into larger fibrils composed 
of multiple collagen molecules.23 
 
Another type of collagen are fibril associated collagens, which has interrupted triple 
helices (FACIT) where regions intersperse the collagen triple helix (due to Gly-X-Y 
interruption), leading to kinks in the final structure that straighten upon strain. 
FACITs integrate into fibrillary collagen and display altered surface properties, which 
enable binding of other ECM components such as proteoglycans or cell surface 
receptors.23 
 
Elastin and elastic fibres 
Elastin proteins form the core of elastic fibres, surrounded by a sheath of 
microfibrillar glycoproteins such as fibrillin and fibrulin.25 Elastic fibres line blood 
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vessels and are a major component of the skin and connective tissue, where it 
provides extensibility to allow for e.g. the stretching of skin. Elastic fibres are only 
assembled during development and any redevelopment, degradation or damage 
during adulthood is irreversible and the loss of elastic fibres is partly responsible for 
wrinkling of skin or artery stiffening.26  
 
Laminin 
Laminins consist of three polypeptide chains, α, β and γ that combine to form triple-
helical coiled coils with Y-shaped structures.27 Several different isoforms of α, β and 
γ-chains have been identified, and the naming of laminins is according to the 
combined chains and their composition, e.g. α1β1γ1 is referred to as Laminin 111. 
Laminins are mainly found in the basal lamina, a component of the basement 
membrane, but are also an intermediary between cells and other ECM-components 
since it binds to cell surface integrins.23 
 
Fibronectin 
Fibronectin forms fibrillary structures that surround cells and act as a main 
connecting protein between cells and other ECM components, e.g. collagen, thus 
acting to regulate cell adhesion and migration. Three modules (Type I, II and III) make 
up fibronectin, each containing specific binding motifs for other ECM components 
and cell surface receptors. Di-sulphide bonds between the modules results in dimer 
formation.28   
 
Proteoglycans and glycosaminoglycans  
Proteoglycans are glycoproteins are ECM components attached to a protein core that 
also are attached to one or more glycosaminoglycans (GAGs), which are negatively 
charged polysaccharides compromised of repeating disaccharide units.23 Common 
ECM proteoglycans include heparan sulphate proteoglycan (HSPG) and chondroitin 
sulphate proteoglycan (GSPG). The GAG heparan sulphate is composed of highly 
sulphated disaccharide repeats of N-acetylated or N-sulphated glucosamine (N-
acetylglucosamine or N-sulphoglucosamine) and uronic acids (glucuronic acid or 
iduronic acid) (Figure 1.2A), and HSPGs are a major component of the basement 
membrane.23,29 Its negative charge enables binding to other ECM components such as 
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Figure 1.2: Structures of common GAGs found in the ECM. A. Heparan sulphate. B. 
Chondroitin sulphate. C. Hyaluronic acid.  
 
Chondroitin sulphate is composed of sulphated disaccharide repeats of glucuronic 
acid and N-acetylgalactosamine (Figure 1.2B) and GSPGs are mainly found in neural 
and cartilage tissue.23 A family of chondroitin sulphates, the lecticans, contain binding 
sites for hyaluronic acid (HA), a negatively charged GAG composed of dimers of 
glucoronate and N-acetyl glucosamine (Figure 1.2C). Since HA is not attached to a 
protein core it is not considered a proteoglycan, but it is a major component of the 
ECM and is capable of retaining large amounts of water, making it a major component 
of soft tissues e.g. neuronal and ocular.23,30 HA is known to bind several cell surface 
receptors including CD44 and CD168.22 
 
ii) Organisation and mechanical properties of the ECM 
It is the specific organisation and combinations of the ECM components that result in 
the varied environments and functions observed in tissues. Broadly speaking, the 
ECM can be divided in two parts; the interstitial matrix rich in collagen I and 
fibronectin and the basal lamina, rich in proteoglycans, laminin and collagen IV.31 As 
already mentioned, collagen I is abundant in tissues capable of withstanding high 
mechanical loads, such as the tendon which is 65-80 % collagen I. The fibrillar collagen 
fibres align to form bundles that together with tendon fibroblast cells connect bone to 
muscle. The fibroblasts also produce a matrix rich in proteoglycans that surround the 





The fibrillar structure is almost entirely absent in the basal lamina, which is one of the 
components that makes up the so-called “basement membrane”, a thin layer of ECM 
proteins that separates endothelial and epithelial cells from adjacent connective 
tissues (Figure 1.3). The basal lamina is connected to the epithelial cells and is rich in 
collagen IV and VII and laminin that is connected to HSPGs and the glycoprotein 
entactin.23 Laminin binds to the epithelial cells through integrins and entactin, 
forming a sheet of ECM that is further stabilised by collagen IV. It is this direct 
interaction between cells and laminin that connects the ECM with intracellular 
signalling pathways, which helps drive cell behaviour such as the establishment of 
polarity of the epithelial cell.23 The other component, the reticular lamina, is rich in 
collagen I, III and V and connected to the connective cells layer. 
 
 
Figure 1.3: Structure of the basement membrane, which forms a sheet of ECM connecting 
epithelial to endothelial cells. The basement membrane is composed of two parts, the basal 
lamina, mainly composed of laminin, collagen IV and VII connected to proteoglycans and 
glycoproteins and the reticular lamina, mainly composed of collagen I, II and II as well as 
proteoglycans.23  
 
As the ECM composition changes so does its mechanical properties, and a common 
way of measuring these properties is through the elastic modulus (the stress applied 
to the material divided by the amount of strain the material is subjected to).20 The 
elastic moduli (or stiffness) of the majority of human tissues range from 1-100 kPa, 
although tissue stiffness ranging from 167 Pa in mammary tissue and 54 GPa in 
cortical bone have been reported.17,33 Mechanical properties are closely linked to ECM 
composition, for example the high collagen content of tendons results in a high elastic 
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modulus (1.2 GPa),34 while the ECM of the inner eye is mainly composed of 
hyaluronic acid, which gives a much lower elastic modulus.30  
 
iii) ECM-cell interactions and mechanotransduction 
ECM-cell interactions are predominantly mediated by cell surface membrane 
receptors, and an important family of these are the integrins with several examples 
of ECM proteins binding to them already mentioned.35 One of the most commonly 
used integrin-binding motifs added to ECM-mimicking materials to improve cell-
binding capacity is the tripeptide Arginine-Glycine-Aspartic acid (RGD), which is 
found in many ECM-proteins, including fibronectin, and vitronectin.36 
 
Integrins are heterodimeric transmembrane proteins that bind to specific amino acid 
sequences found within some ECM proteins e.g. RGD, while internally being 
connected to intracellular signalling molecules e.g. the focal adhesion kinase (FAK). 
These are in turn linked to the actomyosin cytoskeleton and to intracellular signalling 
pathways e.g. the Rho and mitogen–activated protein kinase (MAPK) through linker 
proteins such as vinculin and talin (Figure 1.4).17,26,35 Through these links the 
mechanical properties of the ECM are able to generate biochemical signals 









Figure 1.4: Representation of mechanotransduction process converting a mechanical signal 
from the ECM to a biochemical signal within a cell. Cells are connected to the ECM via 
integrins that intracellularly binds to linker proteins (e.g. vinculin and talin) connected to the 
actin cytoskeleton and intracellular signalling molecules that activates signalling pathways 
(e.g. Rho and MAPK). These in turn relay the original signal from the ECM to the nucleus and 
can result in a change in gene expression and thereby cell behaviour.26 
 
An example of mechanotransduction is how ECM stiffness regulates the cell cycle in 
mammalian epithelial cells and vascular smooth muscles.37 When these cells were 
cultured on fibronectin-coated acrylamide gels with higher stiffness (2.4 kPa), 
formation of ECM-integrin connections caused the phosphorylation (activation) of 
FAK, which in turn activated the extracellular signalling-regulated kinase pathway, 
leading to the production of cyclin D1, a cell cycle regulator that promotes the 
transition from the G1 to the S-phase of the cell cycle. When cultured on lower stiffness 
surfaces however (2 kPa), low levels of cyclin D1 were observed, resulting in cell cycle 
arrest. This has implications for disease progression such as breast cancer where 
overexpression of cyclin D1 is observed, suggesting that tissue stiffening, a hallmark 
of the disease, is partly responsible for oncogenic events such as increased cell 
proliferation.37,38  
 
iv) Remodelling of the ECM 
The ECM is constantly degraded and remodelled by its surrounding cells to control 
tissue homeostasis.26,31 Degradation of ECM components are mainly carried out by 
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proteases, with three main families; matrix metalloproteinases (MMPs), meprins and 
adamalysins. MMPs are the main proteases for ECM degradation with 20 different 
types having been identified in humans, each with specific ECM targets that 
collectively are able to cleave all ECM proteins.31 Meprins are dimeric complexes with 
α and β units known to cleave collagen IV and fibronectin, as well as activating 
collagen by cleaving the procollagen chains, or activation of MMPs, thus regulating 
ECM remodelling.31 Adamalysins are so-called “sheddases”, meaning they cleave 
domains from transmembranes that connect them to the cell surface, releasing the 
extracellular part of the protein.39  
 
1.1.4 Current approaches to 3D cell culture   
 
The modulus of tissue culture plastic polystyrene (TCPS) is about 3 GPa, higher than 
the stiffness of many human tissues and organs.17 Using  materials and methods that 
allow for 3D cell culture, which try to recapitulate the natural ECM environment by 
allowing for cell-cell and cell-matrix interactions, but which simultaneously are cheap 
and easy to manufacture, would be highly advantageous.16  
 
One of the first studies that looked at the benefits of 3D cell culture was published in 
1975 and used floating collagen gels to culture rat hepatocytes.40 Increased cell 
viability (> 20 days) was observed for the 3D culture compared to monolayer cultures 
on collagen-coated plates (6 days viability), with the formation of 3D cell constructs 
observed such as bile canaliculi. A landmark study in 1997 showed that T4-2 cells (a 
cell model for breast cancer) grown in 3D (in Matrigel) or in 2D (on collagen-coated 
surfaces) coupled with blocking the overexpressed cell surface β1-integrin resulted in 
different cell phenotypes.41 Integrin blocking in 3D reversed the cells’ malignant 
phenotype, something that was not observed for 2D cultures with the phenotype 
reversal coupled with cyclin D1 downregulation and cell cycle arrest.  
 
Following these findings, the area of 3D cell culture has grown rapidly, but although 
promising to be better cell models, they also present challenges. The optical analysis 
of 3D cell culture models is more complex, requiring imaging through the depth of 
the 3D structure, which requires confocal microscopy or multi-photon microscopy.16 
Materials need to be optically transparent to allow for imaging in the 3D plane, 
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although sectioning and 2D reconstruction is possible but time consuming. Moreover, 
passaging will be more complex and the ability to do so will depend on the chemical 
composition of the material, and its inherent degradability.  
 
Several methods have been developed for 3D cell culture, and broadly speaking these 
can be divided into scaffold-free or scaffold-based methods. Some of the most 
commonly used methods of each are detailed below.  
 
i) Scaffold-free methods for 3D cell culture  
For scaffold-free methods, the propensity for cells to form 3D clusters, also known as 
spheroids, under certain conditions is utilised. Two of the most commonly used 
techniques to achieve this are the hanging drop method and low-adherence 
plates.2,15,21 In the hanging drop method cells are suspended in a small drop of media 
that is placed on a flat surface and then inverted, resulting in a so-called “hanging 
drop”, and because of gravitational forces the cells are promoted to form clusters. 
Coating the surface of the plates with cell-repellent solutions that promotes cell 
cluster formation is also widely used.  
 
In a recent study, spheroids of several different human tumour cell lines (breast, 
prostate, head and neck and colorectal) were generated using a polydimethylsiloxane 
substrate fabricated into hanging drop arrays.42 It was demonstrated that these 
spheroids were easily manufactured and could be used to better mimic the tumour 
microenvironment for drug screening, cell co-cultures and tumour invasion assays. 
 
A drawback of these methods, however, is the difficulty in generating more complex 
3D cell models, since the larger the spheroid, the larger its necrotic core, because of 
lack of nutrient and oxygen supply.15 To create larger and more complex 3D cell 
models some form of supporting material, or scaffold, is needed. 
 
ii) Scaffold-based methods for 3D cell culture  
In scaffold-based 3D cell culture a material is used to support and confine the cells. 
Several different materials have been used for this, including polymers, proteins, 
peptides, ceramics, metals and glass.14,15 Benefits include their tuneable properties 
and their capacity to incorporate specific cell adhesion groups (e.g. integrin binding 
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sequences).15 Despite the usefulness of the materials mentioned above, another 
scaffold-based material has emerged as one of the most promising for 3D cell culture, 
namely hydrogels.22 Hydrogels are highly hydrated polymeric networks that can be 
designed to have similar mechanical properties to the ECM. Most of the work in this 
thesis relates to the development and use of hydrogels, and therefore the following 
section details the types of hydrogels available, their design and examples of use their 
use in 3D cell culture.  
 
1.2 Hydrogels for 3D cell culture  
 
Hydrogels are networks with high water content that can be good ECM-mimics due 
to their soft mechanics and capacity for diffusion and transport of nutrients and 
oxygen.18,20,43,44 The natural ECM can be considered a hydrogel and many components 
of it are routinely used as 3D cell culture matrices due to their usually cell-compatible 
formation and tuneable biochemical and biophysical properties such as chemical 
composition, adhesive ligand and growth factor presentation and substrate stiffness 
or topography.19,20,33 Several aspects of hydrogel design must be considered in order 
to create materials that mimic the spatial and temporal control of the ECM and aspects 
discussed in further detail in this section include (Figure 1.5):  
 
- The material used for hydrogel formation, i.e. natural or synthetic source. 
- The hydrogel cross-linking method, which will impart specific properties to 
the hydrogel and the 3D cell culture. 
- The hydrogel functionalisation with cell-binding ligands or growth factors to 
induce desired cell behaviour. 
- The control of concentration and composition of the hydrogel components, 
which allows their mechanical properties to be tuned. 
- The tuning of hydrogel topography at the nano- and micro-scale to mimic the 
ECM environment of specific organs and tissues.  





In addition, by tailoring their chemical composition, responsive hydrogels can be 
generated, for example in response to temperature,45 pH46 or light.47  Other factors to 
tune apart from the hydrogel material, is the introduction of gradients e.g. of growth 
factors or material stiffness and the introduction of vascularisation within the 
hydrogel to provide oxygenation.48–50 In vivo, all cells are <100 µm from a blood vessel 
with cells further away turning necrotic due to lack of oxygen supply and larger 
hydrogel structures must be able to recapitulate this.17  
 
Figure 1.5: Hydrogel properties to consider that recapitulates the dynamic and complex in 
vivo ECM environment. These properties range from material origin consideration and cross-
linking methods, the biofunctionalisation of hydrogels with biochemical motifs and tuning 
the hydrogel biomechanical properties, surface topography and degradation characteristics.  
 
1.2.1 Natural hydrogels for 3D cell culture   
Natural materials used for hydrogel formation include ECM-derived proteins such 
as collagen, laminin, fibrin, and fibronectin or proteoglycans like HA and chondroitin 
sulphate.33,51 Other non-ECM derived natural materials are also used, for example the 





Figure 1.6: Structure of non-ECM polysaccharides used for hydrogel formation. A. Chitosan. 
B. Alginate. 
 
Natural-based hydrogels are advantageous due to their inherent biological activity, 
but several disadvantages are associated with their use such as their usually 
exogenous source, imparting batch-to-batch variability and introducing poor 
reproducibility of experimental results.21,51,52 Furthermore, their poorly defined 
structure and limited ability for precise modification makes the tuning of 
biomechanical and biochemical properties difficult.21,52,53 Nonetheless, the use of 
natural hydrogels for 3D cell culture is common and a good starting point. 
 
i) Collagen  
Collagen type I (Figure 1.1) has commonly been used for hydrogel formation, 
although Type II and III have also been reported. The rat-tail tendon, bovine skin and 
human placenta are common sources of collagen type I, usually sold as a low pH 
solutions that require low temperature storage to prevent spontaneous gelling.54 The 
need for low temperatures during preparation is one of the main disadvantages of 
collagen hydrogels, along with its relatively poor mechanical stability. Collagen type 
I gels were used to create a 3D model of breast cancer model using MDA-MB-231 cells 
that compared to monolayer culture were able to recapitulate the tumour necrotic 
core by upregulation of hypoxia-inducible factor (HIF)-1α as well as increase of 
vascular endothelial growth factor (VEGF)-A expression.55  
 
Methacrylate-functionalised monomeric collagen type I were developed in order to 
increase the gel mechanical properties with cross-linking carried out using visible 
light (50 mW/cm2, 30-60 min) and in the presence of rat aortic smooth muscle cells.56 
High cell viability (> 70 %) was observed and the elastic modulus increased from 13.5 
kPa of unmodified collagen type I to 162 kPa of the cross-linked hydrogel that also 
showed improved temperature stability (denatured at 45 °C compared to 39 °C of 




ii) Hyaluronic acid  
HA (Figure 1.2C) used for 3D hydrogel formation is usually isolated from bacteria 
cultures, and is beneficial due to its ease of functionalisation of its hydroxyl and 
carboxyl groups to generate cross-linkable groups, e.g. thiols, aldehydes and 
(meth)acrylate.57 Commercially available HyStem™ hydrogels (BioTime Inc.) are 
composed of thiol-modified HA and cross linker PEG-diacrylate (PEGDA) with other 
thiol-modified components added e.g. thiol-gelatin and thiol-heparin. Thiol-HA, 
thiol-gelatin and PEGDA were used together to form a multi-layered co-culture of 
prostate cancer (C2-4B) and bone marrow stromal (HS27a) cells (Figure 1.7A).58 C2-
4B’s cultured in the HyStem hydrogel containing HA and PEGDA assembled into 3D 
organoids, while the HS27a cells grew on a layer of gel composed of HA, gelatin and 
PEGDA with the system utilised for high throughput (384-well plate) drug screening. 
 
Periodate oxidation is a straightforward way to produce aldehyde functionalised HA 
that can be cross-linked with amines, hydroxylamines or hydrazides to form imine, 
oxime and hydrazine cross-linked hydrogels respectively (Figure 1.7B).57 Aldehyde-
modified HA was cross-linked with chitosan to produce imine cross-linked hydrogels 
that supported the encapsulation and growth of L929 fibroblasts over 48 h and 
demonstrated abdominal tissue regeneration in a rat model, facilitated by the 
deposition of ECM matrix as well as initiation of vascularisation.59 
 
Clinical applications of HA include wound healing and dermis regeneration as it 
directs fibroblast behaviour, the cells responsible for collagen deposition during 
wound healing. The application of long HA chains to these areas have been shown to 
increase the order of collagen deposition, thus contributing to control over the wound 
healing process. HA also improves keratinocyte proliferation and can be used to 
improve their proliferation motility in synergy with other ECM components e.g. 






Figure 1.7: Hydrogels formed from hyaluronic acid (HA). A. Thiol-modified HA and gelatin 
are cross-linked by PEG-diacrylate (PEGDA) to form HyStem™ hydrogels. A co-culture was 
created where C2-4B cancer prostate cancer cells were encapsulated in a HA/Gelatin/PEGDA 
hydrogel with an overlaying layer of HA/PEGDA hydrogel on which bone marrow stromal 
cells Hs27a were seeded.58 B. HA-chitosan hydrogel cross-linked through imine bonds. 
Aldehyde-modified HA was formed by oxidation of HA with NaIO4, and reacted with amines 





One of the most commonly used matrices for 3D cell culture is a mouse-derived 
gelatinous protein mixture sold under different names such as Matrigel® (BD 
Biosciences) and GelTrex™ (ThermoFisher). This mixture is secreted by Engelbreth-
Holm-Swarm mouse sarcoma cells, making up a basement membrane extract mainly 
composed of collagen type IV, laminin, entactin and various growth factors including 
FGF, EGF and transforming growth factor-β.21 The stiffness can be tuned with 
concentration, where gels ranging from 3 to 19.1 mg/mL result in elastic moduli 
increase of 9.1 ± 0.3 Pa to 288.2 ± 9 Pa.61  
 
The tumour-derived origin, poorly defined composition and the requirement of low 
temperature handling to avoid spontaneous gelation are some of the major 
drawbacks of these gels,22 but they are popular materials for 3D cell culture. The 
generation of organoids have frequently been reported by growing cells in basement 
membrane extract matrices with one of the earliest examples being the formation of 
intestinal organoids from Lgr5+ stem cells that formed crypts without the need of 
mesenchymal niche-cells to induce this formation.62  
 
Another common use of basement membrane matrices are for stem cell maintenance 
and differentiation where the encapsulation of human induced pluripotent stem cells 
(iPSCs) resulted in differentiation to ureteric-bud-committed renal progenitor-like 
cells to create a cell model of kidney disease.63 The directed differentiation was 
achieved over a 4-day culture and the subsequent co-culture of the differentiated cells 
with mouse embryonic kidney cells resulted in the formation of complex 3D chimeric 
structures, useful for studying kidney development and ureteric bud morphogenesis.  
 
1.2.2 Synthetic and hybrid hydrogels for 3D cell culture  
Using synthetic materials to produce hydrogels enables the engineering of 
structurally defined materials, unlike their natural counterparts, and commonly used 
building blocks include polymers and peptides.21,53 Poly(ethylene glycol) (PEG), 
poly(N-isopropylacrylamide) (PNIPAAm), poly(methylmethacrylate) (PMMA), 
poly(vinyl alcohol) (PVA), poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) 
(PLGA) are frequently used polymers for hydrogel formation (Figure 1.8).51 
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Combinations of acrylate/acrylamide/vinyl-based monomers have also been used to 
form a range of different polymers that can be cross-linked into hydrogels.45  
 
 
Figure 1.8: Structures of polymers used to form scaffolds for cell culture-based applications. 
A. Poly(ethylene glycol) (PEG) B. Poly(N-isopropylacrylamide) (PNIPAAm) C. 
Poly(methylmethacrylate) (PMMA) D. Poly(vinyl alcohol) (PVA) E. Poly(lactic acid) (PLA) F. 
poly(lactic-co-glycolic acid) (PLGA). 
 
The defined chemical composition and tuneable biochemical and biomechanical 
properties are some of the main advantages of using synthetic-based hydrogels.21 By 
tuning the chemistry of the hydrogel components, a wide variety of hydrogels of 
different cross-linking methods, mechanical properties, bio-functionalisation, 
degradation characteristics and topography have been generated and used for 3D cell 
culture.18,21 
 
i) PEG for hydrogel formation 
Although many kinds of synthetic polymers may be used to form hydrogels, PEG has 
emerged as one of the most frequently used in the field of 3D cell culture, primarily 
because of its cytocompatible nature and high water content.18 Another major 
advantage of PEG is the facile modification of its terminal hydroxyl groups, for 
example to alkenes, alkynes, azides, thiols, activated esters, norbornenes, maleimides 
and more, which enables variation in cross-linking methods to form PEG-based 
hydrogels.18 In addition, the commercial availability of multi-branched PEGs is 




8-arm PEGs were functionalised with lysine and glutamine-containing peptides 
responsive to activated enzyme transglutaminase factor XIII (FXIIIa) that through 
formation of ε-(α-glutamyl)lysine isopeptide side-chain bridges between the peptides 
resulted in hydrogel formation (Figure 1.9).64 These hydrogels were utilised to 
encapsulate and expand intestinal stem cells and with the addition of laminin 111 to 
the hydrogel, formation of intestinal organoids was achieved. 
 
 
Figure 1.9: Hydrogel formation of 8-arm PEG chains functionalised with Lysine (Lys) and 
Glutamine (Gln) peptides that undergo enzymatic cross-linking by transglutaminase Factor 
XIII (FXIIIa). MMP-sensitive peptides were tethered to the lysine sequences to afford 





Using PEGDA and thiol-modifed gelatin (as in Figure 1.7A) a UV cross-linked 
hydrogel was generated allowing 28-day encapsulation of human dermal fibroblasts 
resulting in increased cytoplasmic spreading and formation of cell networks. 
Compared to a control gel where the gelatin was physically encapsulated into a UV 
cross-linked PEGDA hydrogel, high hydrogel swelling and water content as well as 
a lower stiffness was observed.65  
 
ii) Synthetic peptides for hydrogel formation 
Using small peptides for hydrogel formation is beneficial due to the biological 
relevance of their amino acid component, and the cost-efficient synthesis through 
solid-phase peptide synthesis (SPPS) or recombinant technology.14,66 Peptides are 
often attached to other types of components e.g. polymers, to form hydrogels, but 
their self-assembly also enables the formation of peptide-based hydrogels.22 Self-
assembly behaviours of peptides exploited for hydrogel formation, include the a-
helical coiled coil motif of certain peptide chains containing both hydrophobic and 
charged residues,66 or the b-sheets resulting from alternating hydrophobic and 
hydrophilic amino acid combinations, for example the 16-residue peptide 
(FEFEFKFK)2 .67 
 
Polypeptides made up of repeating units of the pentapeptide VPGXG, where X can 
be any natural amino acid apart from proline, derived from the ECM protein elastin 
have been used to form thermally responsive elastin-like polypeptide/protein (ELP) 
hydrogels.68 ELPs display temperature dependent gelation where at low 
temperatures the hydrophobic residues are surrounded by organised water 
molecules, but above a transition temperature the water molecule ordering decreases, 
leading to collapse of the polymer structure and gelation by self-assembly and folding 
of the ELP chains.66 ELPs modified hydrazine residues and with a RGD sequence to 
improve cell attachment were cross-linked with aldehyde-modified HA to form 
double network hydrogels with both thermosresponsive (due to the ELP motif) and 
dynamic properties (due to the semi-reversible hydrazone bond) (Figure 1.10), in 
which mesenchymal stem cells (MSCs) were encapsulated and ejected through a 28G 
needle. Cells maintained viability and capacity for multiple lineage differentiation 






Figure 1.10: Formation of double network Elastin-like peptide/protein (ELP):Hyaluronic acid 
(HA) hydrogels. ELP-hydrazine and HA-aldehyde form hydrazone cross-linked hydrogels 
upon mixing and with heating to 37 °C the ELP-domain (-VPGIG/VPGKG-) self-assembles to 
form the second hydrogel network.69  
 
Short aromatic fluorenylmethoxycarbonyl (Fmoc) peptides have also been used to 
form hydrogels, self-assembled through the p-p stacking and hydrogen bonding of 
the Fmoc moieties.70 By mixing the dipeptide Fmoc-Phe-Phe-OH with Fmoc-Ser-OH 
(Figure 1.11A), hydrogels have been formed that support the growth and 






Figure 1.11: Peptide-based hydrogels. A. Hydrogels formed by the self-assebly of Fmoc-
(Phe)2-OH and Fmoc-Ser-OH have been used in several cell culture-based applications.70–72 B. 
The peptide Ac-(RADA)4-NH2 self-assembles to form hydrogels marketed as PuraMatrix™.  
 
PuraMatrix™ is a commercially available peptide hydrogel formed by the self-
assembly of Ac-(RADA)4-NH2 into nanofibers (Figure 1.12b). Human brain-derived 
neurotrophic factor-engineered human bone marrow MSCs underwent neuronal 
differentiation when gown on RGD-functionalsied PuraMatrix™ gels.73 Neuron 
specific enolase and glial fibrillary acidic protein levels, cell proliferation and growth 
were increased compared to culture within the unmodified PuraMatrix™.  
 
1.2.3 Hydrogel cross-linking methods  
 
i) Non-reversible covalent cross-linking   
Examples of non-reversible covalent bond formation used to form hydrogels include 
carbon-carbon bond formation during polymerisation of acrylate/acrylamide/vinyl-
based monomers, e.g. PEGDA, amide and ester bond formation, thiol-ene reactions, 
copper catalysed or strain-promoted azide-alkyne cycloaddition and tetrazine-based 
cycloaddition (Figure 1.12-1.14).  
 
Hydrogels were formed in PBS under physiological conditions by the thiol-ene 
reaction between cysteine-containing peptides (MMP and RGD sequences) and a 
norbornene-functionalised 4-arm PEG in the presence of initiator (Igracure D-2959 or 
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lithium phenyl-2,4,6-trimethylbenzoylphosphinate) and irradiation (365 nm, 10 
mW/cm2, 5 min) (Figure 1.12).74 In situ encapsulation of hMSCs was afforded by pre-
mixing with the monomer solutions and high cell viability 30 min after hydrogel 
formation was observed. Similar hydrogels have also been used for the encapsulation 
of β-cells,75 to investigate the migration of human fibrosarcoma cells (HT-1080)76 and 
to afford specific patterning of peptides, e.g. MMPs.77  
 
 
Figure 1.12: Use of thiol-ene chemistry between norbornene-functionalised 4-arm PEG and 
cysteine-containing peptides to form hydrogels.74  
 
Strain-promoted azide-alkyne cycloadditon (SPAAC) between azide-modified 4- or 
8-arm PEG and bi-functionalised cyclooctyne PEG formed hydrogels within minutes 
in PBS at 37 °C (Figure 1.13).78 Three variants of the hydrogel with different wt % PEG 
(4.8, 7.2 or 9.6 wt %) were prepared and encapsulated with MSCs. Over 2 weeks, the 
4.8 wt % hydrogels degraded, but the 7.2 and 9.6 wt % remained intact and 





Figure 1.13: Use of strain-promoted azide-alkyne cycloaddition between bis-cyclooctyne PEG 
and 4- or 8-arm PEG-azide to form hydrogels.78  
 
Tetrazine or norbornene-modified alginate-chains have been used to form hydrogels 
that subsequently were functionalised with RGD peptides by reaction of remaining 
norbornene groups with cysteine-containing peptides (Figure 1.14).79 3D cell 
encapsulation of 3T3 fibroblasts over 3 days showed high cell viability, and injection 
of the hydrogels into mice demonstrated low inflammatory response at the injection 





Figure 1.14: Use of tetrazine-based cycloaddition between tetrazine-functionalised alginate 
and norbornene-functionalised alginate to form hydrogels that subsequently were 
functionalised with cysteine-containing RGD sequences.79 
 
Although non-reversible covalent cross-linking methods are useful for creating 
strong and stable hydrogels, these materials are very different from the highly 
dynamic nature of the ECM. Cell spreading and migration is limited in these non-
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adaptable hydrogels, and the introduction of degradation within the scaffold is 
usually necessary to allow for cell movement and growth in 3D.43 This has been done 
by using hydrolytically sensitive polymers/building blocks that degrade over time, 
or by introducing MMP-sensitive peptide sequences that allow for enzymatic cell-
mediated degradation44 (for more on this see Section 1.2.7). Although both are useful 
to improve cell migration and spreading, these methods result in irreversible 
hydrogel degradation, which over time will lead to its collapse.43 
  
ii) Reversible covalent cross-linking 
Using reversible covalent cross-linking results in hydrogels with highly adaptable 
properties, due to the reversible and dynamic nature of the bonds.44 The equilibrium 
of formation and breakage of the bonds allows cells to move and spread through 
these materials, just like in their natural ECM environment and unlike the irreversible 
degradation of MMP sensitive sequences, reversibly cross-linked hydrogels do not 
erode over time.44 In addition, if the cross-linking is cell-compatible it can take place 
in the presence of cells, allowing for in situ cell encapsulation. Examples of reversible 
covalent bonds used for hydrogel formation include imines (Schiff base), hydrazones, 
oximes and disulphide bonds (Figure 1.15).43  
 
 
Figure 1.15: Examples of reversible covalent bonds used to form hydrogels. A. Imine 
formation from an aldehyde and primary amine B. Hydrazone formation from a 
ketone/aldehyde and hydrazine C. Oxime formation from a ketone/aldehyde and 




The imine bond formation between a primary amine and an aldehyde has been used 
to form hydrogels between chitosan and 4-formylbenzoic acid-functionalised PEG 
(Figure 1.16).80,81 HeLa cells showed good viability when encapsulated within the 
resulting hydrogels that formed under physiologically relevant conditions. 
Degradation was afforded by the addition of acid, with reformation of the hydrogel 
network achieved when the pH was re-adjusted to physiological conditions.  
 
 
Figure 1.16: Use of imine-bond formation between chitosan and 4-formylbenzaldehye-
functionalised PEG to form hydrogels.80,81 
 
Aldehydes have also been used to react with hydrazines or hydroxylamines to form 
hydrazone and oxime cross-linked hydrogels respectively, but due to the 
electronegativity of the heteroatom (NH for hydrazone and O for oxime bonds) next 
to the C=N bond, the propensity for nitrogen protonation required for bond 
hydrolysis, is decreased compared to imine bonds. Thus, oxime and hydrazone bonds 
are more stable and less reversible under physiological conditions.82 Cross-linked 
hydrogels from hydrazine and aldehyde-modified multi-arm PEG (4 or 8-arm) 
resulted in hydrogel formation with the gels made solely of the 4-arm PEG having a 
shear modulus of 600 Pa, which increased to 9 kPa for the gels with only 8-arm PEGs 
(Figure 1.17). C2C12 myoblasts and motor neurons encapsulated within these gels 





Figure 1.17: Use of hydrazone-bond formation between 4- or 8-arm PEG (only 4-arm shown) 
functionalised with either aldehydes or hydrazines to form hydrogels.83,84 
 
The usually rapid gelation time of imine, oxime and hydrozone cross-linked gels is 
an advantage for in situ cell encapsulation allowing homogenous cell encapsulation 
within the gel. An added advantage of these hydrogels is the potential to cross-link 
the aldehyde-bearing components with primary amines naturally present in the 
biological environment e.g. in the cell media or on cell surfaces and on ECM 
components produced by the cells in culture, which aid in anchoring the hydrogel to 
the biological environment. The reaction of aldehydes to biomolecules such as 
proteins, however, could also pose a risk of inhibiting protein bioactivity.    
 
Thiol-disulphide exchange has been used to form injectable HA-based hydrogels by 
reacting pyridyl disulphide-functionalised HA with PEG dithiol (3400 g/mol) (Figure 
1.18).85 Hydrogel formation was monitored in real-time by measuring the UV 
absorption increase as an effect of released pyridine-2-thione from the thiol-
disulphide exchange. High viability of Human umbilical vein endothelial cells 
(HUVEC), MSCs and normal human dermal fibroblasts was observed within the gels.  
A drawback of disulphide cross-linked hydrogels, however, is the high concentration 
of reducing agents such as glutathione found within some tissues that can result in 





Figure 1.18: Usage of thiol-exchange to form hydrogels between pyridyl disulphide-
functionalised hyaluronic acid (HA) and di-thiol PEG with the release of pyridine-2-thione.85  
 
iii) Non-covalent cross-linking 
In non-covalent cross-linked hydrogels interactions such as hydrogen bonding, 
electrostatic interactions or ionic coordination, van der Waals forces, hydrophobic 
interactions or specific molecular recognition such as host-guest interactions are 
utilised to form the networks.33,43,44 For example, most peptide-based hydrogels form 
via non-covalent interactions such as the π-π stacking and H-bonding of Fmoc-Phe-
Phe/Fmoc-Ser hydrogels70–72 as discussed in section 1.2.2.  
 
Due to its low cost and low toxicity, alginate (Figure 1.6B) has become a popular 
material to use for 3D cell culture. Alginate forms ionically cross-linked hydrogels via 
the coordination of the alginate chains with positive ions (e.g. Ca2+, Mg2+) with its 
mechanical properties easily tuned by changing the ion concentration.43 Alginate 
hydrogels with varied stiffness (2.5-30 kPa) have been used to direct MSC 
differentiation, with softer hydrogels (2.5-5 kPa) directing adipogenic lineage 
commitment according to gene and protein expression analysis, while osteogenic 




Protein-protein interactions have been utilised to form hydrogels by the molecular 
recognition of a recombinant protein with a WW domain and proline-rich peptides 
(Figure 1.19).87 The WW domain can be found in many intracellular proteins and gets 
its name from conserved tryptophans. By letting recombinant WW domains flanked 
by hydrophilic spacers bearing RGD peptides (to improve cell attachment) react with 
a 13-amino acid peptide with seven proline residues, non-covalently cross-linked 
hydrogels were afforded that have been utilised for several cell-based applications.88–
91 Their assembly was shown to support the encapsulation and viability of adipose-
derived stem cells injected into mice.88 In addition, when functionalised with multi-
branched PEGs hybrid doubly cross-linked hydrogels formed in which human iPSCs 
were encapsulated and injected into an ischemia injury mouse model.89 Reduced 
inflammation and muscle tissue regeneration was observed at the injection site 
compared to PBS control. 
 
 
Figure 1.19: Formation of hydrogels via non-covalent self-assembly of the recombinant 
protein WW domain and a proline-rich peptide. The WW domain is flanked by hydrophilic 
spacers bearing a RGD sequence for improved cell binding. The proline-rich peptide is flanked 





1.2.4 Bio-functionalisation of hydrogels 
 
i) Incorporation of cell adhesive peptides in hydrogels 
Cell adhesive peptides can be added to hydrogels to help mimic ECM-integrin 
interactions with RGD being a common motif. The addition of RGD to 
photopolymerised PEGDA hydrogels improved cell adhesion and spreading of 
human-derived MCS with cell viability increasing from 15 % to 75 % compared to the 
non-modified hydrogel.92 Studies have shown cell adhesion on RGD-functionalised 
biomaterials occurs in a concentration-dependent manner with an increased 
concentration of RGD leading to higher levels of cell attachment and spreading, but 
if the levels are too high, it can hinder cell detachment and thus migration.93  
 
The ability to mimic the spatial and temporal control of ECM-cell adhesion can 
greatly improve the performance of hydrogels and can be mimicked by using 
patterned hydrogels, with specific presentation of cell adhesion ligands to promote 
local attachment and spreading. 3D hydrogels formed via the reaction between a 4-
arm PEG-azide and a bis-cyclooctyne peptide containing both an MMP-sensitive 
sequence and a vinyl-modified lysine were formed in the presence of 3T3 cells 
allowing for in situ cell encapsulation (Figure 1.20).94 RGD-patterning within the 
hydrogel was achieved by reacting the vinyl groups in the hydrogel backbone with 
thiol-functionalised RGD sequences via UV exposure (λ = 365 nm) and use of 
photomasks to spatially control the functionalisation. Over 10 days culture, improved 
cell spreading was observed in the RGD patterned areas compared to those without 
peptide-functionalisation. This type of patterning also allows for the local clustering 
of RGD ligands, a mimic of the ligand clustering of integrins (also known as focal 
adhesions) observed in vivo and crucial for forming stable ECM-cell adhesions.20  
 
Although RGD is a common motif, its selectivity is poor as it binds many different 
cell receptors and cell types.17 As such, more selective cell adhesion peptides can be 
used to improve the adhesion of specific cell types. Cell-adhesive peptides have been 
identified from several ECM-proteins, including REDV and LDV from fibronectin, 
DGEA and GFOGER (O = hydroxyproline) from collagen and IKLLI and YIGSR from 
laminin.17 Although these peptides can promote cell adhesion on their own, it has 
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Figure 1.20: Formation of hydrogels by cross-linking 4-arm PEG-azide and a bis-cyclooctyne-
functionalised peptide with an MMP-sequence and an alkene-functionalised lysine. The two 
components undergo strain-promoted azide-alkyne cycloaddition to form hydrogels. By 
selectively irradiating areas of the hydrogel (λ = 365 nm) and adding a cysteine-containing 
RGD-sequence selective RGD-patterning was afforded.94  
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ii) Incorporation of growth factors in hydrogels 
To mimic the secretion of soluble factors from cells and/or the ECM to direct cell 
communication and behaviour, growth factors (GFs) can be included in the hydrogel 
structure. GFs modulate cell behaviour, including proliferation rates, differentiation, 
cell adhesion, migration and gene expression profiles.95  
 
A challenge of GFs inclusion is to recapitulate their local concentration profiles and 
controlled release as observed in vivo.18,44 One strategy for achieving this is to use 
light-based strategies and a common approach involves the use of an ortho-
nitrobenzyl moiety, which upon irradiation forms an aromatic nitrosocarbonyl 
(Figure 1.21A).96 The release of the functional group at the benzylic position allows 
specific release of GFs/peptides/targeting moieties etc. or selective functional group 
unmasking can be achieved. Using this strategy, a cysteine-containing peptide 
derivatised with a 2-nitrobenzyl-modified lysine and a 4-arm PEG-thiol were cross-
linked with an 8-arm PEG-vinylsulphone to form thiol-ene cross-linked hydrogels 
(Figure 1.21B).97 The 2-nitrobenzyl residues were then cleaved upon irradiation (λ = 
405 nm), which led to the exposure of the primary amine on the lysine side chain. The 
lysine motif was enzymatically linked to a glutamine-containing peptide conjugated 
to VEGF by using FXIII (as in Figure 1.9). The use of laser-scanning lithography to 






Figure 1.21: A. Photocleavage of nitrobenzyl as used for patterning of hydrogels. B. Formation 
of thiol-ene cross-linked hydrogels by mixing an 8-arm PEG vinyl-sulphone with 4-arm PEG-
thiol and a cysteine-containing peptide that contain a FXIIIa sensitive peptide with a 2-
nitrobenzyl-capped lysine residue. After hydrogel formation, irradiation (λ = 420 nm) led to 
the cleavage of the 2-nitrobenzyl moiety, thereby unmasking the lysine residue. Addition of 
FXIIIa and a VEGF-conjugated glutamine-containing peptide resulted in the VEGF-patterning 
within the hydrogel by virtue of the FXIIIa mediated lysine-glutamine linkage.97 
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1.2.5 Tailoring hydrogel biomechanical properties  
As discussed above cells respond to the mechanical properties of the surrounding 
ECM through mechnotransduction and by altering the hydrogel stiffness and 
elasticity this can be tuned. A method of increasing hydrogel stiffness is to simply 
increase the component concentrations and/or introduce higher cross-linking 
levels.33,51 Seminal experiments in this field were done in 2D using collagen-coated 
polyacrylamide hydrogels, where hMSC lineage commitment was shown to be 
dependent on substrate stiffness.98 When cultured on surfaces with low (1 kPa), 
medium (11 kPa) or high (34 kPa) elastic modulus, gene expression profiles showed 
neural, myogenic and osteogenic lineage commitment respectively, in line with the 
observed stiffness of these tissues in vivo.  
 
In recent years, several studies have introduced the concept of spatial control over 
hydrogel mechanics, usually through photochemistry. PEGDA-based hydrogels with 
a nitrobenzyl ether photodegradable unit were formed with 10 kPa elastic modulus.99 
Upon spatially controlled irradiation (λ = 365 nm, 5 mW/cm2, 6 min) patterned 
hydrogels with mechanically softer and stiffer regions were afforded (from 2-10 kPa) 
with both regular and randomly patterned gels fabricated (Figure 1.22). Higher levels 
of cell spreading and Yes-associated protein (YAP) activation (gene known to 
regulate cell behaviour in response to mechanical stimulus) were observed when 
hMSCs were grown on regularly patterned hydrogels with osteogenic lineage 
commitment as assessed by upregulation of the osteogenic marker alkaline 
phosphatase (ALP). By irradiating the hydrogel to afford a randomly patterned 
hydrogel cells became more rounded and showed lower levels of ALP and YAP 
activation. Furthermore, expression of the stem cell marker CD105 increased, 
indicating low levels of differentiation and demonstrated that the spatial control of 





Figure 1.22: Hydrogels with patterned stiffness by inclusion of a 2-nitrobenzyl moiety in a 
PEG-based hydrogel. Initial hydrogels had a stiffness of 10 kPa, which after irradiation (λ = 
365 nm) led to hydrogel network breakage (due to the bond-cleavage of 2-nitrobenzyl) and 
stiffness decrease down to 2 kPa. By controlling the irradiation time and position hydrogels 
with patterned stiffnesses were created.99 
 
1.2.6 Modifying the hydrogel topography and microstructure 
The micro and nanostructure of the ECM varies across tissues and organs with 
integrin-ECM interactions occuring at the nanoscale and controlling hydrogel 
topography at this scale can be used to mimic such properties.17,20 Most studies for 
cell culture have involved the fabrication of a flat 2D surface, or a stiff and rigid 3D 
scaffold with nanostructure,33 such as the nanopatterning of PMMA surfaces with 120 
nm diameter and 100 nm deep nanopits using electron beam lithography.100 The 
nanopits were arranged into either square, hexagonal or disordered arrays and 
seeded with hMSCs to monitor osteogenic differentiation by analysing the expression 
of bone-specific proteins osteopontin and osteocalcin. Higher levels of osteogensis 
was observed with hMSCs cultured on the square-patterned polymers for 21 days, 
compared to both unmodified PMMA and the hexagonal or randomly patterned 






1.2.7 Introducing degradation properties into hydrogels  
The remodelling of the ECM by cells through its degradation and production is an 
important aspect to try to mimic within a synthetic ECM matrix. The use of reversible 
cross-linking methods is one way of introducing a dynamic environment in which 
cells can spread, proliferate and migrate, as with the imine cross-linked hydrogels 
used within this thesis.  
 
Many studies for 3D cell culture have used hydrogels with MMP-sensitive peptide 
sequences functionalised into the hydrogel network to allow for enzymatic 
degradation, with several such examples already given. The rate of hydrogel 
degradation can be tuned by altering the peptide motifs to have different affinities for 
specific MMPs.20 Initial work in this field used vinylsulfone-functionalised 4-arm PEG 
cross-linked with a cysteine-modified MMP-sensitive peptide to form hydrogels 
(Figure 1.23) in which human foreskin fibroblasts were encapsulated and showed 
improved matrix invasion over time because of cell-mediated MMP secretion and 
resultant hydrogel degradation.101  
 
 
Figure 1.23: Formation of hydrogels by cross-linking 4-arm PEG-vinylsulfone with a MMP-




Current work in the area of hydrogel degradation, as in many more regarding 
hydrogel properties, looks to afford spatial and temporal control over the process. 
Several studies have accomplished this by encapsulating 2-nitrobenzyl in the 
hydrogels,102–105 similar to the techniques used above for controlling hydrogel 
biofunctionalisation or biomechanical properties. The reaction between a 4-arm PEG 
functionalised with 2-nitrobezyl linked to a cyclooctyne moiety and azide-modified 
gelatin formed SPAAC cross-linked hydrogels that could be degraded in a spatial 
manner by irradiation (λ = 365 nm, 156 mW/cm2, 30 s) (similar to Figure 1.23) and 
showed high viability of encapsulated HeLa over 24 h.105 Although 2-nitrobenzyl-
based photopatterning has been successful, care must be taken with any photo-based 
method, as short wavelengths can be toxic to cells and the use of external triggers 
adds a layer of complexity to the 3D cell culture platform, which may hinder its 
transition to widespread use.  
 
1.3 High-throughput synthesis, screening and 
microarrays  
 
Although the hydrogels and other biomaterials discussed so far have been beneficial 
in advancing the field of materials for 3D cell culture, their low throughput 
fabrication with the assessment of only one or a few similar variants of the same 
material at a time is a disadvantage. The utilisation of high-throughput synthesis and 
screening (HTSS) is a powerful method to rapidly assess a large number of materials 
at once, thereby reducing the time, cost and amount of material used.106 HTSS can be 
particularly useful for biomaterials identification since the complex and poorly 
understood relationship between a biomaterial and its cellular response makes 
prediction of material/cell performance difficult. HT methods have been utilised for 
biomolecule identification, with microarray technology being particularly advanced  
for DNA and protein microarrays aimed at understanding gene and protein levels 
with specific targets of interest e.g. cell or tissue.106 
 
A microarray is a solid substrate, most commonly a glass slide, but other materials 
have also been used e.g. polymers and nitrocellulose membranes or paper, on which 
probes such as biomolecules e.g. DNA or proteins, or other materials e.g. polymers, 
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are printed or synthesised and immobilised in a defined pattern. Thousands of 
features per cm2 can be afforded with their identification being defined by their 
position. Incubating a microarray with a target e.g cDNA, the relative binding levels 
to the different features can be quantified, commonly through fluorescent 
labelling.106–108 Different types of printers for deposition of biological materials to 
produce microarrays exists and within this thesis two robotic-type printing 
techniques have been used: contact and ink-jet printing.   
 
1.3.1 Printing techniques  
 
i) Contact printing  
In contact printing the printing head carrying the sample to be printed and the 
substrate come in direct contact during the printing process. For pin-based contact 
printing, multiple pins (usually 16, 64 or 96) are attached to a robotic arm with high 
X-Y-Z precision and dipped into a sample-reservoir, usually a 394- or 96-well plate. 
Sample is transferred from the pins to the substrate via physical contact with typically 
400-10,000 spots/cm2 printed per array.106 Printing quality is affected by the viscosity 
of the sample, the pin contact area and its surface properties as well as the surface 
properties of the substrate. Additionally, external factors such as temperature, and 
humidity will also affect the precision and quality printing.106,107 Two main types of 
pins are used for contact printing: solid and split pins (Figure 1.24).  
 
 
Figure 1.24: Types of pins used for contact printing with their associated pin loading and 






Solid pins  
Solid pins are usually fabricated out of metals such as stainless steel, titanium or 
tungsten and dipped into the sample reservoir to load the tip of the pin with ink 
(Figure 1.24A). Following pick-up, the sample is deposited onto the substrate with 
the spot size tuned by changing the pin size. Solid pins are particularly useful for 
samples containing particulates as there is no risk of clogging the interior of the pin, 
but a disadvantage is the regular need for washing and reloading with new sample 
during printing since only a few spots can be printed with each load.106,107   
 
Split pins  
In split pins a narrow microchannel (10-100 µm) is located at the tip of each pin in 
which the sample is loaded through capillary force action (Figure 1.24B). Upon 
contact with the substrate, the sample is deposited in the pico- to nanoliter range. An 
advantage of these pins is the increased throughput compared to solid pins since 
spots can be printed serially without the need for frequent reloading and washing, 
but pre-printing is necessary to remove excess sample on the pin walls and ensure 
uniform printing. Another disadvantage is the risk of pin clogging and precipitation 
with material getting stuck in the pin microchannel, a problem for protein and 
polymer solutions. Although the size of the microchannel can be increased to limit 
this, such pins are subjected to lower printing uniformity.106,107  
 
iii) Ink-jet printing  
In contrast to contact printing, no physical contact takes place between the printer 
nozzle and substrate during ink-jet printing with the advantage of reduced risk of 
contamination and gentler deposition of the sample.106 Ink-jet nozzles have a small 
opening into which the sample is drawn and the high printing precision of the 
printers enables the printing of specific patterns and geometries on the target 
substrate.106,109 Two types of nozzles are commonly used for drop-on-demand ink-jet 





Figure 1.25: Types of nozzles used for ink-jet printing A. (i) Thermal jet nozzle, equipped with 
heater that upon (ii) heating result in the formation of a vapour bubble. (iii) As the heat resistor 
cools down the vapour bubble shrinks and collapses, resulting in droplet formation. B. (i) 
Piezo jet nozzle equipped with a piezoelectric material that (ii) deforms as a voltage is applied. 
(iii) When the voltage is turned off and the piezoelectric material relaxes back to its original 
state pressure builds up inside the nozzle, resulting in droplet formation.  
 
Thermal jet 
In thermal jet, the nozzle is equipped with a heater capable of temperatures up to 300 
°C. Upon heating a vapour bubble is produced that results in a droplet forming at the 
end of the nozzle. As the nozzle cools the vapour bubble collapses, resulting in 
droplet ejection from the nozzle and replacement fluid filling the empty space created 
from the bubble collapse (Figure 1.25A).106,109 Although many commercial desktop 
printers use thermal jet methods, the technique has seen limited use in biomolecule 
printing due to the high temperatures required.  
 
Piezo jet  
For piezo jet printing a deformable (piezoelectric) material e.g. lead zirconium 
titanate is bound to the nozzle that upon application of a voltage pulse shrinks and 
thus restricts the nozzle inner diameter. When the voltage if turned off the 
piezoelectric material relaxes back to its original state, creating a pressure wave inside 
the nozzle that causes droplet ejection (Figure 1.25B).109 The droplet size can be tuned 
depending on the strength (voltage amount) and time (pulse length) applied to the 
piezoelectric material. Piezo jet techniques are compatible with printing of sensitive 
biomolecules, but due to their high cost and fragility of the nozzles it is considered a 




1.3.2 Types of microarrays 
 
i) DNA microarrays  
DNA microarrays enables the parallel analysis of thousands of genes, by 
immobilising oligo-DNA probes on a substrate, with the main application being gene 
expression analysis, although DNA microarrays also are used for transcription factor 
binding analysis or the detection of single nucleotide polymorphisms.110 In a typical 
DNA microarray assay the messenger RNA (mRNA) isolated from the target e.g. cells 
or tissue is converted to its complementary DNA (cDNA) and amplified, usually with 
fluorescent labelling. Incubation with the microarray slide allows for DNA 
hybridisation with the immobilised probes. The level of binding per feature is 
analysed by fluorescence and relative gene expression levels determined.108,110 
 
The probes are typically synthesised directly onto the slide, for example via ink-jet 
printing by sequential spotting of nucleotides (≤ 60 per probe) in the desired order. 
The printing substrate is typically functionalised with amines such a polylysine or 
silylamine-coating to  ensure immobilisation of the probes to the surface.108,111 
Photolithography is another method of DNA microarray fabrication wherein 
oligonucleotides bearing photolabile blocking groups are deposited onto a substrate 
in a spatially controlled manner with the use of masks. After the first round of 
nucleotides are attached on the substrate, masks are applied that allow for the light-
initiated cleavage of the blocking groups, thus rendering them capable to react with 
a second nucleotide. A solution of either A, T, C or G conjugated with blocking groups 
are then added to the chip, allowing for their reaction with the previously unmasked 
nucleotides. This process in repeated for several rounds with a specific mask each 
time to spatially control the nucleotide incorporation. Millions of probes can be 
incorporated per microarray using this technology with up to 25 nucelotides in 
length.111 The need for custom-made masks is a limitation of this method however, 
but is overcome in so-called mask less photolithography where digital micromirror 
devices guide the position of the light on the array, thus controlling on which probes 
the photolabile blocks are cleaved to allow for further nucleotide incorporation 
generating arrays with millions of probes and of longer nucleotide chains (≤ 85) 




ii) Protein microarrays  
For protein microarrays, the immobilised probes are typically antibodies (typically 
IgG-based libraries), aptamers or short peptides, and are used to investigate protein 
expression levels found in samples of interest.108 These “analytical” protein 
microarrays are used for profiling protein expressions in certain disease states and 
compared to healthy samples. Recombinant proteins (full-length or fragments) can 
also be printed, immobilised and screened with proteins, drugs or antibodies to assess 
protein-protein, protein-drug and antigen-antibody interactions for so-called 
“functional” protein microarrays.108  
 
Drawbacks of protein microarrays include the limited protein stability once printed 
and the limited bioactivity of printed fragments compared to DNA, as well as the lack 
of protein amplification methods, which means it is difficult to detect low 
concentration proteins. In biological samples protein concentrations range from 
nanomolar  (nM) to zeptomolar (zM, 10-21) concentrations, and in biological 
environments these low concentration proteins typically co-exist with abundant non-
target proteins e.g. serum, which can cause antibody cross-reaction and high 
background signals.108,112 
 
iii) Polymer microarrays  
For the high-throughput screening of biomaterials polymer microarrays have 
emerged as a powerful tool to screen polymeric materials, with notable developments 
within the Bradely113 and Langer114 groups for the past 15 years. Libraries of polymers 
are printed via contact or ink-jet printing onto glass slides and screened with a 
biological target, typically cells, to rapidly identify promising materials that are 
scaled-up for further interrogation (Figure 1.26). Polymers can both be printed as pre-
made polymer solutions or polymerised in situ by the sequential printing of 





Figure 1.26: A polymer microarray printed with over 1000 different polymer features. 
 
Within the Bradley group several polymer libraries have been synthesised and 
screened in this manner. For the purpose of contact printing and the deposition of 
pre-made polymers, libraries of polyacrylate/acrylamide/vinyl and polyurethanes 
have been utilised.115–118 Applications of these libraries in array format have included 
identification of substrates that support skeletal progenitor cells (STRO+1)119, bind 
K562 suspension cells,120 induce platelet activation,121 trap or repel water-borne 
parasites122,123 and bacteria124 as well as polymers that support stem cell growth, 
including mesenchymal stem cells (MSCs)125 and the identification of polymers that 
bind proteins able to maintain the rat glioma cancer stem cells (CSCs) niche.126  
 
To achieve in situ polymer formation on glass slides, ink-jet printing has been the 
preferred method as it allows for the precise and sequential deposition of monomers, 
cross-linkers and initiators, enabling huge scope in polymer variation on the 
microarray slide by simple tweaking of the component composition of each spot. 
Following in situ polymerisation (e.g. UV or redox polymerisation) very large 
polymer libraries have been fabricated127–130. Using this approach with a 
SciFLEXARRAYER S5 printer over 600 polyacrylate and polyacrylamide-based 
hydrogels were screened with human embryonic stem cells (hESCs).45 This led to the 
identification of a hydrogel composed of the monomers 2-(acryloyloxyethyl) 
trimethylammonium chloride and 2-(diethylamino)ethyl acrylate and cross-linked 
with N-N’-methylenebisacrylamide that supported the long-term growth of hESCs (> 
30 passages) and maintained their pluipotency, as measured by the expression of  
pluripotency markers Oct3/4, Nanog and Sox2. Due to the thermal responsiveness of 
the hydrogel, thermal detachment of the hESCs was possible by lowering the 
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temperature to 15 °C. Thereby an enzyme-free passaging system was developed. A 
similar high-throughput approach identified hydrogels that supported the long-term 
culture of primary hMSCs131 and of mouse embryonic stem cells (mESC).132  
 
Ink-jet printing and in situ polymersiation were also used to form high-density 
polymer microarrays (> 7000 different features per array) that led to the identification 
of polymers capable of supporting hESC growth and maintenance.130 Scaled-up hit 
polymers were incubated with RH1 cells and passaged over 35 days. Maintained 
pluripotency was demonstrated by Nanog and Oct4 protein expression, and further 
confirmed by flow cytometry, qPCR and EB differentiation.  
 
Arrays of double network hydrogels were also fabricated using an ink-jet based 
bioprinter (PolyPico) equipped with cartridges of 100 µm aperture, loaded with 
monomers, initiator or cross-linker.133 In contrast to the costly nozzles used for the 
SciFLEXARRAYER printer the PolyPico uses disposable, low-cost cartridges, 
reducing the risk of contamination as well as the cost of printing. The first network 
was composed of combinations of UV-polymerised polymers made of cross-linked 
methacrylate, acylate and acrylamide monomers that were printed as an array of 80 
different polymers. The second network was made up of polyacrylamide UV-
polymerised inside the first network offering improved mechanical properties of the 






The aim of this thesis was to develop a novel approach to generate a library of new 
hydrogel-based materials that could be screened in a high-throughput manner for 
biomedical applications. The hypothesis was that these 3D structures would provide 
a good mimic of the complex ECM environment surrounding cells and that 
modulation of the hydrogels chemical structure and composition would allow a 
hydrogel library to be established. Here a library of 100’s of hydrogels was fabricated 
using ink-jet printing technology, with the aim of making this procedure facile to 
allow longer-term screening of 1000’s of materials simultaneously.  
 
Coupled with the establishment of a hydrogel library fabrication platform, another 
aim was to enable a cell-compatible was to break the hydrogel structure and thus 
allow passaging. To this end a mild hydrogel passaging system using Vitamin B6-
derivatives to afford hydrogel degradation and cell release was developed, in which 
the dynamic bonds in the gel were broken with competing external ligands. 
 
Outside this work was a collaboration project that used 2D 
acrylate/acrylamide/peptide polymers to explore enrichment of pancreatic cancer 





Chapter 2: Development of a high-





A drawback of the microarrays described in 1.3.2 is that the materials screened did 
not permit a large amount of 3D cell encapsulation, but mainly allowed surface cell 
attachment. Although subsequent scale-up studies enable their fabrication as 3D 
substrates, it is attractive to study 3D cell encapsulation in a HTS format. As such, in 
addition to the previously mentioned microarrays developed within the Bradley 
group, microarrays of polymer blends have also been produced wherein 3D 
encapsulation is possible.134,135   
 
Microarrays with 3D polymer scaffolds were fabricated by the Bradley group with 
the contact printing of polymer blends.134 Seven commercially available and 
biodegradable polymers (chitosan, PEG, PLA, PVA poly(ethyleneimine) (PEI), 
poly(ε-caprolactone) (PCL), poly(2-hydroxyethyl methacrylate)) with poor cell-
attachment on their own were blended together with certain combinations found to 
form scaffolds that supported the attachment of two osteosarcoma cell lines (MG63 
and SaOs) on the microarray platform. Subsequent scale-up of a hit blend 
(PLLA/PCL 80/20) demonstrated osteogenic differentiation of STRO-+1 skeletal 
stem cells and bone regeneration in a mouse model implanted with the cell-laden 3D 
scaffold.  
 
Polymer blends of chitosan and PEI formed hydrogels when mixed at different molar 
ratios (90:10 to 10:90), which were fabricated as polymer microarrays, and screened 
with HeLa and primary foetal skeletal cells over 28 days, demonstrating 3D cell 
encapsulation within the hydrogels and maintained cell proliferation.135 The skeletal 
cells remained spherical (a chondrocyte-like morphology) when encapsulated within 
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the chitosan:PEI hydrogels over the 28-day period as opposed to their fibroblast 
morphology as monolayer cultures, demonstrating these hydrogels capacity to 
prevent human skeletal cell fibroblast dedifferentiation. This was confirmed by gene 
expression analysis with increased expression of the chondrogenic markers Col2a1 
(collagen type II) and aggrecan over the 28 days, while the expression of Col1a1, a 
marker for fibroblasts, remained low over the incubation period.  
 
The Lutolf group produced hydrogel arrays by printing PEG monomers bearing 
MMP-sensitive peptides and being susceptible to enzymatic cross-linking with FXIIIa 
(see Figures 1.9 and 1.21) into 1,536-well plates with the use of a liquid handling 
robot.136 By changing the amounts of the PEG monomers and varying the amount of 
MMP-sensitive peptides, ECM components (collagen IV, laminin or fibronectin), cell–
cell interaction mediating molecules (E-cadherin, jagged or EpCAM) and soluble 
factors (fibroblast growth factor 4, bone morphogenic protein 4 or leukaemia 
inhibitory factor) in the PEG hydrogels, plus varying the cell seeding density, over 
1000 different materials were created that could undergo HTS to look for 3D 
encapsulation of mESCs. 
 
The aim of the work presented in this chapter was to develop a library of synthetic 
hydrogels that could be printed and screened in a high-throughput manner, while 
simultaneously allowing for 3D cell encapsulation. Here it was desired to form 
hydrogels simply by mixing the components by using an inkjet-printing approach as 
it allowed variation in hydrogel compositions by varying the component ratios of 
each spot. Imine cross-linked hydrogels were chosen, allowing primary amines and 
aldehyde-bearing components to quickly form hydrogels due to the rapid imine 
cross-linking. In addition, the dynamic nature of the imine bond should allow for cell 
movement within the hydrogels. Using this system, a novel family of hydrogels 
formed from the imine cross-linking of aldehyde-functionalised PEG cross-linkers 
and ECM-based peptides were developed. Their inkjet-printing onto glass slides 






2.2 Hydrogel Library Development  
 
2.2.1 Hydrogel Library Component Synthesis 
For imine-mediated hydrogel formation and array fabrication two ECM-based 
peptides (RGD and LamIII) and three PEG cross-linkers (PEG2000-CL, PEG3000-CL and 
(PEG-NH2)4) were used. The two ECM-based peptides were designed to have free 
primary amines at both the amino and carboxyl termini (Figure 2.1) and were based 
on the cell attachment promoting peptide GRGDS (referred to as RGD) and the 
pentapeptide YIGSR from laminin 111 (referred to as LamIII). RGD is a recognition 
marker for integrins responsible for cellular adhesion36 that is found in multiple ECM 
proteins including fibronectin, collagen and fibrinogen.137 YIGSR is located within the 
β1 arm of laminin 111,138 and has been shown to increase cell adhesion,139 improve 
hepatocyte attachment,138,140 and decrease tumour growth.141 
 
 
Figure 2.1: Structures and solid phase synthesis of peptides used for hydrogel formation. A. 
RGD (H-Ahx-GRGDSK-NH2). B. LamIII (H-Ahx-YIGSRK-NH2) (i) Fmoc-AA-OH, oxyma, 
DIC, DMF, 1 h. (ii) 20 % piperidine/DMF, 2 × 10 min. Steps i and ii repeated with the required 
Fmoc-AA-OH. (iii) TFA/TIS/H2O (95:2.5:2.5), 3 h.  
 
To allow crosslinking of the peptides, two linear PEG-based cross-linkers of varying 
PEG chain length (referred to as PEG2000-CL, Mn = 2000 g/mol and PEG3000-CL, Mn = 
3000 g/mol) were bifunctionalised with 4-formylbenzoic acid (Figure 2.2). In 
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addition, a commercially available 4-armed amino-terminated PEG crosslinker 
(referred to as (PEG-NH2)4, Mn = 10 000 g/mol) was used to improve the rigidity of 
the hydrogels.  
 
Figure 2.2: Synthesis of PEG cross-linkers used for hydrogel formation. PEG-OH Mn = 2000 
g/mol (n = 44) or 3000 g/mol (n = 66)  
 
Hydrogel formation was envisaged to take place via imine-bond formation between 
the amines on the peptides and (PEG-NH2)4 and the aldehydes on the linear PEG 
cross-linkers (Figure 2.3). Due to the reversibility of the imine bond, the gels would 





Figure 2.3: The formation of dynamic, imine cross-linked peptide/PEG-based hydrogels with 
cell encapsulation. Hydrogels form via the combination of ECM-based peptides (RGD and 
LamIII) with free primary amines at amine and carboxyl termini and bis-aldehyde PEG cross-
linkers (PEG2000-CL, PEG3000-CL), as well as a 4-arm amine terminated PEG ((PEG-NH2)4).  
 
2.2.2 Bulk Hydrogel Formation and Cell Encapsulation 
For hydrogel formation, the five described components (RGD, LamIII, PEG2000-CL, 
PEG3000-CL and (PEG-NH2)4) were dissolved separately in Dulbecco’s Modified Eagle 
Medium (DMEM) cell media. Different combinations of the peptides (RGD, LamIII) 
53 
 
and (PEG-NH2)4 were mixed with the cross-linkers (PEG2000-CL, PEG3000-CL), which 
resulted in gelation for certain combinations (Table 2.1).  
 
Table 2.1: Assessment of hydrogel formation for different combinations of components. 
Hydrogel formation was assessed at room temperature 30 s after mixing and after 1 h and 24 
h incubation at 37 °C. ü = hydrogel formed, û = no hydrogel formed, ~ = very soft gel-like 
structure formed. Hydrogel numbers in red: Components dissolved in DMEM cell media 
supplemented with 10 % FBS. In all other cases the components were dissolved in DMEM 
without FBS.  
Hydrogel 
Number 




37 °C, 1 h 
Hydrogel 
37 °C, 24 h 
1 
LamIII 2.5 
ü ü ü PEG2000-CL 5 
2 
LamIII 2.5 
û û û PEG2000-CL 5 
3 
LamIII 1.7 
ü ü ü PEG2000-CL 3.3 
4 
LamIII 3.3 
ü ü ü PEG2000-CL 6.7 
5 
LamIII 5 
û û û PEG2000-CL 10 
6 
LamIII 7.5 
~ ~ ü PEG2000-CL 15 
7 
LamIII 3.75 








~ ü ü PEG3000-CL 15 
10 
LamIII 1.7 




The hydrogels formed were transparent (Figure 2.4), an important feature for 
subsequent fluorescence and bright-field imaging. Furthermore, the hydrogels all 
had a pH of 7, making the hydrogels compatible for cell encapsulation. 
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Figure 2.4: Formation of peptide hydrogels made-up of the peptide LamIII and cross-linker 
PEG2000-CL in DMEM cell media with 10 % FBS. A. 2.5 % and 5 %; B. 1.7 % and 3.3 %; C. 3.3 % 
and 6.7 % respectively.  
 
Using DMEM supplemented with 10 % foetal bovine serum (FBS) resulted in 
hydrogel formation at lower component concentrations than when using DMEM 
without FBS (see Table 2.1). When using DMEM with 10 % FBS, hydrogels composed 
of LamIII and PEG2000-CL were observed to form at lower concentrations (1.7 %* 
LamIII and 3.3 % PEG2000-CL). However, when DMEM without FBS was used 7.5 % 
LamIII and 15 % PEG2000-CL were required to allow hydrogel formation, and these 
only formed stable features after 24 h incubation at 37 °C. Considering that the 
globular protein bovine serum albumin (BSA) is a major component of FBS, it is 
plausible that the BSA aids hydrogel formation due to the many primary amines 
present in its structure, resulting in increased imine cross-linking and explaining the 
improved hydrogel formation in FBS-containing media 
To assess the capacity for 3D cell encapsulation within the imine hydrogels, HeLa 
cells were incubated within hydrogel 8 (see Table 2.1 for composition) and stained 
with Hoechst (nuclei stain) and CellTracker® CMPTX (cytoplasm stain). Good 3D cell 
encapsulation within the hydrogel to a depth of 75 µm indicated the promising use 







Figure 2.5: HeLa cells stained with Hoechst (λex/em = 361/497 nm) and CellTracker Red 
CMTPX (λex/em = 577/602 nm) were encapsulated within a hydrogel made-up of RGD (2.5 % 
w/v), LamIII (2.5 % w/v) and PEG2000-CL (15 % w/v) in FBS-free DMEM followed by 
incubation for 48 h. Merge = merge of Hoechst and CellTracker Red CMTPX images. Scale bar 
100 µm. 
 
2.3 Hydrogel Array Fabrication 
 
2.3.1 Initial Hydrogel Printing and Slide Functionalisation  
After confirming hydrogel formation using the synthesised components, a strategy 
for array fabrication was developed. For the first printing trials, combinations of 
LamIII and PEG2000-CL were used as a model system and printed with a drop-on-
demand sciFLEXARRAYER s5 inkjet printer. For printing, each component was 
dissolved in water and printed layer-by-layer in varying ratios. To determine the 
optimal ratios/concentration of each component, different % solutions were tested. It 
was found that concentrations higher than 2.5 % resulted in poor droplet formation 
for both LamIII and PEG2000-CL. 
 
The optimal printing parameters for the array was investigated, initially with each 
feature printed as a single spot (Figure 2.6A). Since LamIII and PEG2000-CL were 
printed at very low concentrations, no hydrogels formed during printing. However, 
drying and subsequent addition of cell media to spots on the slides where hydrogel 
components were printed resulted in hydrogel formation, but these small features 
lifted once the whole glass slide was submerged in cell media. Therefore, a pattern 
was designed where each feature was made up of “four spots” arranged as a 2×2 




into a single feature during printing. After printing of LamIII and PEG2000-CL and 
drying of the slide, DMEM cell media was printed onto the larger features, resulting 
in hydrogel formation. However, when the whole slide was submerged in cell media, 
the hydrogels lifted, and thus a strategy to allow hydrogel attachment to the glass 
surface was required.  
 
 
Figure 2.6: Printing patterns used for the hydrogel array using an inkjet printer. A. Pattern 
where each feature is made up of one spot of 1000 drops. B. Pattern where each feature is 
made up of four spots (each 400 drops) that merge upon printing. Pitch distance between 
adjacent spots was 0.6 × 0.6 mm in both A. and B. Images are screenshots from the 
sciFLEXARRAYER s5 software. 
 
Several different functional groups on glass slides were tested for their ability to allow 
hydrogel anchoring (Figure 2.7). Initially printing onto standard microscope glass 
slides with hydroxyl (OH) functional groups on the surface was investigated. A 
method developed within the Bradley group was used (Figure 2.7A),127 where an 
aqueous sucrose solution was printed in the pattern desired for the final hydrogel 
array and dried. A fluorous mask across the remaining area was created by treating 
the glass surface with (tridecafluoro-1,1,2,2-tetrahydrooctyl)-1-dimethylchlorosilane 
(FDS). Removal of the sugar mask creates confined areas for the hydrogels features, 
surrounded by a fluorous surface that limit non-specific cell attachment.  
 
Using this masking method, a combination of LamIII and PEG2000-CL were printed, 
after which the slide was dried at 40 °C overnight, before being submerged in FBS-




rapidly detached from the slide. This suggested that the hydroxyl-functionalisation 
on the glass slide was insufficient to keep the hydrogels attached to it. Therefore, 
primary amine groups on the glass surface were investigated for their ability to 
provide improved hydrogel anchoring, as imine bond formation with the PEG-CLs 
and the glass surface would be possible. Two methods of primary amine surface 
functionalisation were evaluated, using standard microscope glass slides with (3-
aminopropyl)triethoxysilane (APTES) or using commercially available 
aminoalkylsilane-functionalised glass slides. 
 
In the first method, following sucrose patterning, FDS treatment and sucrose 
removal, APTES was reacted in the exposed areas to afford primary amine 
functionalisation (Figure 2.7B). Using this method, LamIII/PEG2000-CL features were 
printed and dried, followed by submerging the slide in DMEM (both with and 
without 10 % FBS). This resulted in hydrogels forming on the slide, but most of the 
features had detached after overnight incubation both with and without FBS in the 
DMEM. In the second method, commercially available primary amine functionalised 
slides were used (SilanePrep slides, aminoalkylsilane functionalisation) (Figure 2.7C) 
and printing the same LamIII/ PEG2000-CL features, followed by drying and 
rehydrating in DMEM without FBS, uniform and stable hydrogels formed that stayed 
intact on the slide after overnight incubation at 40 °C. When the DMEM was 
supplemented with 10 % FBS, however, the features immediately lifted. Based on 
these results, it was decided to continue subsequent array printing using the 





Figure 2.7: Different glass surface functionalisation methods investigated to improve imine hydrogel anchoring to glass slides. A. (i) 20 % aqueous sucrose 
(orange sphere) patterning onto a standard microscope glass slides. (ii) Functionalisation of the remaining areas with FDS, overnight. (iii) Washing with 
water to remove the sucrose. B. (i), (ii) and (iii) as in A. (iv) Functionalisation of the previously sucrose-covered areas with APTES overnight, followed by 
washing with ethanol and water. C. Printing directly onto aminoalkylsilane functionlised slides. D. (i) 20 % aqueous sucrose patterning onto 
aminoalkylsilane functionalised slides. (ii) Functionalisation of the remaining areas with PFOA using EDC, N-hydroxysuccinimide, DIPEA, DCM, 1 hr, 
r.t. (iii) Washing with water to remove the sucrose. FDS = (tridecafluoro-1,1,2,2-tetrahydrooctyl)-1-dimethylchlorosilane. APTES = (3-




Arrays with 30 features (n = 3) made up of different ratios of RGD, PEG2000-CL and 
(PEG-NH2)4 (see Appendix Table A1.1, HG1-HG30 for compositions) were printed 
and incubated with HeLa cells overnight to assess the compatibility of the array 
format with cell encapsulation. Since DMEM containing FBS caused the hydrogels to 
lift, the DMEM used for cell incubation was supplemented with a serum-alternative, 
Knock-Out™ Serum Replacement (KOSR, Gibco™). KOSR is a FBS-free and more 
defined serum supplement that is commonly used for stem cell cultures (e.g. 
pluripotent stem cells cultured on feeder layers), but can be used for any cell type as 
a replacement for FBS. Supplementing the DMEM with KOSR did not cause the 
hydrogel features to lift from the glass slides. After overnight HeLa incubation, cell 
viability was assessed using fluorescein diacetate/propidium iodide (FDA/PI) 
staining. Although cell viability was high for most features, a high level of 
background cell binding to the glass surface was observed (Figure 2.8A). It was 
therefore decided to develop a capping method to create a fluorous mask analogous 
to the FDS treatment previously described.  
 
To create a fluorous mask and thus creating confined areas for the hydrogel features, 
an amide coupling strategy was chosen. On an aminoalkylsilane-functionalised glass 
slide patterned with sucrose, the N-hydroxysuccinimide (NHS)-ester of 
perfluorooctanoic acid (PFOA) was reacted with the primary amines in the remaining 
areas to result in amide bond formation (Figure 2.7D). HeLa cells were then seeded 
on test arrays printed on either non-functionalised aminoalkylsilane slides (Figure 
2.7C) or on the perfluorooctanoic acid-functionalised glass slides (Figure 2.7D). After 
overnight incubation and viability staining (FDA/PI) a clear reduction in background 
cell binding was observed on the perfluoroocotanoic acid-functionalised slides 
compared to the non-functionalised slide (Figure 2.8B). For all subsequent hydrogel 






Figure 2.8: Effect of the capping of aminoalkylsilane glass slides with perfluorooctanoic acid 
on non-specific HeLa cell attachment. A. HeLa cell attachment on the hydrogel and on the 
aminoalkylsilane glass slide, demonstrating high levels of unspecific cell attachment. B. 
Reduction of unspecific HeLa cell attachment on the perflurooctanoic acid functionalised glass 
slide. Scale bar 200 µm. Scale bar of cut-out 100 µm. Right: Quantification of cells/mm3 in 
terms of non-specific cell attachment (cells attached outside hydrogel area) in Image A and B.  
 
2.3.2 Hydrogel library screening 
Having developed a method for hydrogel array printing, 250 hydrogels (n = 3) were 
inkjet fabricated (HG1–HG250, see Appendix Table A1.1) and investigated for their 
ability to form stable hydrogels and facilitate cell encapsulation. By combining 
different ratios of the components different hydrogels were generated. Compositions 
with only RGD or LamIII as the peptide component, as well as the combination of the 
two peptides (RGD/LamIII) were printed. These were then cross-linked with either 
PEG2000-CL or PEG3000-CL to form hydrogels. Finally, (PEG-NH2)4 was also added to 
some of the features to promote hydrogel cross-linking and feature stability. Each was 
printed as 2×2 spots (1600 drops in total, 400 drops/spot, ~300 pL/drop) and on each 
glass slide a maximum of 96 features could be printed (16 rows × 6 columns)  After 
drying the slide and submerging it in media containing cells, arrays of uniform 3D 






Figure 2.9: Strategy for hydrogel array printing. Hydrogel components were dissolved in 
water (2.5 % w/v) and printed sequentially onto a masked glass slide to form hydrogel 
features. Each feature was printed as a 2×2 square composed of four spots that merged 
together. (400 drops/spot, 1600 drops in total). Feature diameter was around 1000 µm and the 
distance between features was 1800 µm. On one glass slide a maximum of 96 features were 
printed. Right: colour image of a dried hydrogel array. 
 
As an initial array, HeLa cells were incubated overnight, which resulted in cell 
encapsulation with high viability (as analysed by FDA/PI staining) (Figure 2.10, for 
all features see Appendix Figure A1.1). The number of cells/mm3 could be calculated 
by counting the cells per feature and approximating the hydrogel volume to that of a 
semi-ellipsoid (Figure 2.11). The radii of each feature were measured by analysing 
their BF images in ImageJ and the height of each hydrogel was estimated to be 200 
µm. This was chosen as an average height after measuring the height of features in 






Figure 2.10: Examples of hydrogels from the 250-member hydrogel array screen with HeLa 
cells incubated on the array for 18 h followed by viability staining with FDA (green, live stain, 
(λex/em = 490/514 nm) and PI (red, dead stain, λex/em = 570/602 nm). The merged images of the 




Figure 2.11 Approach to calculate the volume of the hydrogels on the array. The volume of 
each hydrogel was approximated to that of a semi-ellipsoid, with r1 and r2 measured from the 
microscopy images acquired by hydrogel array analysis. The height (r3) of each hydrogel was 





To rank the hydrogels in terms of physical stability, each feature was given a 
morphology grade from 0-5 (with 5 being the highest) (see Figure 2.12 for an example 
of each grade).  
 
Figure 2.12:  Representative bright-field images of each morphology grade assigned to 
hydrogel features.  Grade 0 was given to features that had lifted from the glass slide.  Grade 5 
was given to the most promising hydrogel features in terms of stability and 3D cell 
encapsulation capacity. Scale bar 200 µm. 
 
Each feature was then analysed both for cells/mm3 and morphology grade (see 
Appendix Figure A1.3 for all combinations individual results). To further understand 
the factors that drove hydrogel formation between the different components and 
which of these combinations lead to better morphology and cell attachment several 
analyses were done (Figure 2.13A-G). Firstly cells/mm3 was plotted against 
morphology grade (Figure 2.13A) to examine whether a higher morphology grade 
equated to higher cell attachment. The effect on morphology and cell attachment of 
hydrogels containing either RGD or LamIII or a combination of the two peptides was 
also assessed (2.13B-D). Furthermore, the effect of using either PEG2000-CL or PEG3000-




(Figure 2.13E-F). Finally, the effect on cell attachment and hydrogel morphology by 
































Figure 2.13: Hydrogels from the 250-member hydrogel array screen with HeLa analysed based on their component make-up. A. All combinations of 
hydrogels plotted as HeLa/mm3 vs morphology grade. B. Combinations with RGD as the peptide component (i) HeLa/mm3 vs RGD (nmol) (ii) 
morphology grade vs RGD (nmol). C. Combinations with LamIII as the peptide component (i) HeLa/mm3 vs RGD (nmol) (ii) morphology grade vs RGD 
(nmol). D. Combinations with both RGD and LamIII as the peptide component (i) HeLa/mm3 vs %mol RGD to LamIII (ii) morphology grade vs %mol 
RGD to LamIII. E. Combinations with PEG2000-CL as the cross-linker (i) HeLa/mm3 vs molar % ratio of peptide (RGD and/or LamIII) to PEG2000-CL (ii) 
morphology vs molar % ratio of peptide (RGD and/or LamIII) to PEG2000-CL. F. Combinations with PEG3000-CL as the cross-linker (i) HeLa/mm3 vs molar 
% ratio of peptide (RGD and/or LamIII) to PEG3000-CL (ii) morphology vs molar % ratio of peptide (RGD and/or LamIII) to PEG3000-CL. G.  (i) HeLa/mm3 
and (ii) Morphology grade both plotted against combinations with or without (PEG-NH2)4. For all graphs binning of n = 10 was used and with ± s.e.m. 
See Appendix Table A1.1 for a full list of hydrogel compositions. 
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Based on the assessment of cells/mm3 and hydrogel morphology, 82 hydrogels with 
a morphology grade ≥ 1 were chosen to fabricate a “hit array” and screened with 
HUVEC (see Appendix Table A1.2). After 24 h incubation, viability staining (FDA/PI) 
indicated that high viability was observed on most hydrogels (Figure 2.14, for all 
hydrogel features see Appendix Figure A1.2) with HUVEC encapsulation within the 
hydrogels ranging from 0–550 cells/mm3 (see Appendix Figure A1.4 for individual 
results of all hydrogels). As with the HeLa array the effect of the different components 
on hydrogel morphology and cell attachment was analysed (Figure 2.15). Based on 
these results scale-up studies of identified “hit hydrogels” were carried out using 
both immortalised and primary HUVEC, as discussed in Chapter 3.  
 
 
Figure 2.14: Examples of hydrogels from the 82-member hydrogel array screen with HUVEC 
cells incubated on the array for 18 h followed by viability staining with FDA (green, live stain, 
(λex/em = 490/514 nm) and PI (red, dead stain, λex/em = 570/602 nm). The merged images of the 






























Figure 2.15: Hydrogels from the 82-member hydrogel array screen with HUVEC analysed based on their component make-up. A. All combinations of 
hydrogels plotted as HUVEC/mm3 vs morphology grade. B. Combinations with RGD as the peptide component (i) HUVEC/mm3 vs RGD (nmol) (ii) 
morphology grade vs RGD (nmol). C. Combinations with LamIII as the peptide component (i) HUVEC/mm3 vs RGD (nmol) (ii) morphology grade vs 
RGD (nmol). D. Combinations with both RGD and LamIII as the peptide component (i) HUVEC/mm3 vs %mol RGD to LamIII (ii) morphology grade vs 
%mol RGD to LamIII. E. Combinations with PEG2000-CL as the cross-linker (i) HUVEC/mm3 vs molar % ratio of peptide (RGD and/or LamIII) to PEG2000-
CL (ii) morphology vs molar % ratio of peptide (RGD and/or LamIII) to PEG2000-CL. F. Combinations with PEG3000-CL as the cross-linker (i) HUVEC/mm3 
vs molar % ratio of peptide (RGD and/or LamIII) to PEG3000-CL (ii) morphology vs molar % ratio of peptide (RGD and/or LamIII) to PEG3000-CL. G.  (i) 
HUVEC/mm3 and (ii) Morphology grade both plotted against combinations with or without (PEG-NH2)4. For all graphs binning of n = 10 was used and 






In this chapter, the development of a hydrogel array, using reversible cross-linking, 
while allowing for 3D cell encapsulation has successfully been demonstrated. Using 
biologically relevant hydrogel components makes this system highly biocompatible, 
as indicated by the FDA/PI staining of the cells on the arrays. Hydrogels were formed 
by inclusion of ECM-based peptides (RGD and LamIII). The use of PEG-based cross-
linkers was made because of their current wide use in biomaterials and proven 
biocompatibility.142 Using materials already approved by regulatory bodies simplifies 
the potential future use of these materials for regenerative medicine or in vivo 
applications. 
 
The initial formation of these hydrogels when tested in Eppendorf tubes occurred at 
quick time-scales (around 30 s, although this was concentration dependent) and 
formed under physiologically relevant conditions (pH 7, 37 °C). Their formation was 
also done in cell media, important for in situ cell encapsulation where cells can be 
suspended in one of the component solutions prior to hydrogel formation. 
Furthermore, the fact that the hydrogels were relatively clear facilitated their 
imaging. A common hurdle for 3D cell culture, whether using scaffolds or softer 
hydrogel structures, is the usually opaque nature of materials. This makes imaging in 
3D difficult and thus limits their compatibility with methods such as fluorescence 
microscopy or high-throughput apparatus. 
 
The presence of FBS in the cell media used for component solvation seemed to aid in 
hydrogel formation. However, it was later found that FBS caused detachment of 
hydrogel features from the glass slides used for array fabrication. FBS is a necessary 
supplement for conventional cell culture as it provides molecules necessary for cell 
growth, proliferation, metabolism and spreading.143–145 Examples of these molecules 
include growth factors, hormones, lipids, minerals and transport proteins to name 
but a few. However, the animal-derived nature along with its poorly defined nature 
and batch-to-batch variability makes FBS a poor supplement to use for sensitive cell 
cultures where very little variability in components can be tolerated. In fact, FBS-free 





cell cultures such as for pluripotent stem cells.146,147 Therefore, the incompatibility of 
FBS with the hydrogel array platform is not a major concern.  
 
Surface functionalisation of the glass slides was necessary to allow for the hydrogels 
to anchor properly to the surface. The strategy used in this work is similar to the 
previously deployed strategies within the Bradley group using APTES 
functionalisation. However, the amide coupling strategy of forming the NHS-ester of 
perfluorooctanoic acid followed by EDC amide coupling with the primary amines of 
aminoalkylsilane-functionalised glass slides had not been utilised before. APTES 
functionalisation is usually done by overnight incubation, but the perflurooctanoic 
acid amide coupling only required one hour for completion, shortening the overall 
time for array fabrication. 
 
The pattern designed for fabricating the hydrogel array by ink-jet techniques allowed 
for the printing of 96 features onto one glass slide. Although this is fewer features 
than previously reported by the Bradley group for ink-jet printed arrays, the need for 
printing larger features was necessary for several reasons. Firstly, it was found that 
printing smaller features (~ 250 µm in diameter) resulted in them detaching upon 
submerging the slide in cell media. Furthermore, it can be argued that to achieve 3D 
cell encapsulation larger features are necessary that allows for greater cell numbers 
per feature, and facilitate cell-cell interaction and communication characteristic for 
3D cell environments. The hydrogels formed had diameters ranging from 0.8-1.5 µm 
and average heights of 200 µm. By assuming semi-ellipsoid geometries, the volume 
of each feature could be calculated, resulting in a range from around 250-500 nL (for 
more detail see Figure 3.3).  
 
The hydrogels were very soft in nature, allowing the cells to migrate throughout the 
materials. To be able to assess the 3D cell behaviour during the array screen is very 
important when choosing which hydrogels to progress for scale-up and further 
experiments. Furthermore, the drying of features and rehydrating in cell media with 
cells eliminates the need for simultaneous array fabrication and cell seeding. This is 
favourable in terms of handling, storage and transport of the arrays, but would also 






The initial screen of the 250-member hydrogel library with HeLa cells showed good 
cell compatibility of the majority of combinations of components printed with little to 
few dead cells. (see Appendix Figure A1.1 for FDA/PI staining of all features). Based 
on counting the number of viable cells per feature and considering the morphology 
grade given some conclusions could be made (Figure 2.13A-G, see also Appendix 
Figure A1.3 for graphs with cells/mm3 and morphology grades of each feature). 
Firstly, a trend of combinations with higher morphology grade resulting in increased 
cell attachment was observed (Figure 2.13A), which was to be expected. Examining 
combinations only containing RGD (Figure 2.13B) or LamIII (Figure 2.13C) indicated 
that for combinations with RGD, cell attachment varied stochastically with increased 
RGD mol content and cell attachment dropping below 100 cells/mm3 only above 13 
nmol (Figure 2.13A-i). In contrast combinations with only LamIII showed cell 
attachment of £ 100 cells/mm3 already at ³ 7 nmol LamIII, indicating that higher 
levels of the LamIII peptide resulted in lower cell attachment compared to higher 
levels of the RGD peptide. Furthermore, a trend of higher mol content of LamIII 
resulting in poorer hydrogels was observed (Figure 2.13C-ii), while higher 
morphology scores were observed for similar levels of RGD content (Figure 2.13B-ii). 
In fact, out of the 60 compositions containing only RGD, 43 formed hydrogels while 
17 combinations washed away upon media addition to the array. Out of the 60 
combinations with only LamIII however, only 34 formed hydrogels, further 
suggesting that RGD facilitated hydrogel formation better than LamIII. The 
combinations containing both RGD and LamIII showed little variation in both cell 
attachment and morphology grades as the mol% of RGD to LamIII increased from 0-
100 %(Figure 2.13D). The highest cell attachment was observed for combinations with 
80-90 mol% RGD to LamIII, indicating higher cell attachment with the RGD peptide, 
although this was expected considering the integrin-binding motif of RGD (note that 
no combinations with 90-100 mol% RGD relative to LamIII were printed for this 
array).  
 
For hydrogel combinations with either PEG2000-CL or PEG3000-CL as the cross-linker, 
clear cut-offs for hydrogel formation (indicated by morphology grade = 0) were 
observed (Figure 2.13E-ii and 2.13F-ii). At molar ratios between the cross-linker and 





respectively no hydrogels formed. Consequently, the cell attachment also decreased 
for both cross-linkers as the molar ratio of peptide to cross-linker increased (Figure 
2.13E-i and 2.13F-i). Thus, any further hydrogel formation with these components 
should use molar ratios between cross-linker and peptide below those identified 
herein. Combinations with or without (PEG-NH2)4 showed similar levels of both cell 
attachment and morphology (Figure 2.13G), suggesting that increased amount of the 
tetra-cross-linker would be necessary for future arrays to gain further feature 
stability.  
 
For the HUVEC screen of 82 hydrogel features identified in the HeLa screen, high 
levels of viability were also observed (Figure 2.14, see Appendix Figure A1.2 for 
FDA/PI staining of all features) and doing similar analysis of component effect on 
cell attachment as for the HeLa screen revealed that cell attachment was similar across 
morphology grades (Figure 2.15A) apart from those with morphology grade < 0.5. It 
should also be noted that although the hydrogels for the “hit array” were chosen 
based on having morphology grade ≥ 1 in the HeLa screen some hydrogels did exhibit 
lower morphology grades in the HUVEC screen. This could be due to the different 
media used for this screen (Medium 200) compared to the HeLa screen (DMEM) 
seeing as a stabilising effect on hydrogels due to the media composition is possible. It 
could also, however, indicate that hydrogels do not form identical each time on the 
glass slide, particularly when the structures are relatively poor.  
 
No clear trends to hydrogels with either only RGD or LamIII as the peptide 
component or those with both peptides (Figure 2.15B-D) was observed in terms of 
HUVEC attachment or hydrogel morphology. For the “hit array” only hydrogels with 
a molar ratio of cross-linker to peptide(s) < 1:10 were chosen for both PEG2000-CL and 
PEG3000-CL (Figure 2.15E-F). The main discernible trend for these combinations was 
the higher morphology grade of hydrogels with molar ratio of peptide(s) to PEG3000-
CL £ 1:2. Finally, as with the HeLa screen, no effect on cell attachment or morphology 
grade was observed for hydrogels containing (PEG-NH2)4 compared to those that did 
not (Figure 2.15G). 
 
Overall, the results in this chapter demonstrated the successful screen of novel imine 





fabrication and HTS to find which combinations of components that formed stable 
hydrogel features and their capacity for cell encapsulation. The subsequent “hit 
array” screen with HUVEC identified novel 3D matrices that could support 




A new method for the array fabrication of dynamic imine cross-linked hydrogels as 
novel cell culture matrices was developed, adding to the already vast family of 
polymer-based microarrays developed within the Bradley group. Using a 
combination of ECM-based peptides and PEG-based cross-linkers, 250 different 
dynamic hydrogels were fabricated (formed via reversible imine bond formation) and 
screened with HeLa cells to assess the feature stability and cell compatibility. Further 
screening of a “hit array” of 82 hydrogels with HUVEC enabled the selection of 
materials to scale-up for further studies (see Chapter 3). Overall, the results 
demonstrate the capacity of these imine cross-linked hydrogels to form stable 3D cell 
culture matrices that enable 3D cell encapsulation. Considering their facile high-
throughput fabrication, ease of handling and efficient cell encapsulation, this 
approach is highly attractive for a range of future cell-based applications.  
 
2.6 Materials and Methods  
 
2.6.1 Instruments used for array fabrication 
 
Scienion S5 SciFLEXARRAYER equipped with a Piezo Dispense Capillary PDC 80 
with a 50 µm aperture (Scienion AG, Germany) 
 
2.6.2 Instruments for cell experiments and analysis 
 
HERAcell 150 incubator (Heraeus, Germany) 
 








2.6.3 Imaging instruments 
 
Axiovert 200m inverted fluorescence microscope with Axiovision 4.8 software (Carl 
Zeiss AG, Germany). Filters: DAPI (λex/em = 300-395/430-505 nm), GPC/FITC (λex/em 
=  447-494/500-554 nm), YPF (λex/em = 490-512/520-554 nm), TRITC/Rhodamine/Cy3 
(λex/em = 527-563/570-650 nm) and Cy5 (λex/em = 620-659/663-725 nm) filters. 
Magnification: x10, x20 and x40  
 
Leica SP5 confocal microscope (Leica Camera AG, Germany) 
 
Image analysis was carried out in ImageJ 
 
2.6.4 Instruments for characterisation and purification 
 
Agilent 1100 ChemStation analytical RP-HPLC (Agilent, USA) with a Zorbax Eclipse 
C18 reverse phase column (4.6 mm × 100 mm, 3.5 µ) with an evaporative light 
scattering and a multi-wavelength detector eluting with a gradient of water to 
acetonitrile (5 – 95 %), both with 0.1% formic acid with a flow rate of 1 mL/min 
 
Agilent 1100 GPC equipped with a PLgel MIXED-C columns and a RI detector eluting 
with DMF containing 0.1M LiBr at 60 °C at 1 ml/min (Agilent, USA) 
 
Isolera One equipped with a Biotage® SNAP HP-BioSphere C18 10 g column 
detection at 250 nm, eluting with a gradient of water to acetonitrile, both with 0.1 % 
formic acid with a flow rate of 12 ml/min (Biotage, Sweden) 
 
BenchTop Pro with Omnitronics lyophiliser (SP scientific, USA) 
 
1H NMR at 500 MHz Bruker AVA 500 (Bruker, USA) 
 






HRMS on a Bruker 3.0 T Apex II spectrometer (Bruker, USA) 
 
2.6.5 Chemicals  
 
All protected amino acids, aminomethyl polystyrene resin, and the Fmoc-Rink amide 
linker were purchased from GL Biochem Ltd (Shanghai) or NovaBiochem. 
Poly(ethylene oxide), 4-arm, amine terminated ((PEG-NH2)4) (Mn = 10 000 g/mol), 
was purchased from Sigma Aldrich. All other chemicals were from Sigma Aldrich or 
Acros, and used as received. 
 
2.6.6 Cells, media and biological equipment 
 
HUVEC were donated by Dr Kate Cameron (University of Edinburgh) 
 
Complete DMEM: DMEM, 10% v/v FBS, 1% v/v penicillin/streptomycin and 1% 
v/v 200 mM glutamine 
 
Complete Medium 200: Medium 200, Low Serum Growth Supplement (LSGS) kit 
(Thermo Fisher, USA) 
 
2.6.7 Cell Culture on Tissue Culture Polystyrene  
 
HeLa cells were cultured in complete DMEM. HUVEC were cultured in complete 
Medium 200. Cells were grown to 70–80% confluency in T25 flasks (37 °C, 5% CO2) 













2.6.8 Synthesis of PEG2000-CL 
 
4-Formylbenzoic acid (600 mg, 4 eq.), DCC (1.03 g, 5 eq.) and DMAP (489 mg, 4 eq.) 
were dissolved in anhydrous THF (140 mL, 0.1 M) and stirred at room temperature 
under a N2 stream for 15 min. Poly(ethylene glycol) (Mn = 2000 g/mol) (2.0 g, 1 eq.) 
was added to the reaction mixture and stirred at room temperature under N2 
overnight.  The reaction mixture was concentrated in vacuo and the residue was 
dissolved in MeOH (the minimal volume required). The product was precipitated by 
the addition of diethyl ether followed by centrifugation and decanting (repeated 
thrice). The precipitate was dissolved into deionised water (50 mL) and freeze-dried 
to obtain the product as a white waxy solid (1.53 g, 77 %). 1H NMR (500 MHz, CDCl3) 
δ 10.13 (s, 2H, CHO), 8.24 (d, J = 8.3 Hz, 4H, CHCCHO), 7.98 (d, J = 8.0 Hz, 4H, 
CHCHCCHO), 4.56 – 4.51  (m, 4H, COOCH2), 3.90 – 3.85 (m, 4H, COOCH2CH2), 3.68 
– 3.64 (m, 160H, OCH2CH2O). IR (neat) ν (cm-1) = 2880, 1705, 1466, 1096.  
 
2.6.9 Synthesis of PEG3000-CL 
 
The method was as for PEG2000-CL. Amounts and equivalents used: 4-Formylbenzoic 
acid (400 mg, 4 eq.), DCC (688 mg, 5 eq.) and DMAP (326 mg, 4 eq.), Poly(ethylene 
glycol) (Mn = 3000 g/mol) (2.0 g, 1 eq.), anhydrous THF (90 mL, 0.1 M). Yield: 1.41 g, 
70 %. 1H NMR (500 MHz, Chloroform-d) δ 10.09 (s, 2H, CHO), 8.20 (d, J = 7.9 Hz, 4H, 
CHCCHO), 7.94 (d, J = 7.9 Hz, 4H, CHCHCCHO), 4.55 – 4.51 (m, 4H, COOCH2), 3.88 
– 3.85 (m, 4H, COOCH2CH2), 3.63 (s, 268H, OCH2CH2O). IR (neat) ν (cm-1) = 2877, 






2.6.10 Solid Phase Peptide Synthesis 
 
H-Ahx-GRGDSK-NH2 (RGD) and H-Ahx-YIGSRK-NH2 (LamIII) were synthesised on 
solid-phase using the Fmoc/tBu route.148 The Fmoc-Rink amide linker was coupled 
to the aminomethyl polystyrene resin (1 g, loading 0.745 mmol/g) prior to peptide 
synthesis. 
Coupling of the protected Rink linker and protected amino acids. Fmoc-Rink or 
Fmoc-protected amino acids (3 eq.) and Oxyma (3 eq.) were dissolved in DMF (1 M) 
and stirred for 5 min followed by the addition of DIC (3 eq.) and further stirred for 5 
min. The mixture was added to the resin and shaken at room temperature for 1 hour. 
The resin was washed with DMF, MeOH and DCM. 
Fmoc deprotection. The N-Fmoc protected peptide on the resin was treated twice with 
20 % piperidine in DMF for 10 minutes. The resin was subsequently washed with 
DMF, MeOH and DCM. 
Deprotection of the peptide and cleavage off the resin. TFA/H2O (95:5) was added to 
the pre-swollen resin (in DCM) and shaken at room temperature for 3 h. The peptide 
was precipitated from the filtrate by the addition of cold diethyl ether, collected by 
centrifugation and washed twice with ether. The peptides were re-dissolved in H2O 
(10 mL) and purified by RP-HPLC (Biotage Isolera) (5% to 20 % MeCN/H2O over 20 
min, 20 % to 95 % MeCN/H2O over 5 min, 95 % MeCN/H2O over 1 min and 95 % to 
5 % MeCN/H2O over 1 min) followed by lyophilisation. RGD (480 mg, 88 %). LamIII 
(375 mg, 60 %). The peptides were analysed by RP-HPLC were > 95 % purity and 
HRMS (RGD m/z calculated 730.4086, m/z found 730.4127, LamIII m/z calculated 834.5076, m/z 
found 835.5146). 
 
2.6.11 Hydrogel bulk formation 
 
Solutions of RGD (5% w/v), LamIII (5 or 15% w/v), PEG2000-CL (10 or 30% w/v), 
PEG3000-CL (30% w/v) and (PEG-NH2)4 (10% w/v) were prepared in complete 
DMEM or in FBS-free DMEM. The components were gently mixed (see Table 2.1) 
(total volume 30 or 40 µL), and allowed to stand for 30 s at room temperature to allow 





and after 1 h and 24 h incubation at 37 °C. The pHs of the hydrogels were evaluated 
using pH paper. 
 
2.6.12 HeLa cell encapsulation in an imine cross-linked hydrogel  
(2.5 % RGD, 2.5 % LamIII and 15 % PEG2000-CL)  
 
HeLa cells (1.25 × 106) were suspended in 2 mL of CellTracker® Red CMTPX (1 µL of 
10 mM stock in DMSO diluted with 2 mL serum-free DMEM) (λex/em = 577/602 nm) 
for 10 min (37 °C, 5% CO2) followed by centrifugation (1500 rpm, 5 min) and removal 
of staining the solution. The cell pellet was dissolved in 2 mL Hoechst staining 
solution (1 µL of 10 mg/mL stock diluted into 10 mL PBS) (λex/em = 361/497 nm) and 
incubated for 15 min (37 °C, 5% CO2) followed by centrifugation (1500 rpm, 5 min), 
removal of the supernatant and resuspension in 2 mL of media. Pre-stained HeLa 
cells (50 000 cells per hydrogel) were suspended in the LamIII solution (25 µL). 
Hydrogels (n = 3) prepared in a 96-well plate by mixing RGD (5 % w/v in FBS-free 
DMEM, 25 µL/well), LamIII (10 % w/v in FBS-free DMEM, 25 µL/well, with 50 000 
HeLa cells) and PEG2000-CL (30 % w/v in FBS-free DMEM, 50 µL/well). Following 
incubation (37 °C, 5% CO2) for 48 h imaging was carried out on a Leica SP5 confocal 
microscope. 
 
2.6.13 Inkjet printing with Scienion S5 SciFLEXARRAYER 
 
All printing was carried out in HPLC-grade water using a voltage range of 95-100 V 
and a pulse range of 45-50 µs, with droplet volumes of ~ 300 pl/drop. The pitch 
distance between the adjacent spots was 0.6 × 0.6 mm. Glass slides were either 
microscope glass slides slides (76 × 26 mm) (Menzel GmbH Co. KG, Braunschweig, 
Germany) or SilanePrep aminoalkylsilane-functionalised glass slides (76 × 26 mm) 
(SigmaAldrich).  
 
2.6.14 Optimisation of array printing patterns  
 
i) 1×1 printing pattern 
Aqueous solutions of LamIII (2.5 or 5 % w/v) and PEG2000-CL (2.5 or 5 % w/v) were 





2.5 % solutions were used. LamIII and PEG2000-CL solutions were printed sequentially 
at varying ratios (1000 drops total per feature) (n = 3). Following drying at 40 °C 
overnight, the slides were submerged in FBS-free DMEM. 
ii) 2×2 printing pattern 
Aqueous solutions of LamIII and PEG2000-CL were printed onto the slides as above in 
varying ratios. Each feature was made-up of four spots printed as a 2×2 square (400 
drops/spot) that merged when printed (see Figure 2.9). Following drying at 40 °C 
overnight, FBS-free DMEM was printed on top of each feature, resulting in hydrogel 
formation. The slide was then submerged in FBS-free DMEM. 
 
2.6.15 Optimisation of glass slide surface functionalisation 
 
i) Microscope glass slide with a flurosilane coating 
Microscope glass slides were plasma treated with an O2 plasma for 10 minutes at 1.5 
bar oxygen pressure. 20 features of aqueous sucrose (20 % w/v) were printed onto 
the slides with each feature printed as a 2×2 square (100 drops per spot) that merged 
when printed (See Figure 2.9). After drying at room temperature, tridecafluoro-
1,1,2,2-tetrahydrooctyl-dimethylchlorosilane (FDS) (5 µl/slide) was dropped onto 
five different areas of the slides (1 µl/drop) and reacted overnight in a sealed 
Tupperware box followed by washing of the slides with acetone (10 mL) and water 
(10 mL). The dried slides were coated with (3-aminopropyl)triethoxysilane (APTES)  
(10 µl/slide) by spreading with a pipette tip, and put into a sealed box, reacted 
overnight and then washed with water and ethanol before drying under N2 stream. 
Aqueous solutions of LamIII (2.5 % w/v) and PEG2000-CL (2.5 % w/v) were printed 
sequentially in varying ratios in the previously sucrose-masked 2×2 squares (400 
drops/spot). Following drying overnight at 40 °C, the slide was submerged in FBS-
free DMEM or complete DMEM. 
 
ii) Aminoalkylsilane-functionalised microscope glass slide 
Solutions of LamIII and PEG2000-CL were printed onto aminoalkylsilane 
functionalised glass slides (Sigma Aldrich) as 2×2 square features as described above. 
Following drying overnight in a 40 °C oven, the slide was submerged in FBS-free 






iii) Aminoalkylsilane-functionalised microscope glass slide with 
perfluorooctanoic acid functionalisation 
Features of 20% aqueous sucrose (w/v) were printed on aminoalkylsilane 
functionalised glass slides as 2×2 square features as explained above, and dried at 40 
°C for 2 h. Perfluorooctanoic acid (2.0 g, 4.8 mmol), EDC.HCl (926 mg, 4.8 mmol) and 
DIPEA (5.1 mL, 29 mmol) were dissolved in DCM (200 mL) and stirred for 5 min. N-
hydroxysuccinimide (556 mg, 4.8 mmol) was added and the mixture was stirred at 
room temperature for 45 min (final reaction concentration 0.2 M). The dried glass 
slides were immersed into this mixture and gently shaken for 1 h. The slides were 
washed with DCM, water (to remove the sucrose features) and ethanol. Following 
drying at room temperature, the slides were submerged in FBS-free DMEM or 
complete DMEM.  
 
2.6.16 HeLa incubation on test array  
 
Aminoalkylsilane glass slides without perfluorooctanoic acid 
functionalisation 
30 features (n = 3) of different ratios of aqueous solutions of RGD, PEG2000-CL and 
(PEG-NH2)4 (all 2.5 %) (see compositions HG1- HG30 in Appendix Table A1.1) were 
printed on aminoalkylsilane functionalised glass slides. Each feature was printed as 
a 2×2 square as described above. Following drying at 40 °C overnight, the hydrogel 
arrays were sterilised under UV light for 45 min using the UV source of a HERAsafe 
KS 18 class II biosafety cabinet (Heraeus, Germany) and then placed in 4-well slide 
dish (Nunc™). HeLa cells (525 000 cells/array) in 5 mL of DMEM (supplemented 
with 10% knock-out serum, 1% penicillin/streptomycin and 1% 200 mM glutamine) 
were added to each slide, resulting in in situ formation of hydrogels with cell 
encapsulation. Following incubation overnight (37 °C, 5 % CO2) the DMEM was 
removed, the slides washed with PBS (1×5 mL) and stained with Fluorescein diacetate 
(FDA) and propidium iodide (PI). 8 µL of FDA stock solution (5 mg/mL in acetone) 
and 50 µL of PI stock solution (2 mg/mL in PBS) were added to 5 mL of serum-free 
DMEM and added to each slide and incubated for five minutes in the dark at room 
temperature. The solution was removed, the slides washed with PBS (1 × 5 mL) and 





AxioVert 200m fluorescence microscope. Microscope lasers settings were: λex/em = 
447-494/500-554 nm for FDA, λex/em = 527-563/570-650 nm for PI. 
 
2.6.17 Hydrogel Array fabrication 
 
i) Preparation of masked glass slides 
96 features of 20% aqueous sucrose were printed on aminoalkylsilane functionalised 
glass slides using a sciFLEXARRAYER S5 printer (16 rows × 6 columns). Each feature 
was printed as a 2×2 square (400 drops/spot) as described above. The slides were 
dried at 40 °C for 2 h and functionalised with perflurooctanoic acid as described 
above. 
 
ii) Inkjet-printed hydrogel arrays 
2.5% solutions of peptides (RGD and LamIII), cross-linkers (PEG2000-CL, PEG3000-CL) 
and (PEG-NH2)4 were prepared in water and ink-jet printed on the masked glass 
slides. By varying the ratios of the components 32 different combinations (n = 3) were 
printed on each slide (96 features per slide). The slides were dried at 40 °C overnight, 
irradiated under UV light for 1h and stored at room temperature until use. For the 
hydrogel compositions on each array, see Appendix Tables A1.1 and A1.2.  
 
2.6.18 Encapsulation of cells on hydrogel arrays 
 
The hydrogel arrays were sterilised under UV light for 45 min and placed in 4-well 
slide dish (Nunc™). HeLa cells (500 000 cells/array) in 5 mL of DMEM 
(supplemented with 10% knock-out serum, 1% penicillin/streptomycin and 1% 200 
mM glutamine) were added to each slide, and incubated for 24 h (37 °C, 5% CO2) after 
which media was removed and the slides were stained with fluorescein diacetate 
(FDA) and propidium iodide (PI) as above and imaged with a Zeiss AxioVert 200m 
fluorescence microscope. For HUVEC (300 000 cells/slide), the encapsulation, 




Chapter 3: Identification and scale-up of an 
imine cross-linked hydrogel that supports 





The power of a HTSS platform is only truly realised if the materials used can be 
scaled-up to allow for larger and long-term studies to confirm and expand upon the 
results found in the HTSS. Therefore, it was necessary to develop a strategy for scaling 
some of the “hit” hydrogels from the array screen described in Chapter 2.  
 
When it comes to cell behaviour and hydrogels many parameters must be considered. 
Importantly, maintenance of cell viability in the presence of the material is crucial, as 
is demonstrating that the gene and protein expression profiles of the cell of interest 
displays the desired properties as an effect of hydrogel encapsulation/incubation. 
Hydrogels can be used to create both cultures to maintain cells in their original state 
e.g. maintain pluripotency of stem cells, or that causes a desired change in cell 
phenotype e.g. directed stem cell differentiation. In addition, if 3D cell encapsulation 
is enabled within the hydrogel, the cellular behaviour and organisation should be 
considered, to analyse the specific 3D cell construct generated and their differences 
in gene and protein expression, cell polarity and heterogeneity etc. compared to 
traditional monolayer culture. 17,51,149,150  
 
To demonstrate that the imine cross-linked hydrogels developed in this thesis were 
tuneable for different cell types, both immortalised HUVEC (referred to here as 
HUVEC) and primary HUVEC sourced from a single donor (referred to here as 
pHUVEC) were used. HUVEC are routinely used as a model for the angiogenic 
function of endothelial cells.151,152 HUVEC and pHUVEC differ in their in vitro 
behaviour however, with HUVEC capable of growing on TCPS over many passages 
(> 20) and are recognised by their cobble like shape and organisation (Figure 3.1A)151. 
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pHUVEC, on the other hand, are directly obtained from human donors. When 
cultured as a monolayer they are more rounded and less spread out compared to 
HUVEC (Figure 3.1B), and it is recommended that they are only kept in culture for a 
few passages (< 5), with their gene and protein expression profile changing due to the 
2D in vitro culture conditions.153 
 
 
Figure 3.1: Bright-field images of A. Immortalised HUVEC. B. Primary HUVEC. Scale bar 100 
µm.  
 
In this chapter is presented the scale-up studies of identified hit hydrogels from the 
screen in Chapter 2. After optimisation of the platform in which the hydrogels were 
formed, several parameters relating to cell behaviour were analysed, including cell 
viability, protein levels and gene expression and scanning electron microscopy (SEM) 
characterisation. Furthermore, material characterisation by rheology was carried out. 
 
3.2 Choosing hydrogels for scale-up 
 
After the hit hydrogel array screening with HUVEC (see Chapter 2), it was decided 
to scale up eight hydrogels (HG2, HG5, HG6, HG7, HG15, HG16, HG63 and HG80, 
see Appendix Table A1.2 for printing patterns) based on their hydrogel morphology 
grade and number of cells/mm3. The eight hydrogels chosen all had morphology 
grades ³ 3, apart from HG80 (grade 1.75), which was chosen based on its number of 





Figure 3.2: Hydrogels chosen for scale-up from the HUVEC hydrogel array screen. Left axis 
is the number of HUVEC encapsulated per mm3 on each hydrogel (black bars). Right axis is 
plotted the morphology score (scale 0-5, with 5 being the highest) (red dots). Mean with ±SEM 
is plotted in each instance, n = 3. 
 
The five components used for hydrogel array fabrication were all represented in the 
hits. All hits contained the RGD peptide, and six out of the eight (HG6, HG7, HG15, 
HG16, HG63 and HG80) contained both RGD and PEG3000-CL, indicating the 
favourability of the RGD and PEG3000-CL to form hydrogels with good morphology 
and high level of cell encapsulation. By approximating the hydrogel volume to that 
of a semi-ellipsoid as in Chapter 2 (see Figure 2.11), the % w/v of each hydrogel could 
be calculated (Table 3.1). The radii of each feature were measured by analysing their 
bright field images in ImageJ with the height of each hydrogel was estimated to be 
200 µm. This was chosen as an average height after measuring the height of features 










Table 3.1: Composition of hydrogels chosen for scale up as % w/v. The volume of each feature 
was estimated as a semi-ellipsoid (see Figure 2.11) The mass printed of each component was 




Component % (w/v) 
HG2 
RGD 1.1  
PEG2000-CL 1.9  
(PEG-NH2)4 0.4  
HG5 



























3.3 Scanning electron microscopy analysis 
 
To investigate the interaction between cells and hydrogels in more detail dry 
scanning electron microscopy (SEM) was carried out. The eight hit hydrogels were 
printed onto masked aminoalkylsilane glass slides followed by HUVEC 
encapsulation over 24 h. For SEM sample preparation, the cells were fixed and 
thereafter post-fixed with Osmium tetroxide (OsO4) for improved contrast. The 
hydrogels were then dehydrated in graded concentrations of acetone followed by 
critical point drying with liquid CO2, and finally mounted and sputter coated with 
gold/palladium before SEM analysis. Imaging showed cell attachment throughout 
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the gels, cell–cell interactions and formations of cell clusters, although the amounts of 
this differed across the sections of the different gels that were analysed (Figure 3.3). 
 
 
Figure 3.3: SEM image analysis of eight hit hydrogels encapsulated with HUVEC over 24 h. 








3.4 Optimising the hydrogel scale-up platform 
 
To scale-up the hydrogels, several different formats were attempted. Firstly, standard 
96-well plates or Ibidi µ-slide 8-well chamber slides with “coverslip-like bottoms”, 
useful for high-resolution microscopy and ease of sample preparation. However, 
these formats were unable to keep the hydrogels stable, and media change or staining 
caused significant hydrogel disruption. Forming the hydrogels in 96-well plates with 
amine-functionalised surfaces (Corning® PureCoat™) was also attempted to afford 
imine-linkage between the plate and the hydrogel, but this was still not sufficient to 
generate stable hydrogel features. Instead, an approach of scaling up the hydrogels 
on aminoalkylsilane-functionalised glass slides was attempted.  
 
 
Figure 3.4: Different platforms used for hydrogel formation. A. 16-well Pro Plate (Grace Bio-
Labs). Top and side view shown. B. 4-well silicone gasket (Grace Bio-Labs). Both A and B are 
fitted on to the top of aminoalkylsilane-functionalised glass slides.  
 
16-well Pro Plates (Figure 3.4A) were fitted on top of aminoalkylsilane slides and the 
chosen hydrogels formed inside and seeded with HUVEC. After incubation for four 
days, the cells were fixed and their nuclei stained with 4′,6-diamidino-2-phenylindole 
(DAPI). It was also attempted to stain with a cluster of differentiation 31 (CD31) 
antibody conjugated to fluorescein (FITC). CD31 is a cell adhesion protein found on 
endothelial surfaces and widely used as a endothelial cell marker.154 The antibody 
staining was not successful as the many incubation and washing steps required 
disrupted the hydrogels and cells dislodged from the structure. Based on these results 
an alternative approach to in situ hydrogel antibody labelling was used for future 
protein expression studies. For all eight hits, cell clusters formed within the hydrogels 
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(Figure 3.5), a stark contrast to the flat and stretched out shape of HUVEC observed 
when grown as a monolayer. 
 
  
Figure 3.5: Incubation of HUVEC within hydrogels for 4 days. The cell nuclei were stained 
with DAPI (λex/em = 358/461 nm). Note a high propensity for cell cluster formation was 
observed across all hydrogels. Scale bar 100 µm. 
 
After the initial 4-day incubation with HUVEC in the eight hit hydrogels, it was clear 
that the soft nature of these imine cross-linked hydrogels would require much 
optimisation for future staining protocols and analysis. As such, one of the eight 
hydrogels, HG15, was taken forward to optimise the protocols since it had emerged 
as the most stable hydrogel to handle and showed good 3D cell encapsulation 
morphology. All the following scale-up experiments in this chapter were thus done 
with HG15.  
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3.5 Investigating cell viability in HG15 
 
Firstly, the strategy to form HG15 was modified. Silicone gaskets of 1 mm thickness 
(Figure 3.4B) were chosen instead of the ProPlates, because the reduced height of the 
gaskets made it easier for microscope set-up and imaging. Using gaskets with 4 wells 
fitted on top of the aminoalkylsilane-functionalised glass slides, cell viability within 
HG15 was evaluated. HUVEC and pHUVEC were encapsulated into HG15, and the 
cells incubated for 4 and 30 days, after which cell viability was assessed by Calcein 
AM/PI staining (Figure 3.6).  
 
 
Figure 3.6: HUVEC viability analysis within HG15 with Calcein AM (live stain) (λex/em = 
488/515 nm) and PI (dead stain) (λex/em = 570/602 nm). A. HUVEC after 4-day incubation. B. 
HUVEC after 30-day incubation. C. Primary HUVEC after 4-day incubation. D. Primary 
HUVEC after 30-day incubation. PI = propidium iodide. BF = bright field. Merge = merge of 




For both incubations and cell types high cell viability was observed, with small 
numbers of dead cells within the gels. Cell clusters formed within 24 h of culture, 
indicative of the capacity of cells to move and interact within the 3D matrix. After 4 
days, both cell types showed a similar propensity for cluster formation with “ball-
like” and “string-like” clusters being formed. Interestingly the string-like clusters 
were observed to grow along the strands of the hydrogel network structure, showing 
the interaction between the cells and HG15, presumably via the RGD peptide (see 
Figure 3.6A and 3.6B).  
 
3.6 Protein expression analysis in HG15 
 
Following the confirmation of cell viability within HG15, protein expression was 
analysed. After encapsulation of HUVEC and pHUVEC within HG15 for 4 days, the 
cells were harvested and re-plated onto uncoated TCPS well plates. After 24 h 
incubation to allow for cell attachment, staining for CD31 was carried out. However, 
most cells detached from the well plates during the staining protocol. The cells that 
were still there though were positive for CD31 expression, and maintained the 






Figure 3.7: Immunofluorescent staining for CD31, a marker of HUVEC and primary HUVEC. 
Cells were incubated within HG15 for 4 days followed by re-plating on TCPS for 24 h. A. 
HUVEC B. primary HUVEC. Cells were stained with a CD31 primary antibody followed by 
an Alexa Fluor 568 secondary antibody (λex/em = 578/603 nm) shown in red in merge, and with 
DAPI nuclei stain (λex/em = 358/461 nm) shown in bluein merge. Scale bar 30 µm. 
 
Instead of immunofluorescence, immunohistochemistry (IHC) staining of hydrogel 
slices was attempted to visualise cells within the hydrogel structure and analyse 
protein expression. For IHC analysis of cells encapsulated within HG15, the 
hydrogels were incorporated into agarose and paraffin-embedded with subsequent 
sectioning for IHC analysis. Sections of HUVEC encapsulated in HG15 for four days 
were stained with haematoxylin and eosin (H&E staining) (Figure 3.8) to visualise the 
cell nuclei and cytoplasm of the cells respectively. The staining showed the presence 
of cell clusters within the hydrogel network, and also evidence of hollow areas within 
the cluster, similar to lumen observed in endothelial cells when developing new 





Figure 3.8: Haematoxylin and Eosin (H&E) staining of hydrogel sections. HUVEC were 
encapsulated in HG15 for four days and then embedded in agarose, paraffin-embedded, cut 
into slices and stained with Haematoxylin and Eosin Y, staining the cell nuclei and cytoplasm 
respectively. Two cell clusters are shown, with examples of nuceli indicated with red arrows. 
Black arrows indicate the presence of empty space, or lumina, in the clusters. Scale bar 20 µm.  
 
Thereafter, gel/cell sections were stained with protein markers for endothelial cells 
(CD31, VE-cadherin and von Willebrand factor (vWf)), proliferation (Ki-67) and 
apoptosis (cleaved caspase-3) (Figure 3.9A-D). Semi-quantitative analysis of 












Figure 3.9:  Immunohistological analysis of endothelial (CD31, VE-cadherin, vWf), 
proliferation (Ki-67) and apoptosis (cleaved caspase 3) markers in HUVEC and primary 
HUVEC after incubation in HG15 (4 or 30 days). Following cell incubation for the desired time 
point and cell fixation, the gels were embedded in agarose, paraffin-embedded, cut into slices, 
permeabilised and stained with primary and secondary antibodies and haematoxylin. 
Visualisation was done with 3,3-diaminobenzidine (DAB). Positive DAB staining is shown in 
brown and the nuclei counterstain in blue with haematoxylin. A. HUVEC 4 days. B. HUVEC 
30 days. C. Primary HUVEC 4 days. D. Primary HUVEC 30 days. E. Semi-quantitative 
evaluation of marker levels compared to a negative control (= no primary antibody staining 
with secondary antibody staining only) (images shown in Appendix Figure A2.1). Analysis 
was carried out in Image J using the colour deconvolution plug-in, H DAB vector. (−) = very 
low to no expression (+) = low expression, (++) = moderate expression, (+++) = high 






3.7 Gene expression analysis in HG15 
 
To supplement the protein expression analysis, gene expression was analysed by the 
quantitative polymerase chain reaction (qPCR).  Five genes relevant for endothelial 
cell expression were investigated (vWf, CDH5, PECAM-1, KDR and TEK). CDH5 is 
the gene encoding VE-Cadherin, while PECAM-1 encodes CD31. KDR encodes for 
the vascular endothelial growth factor receptor 2, which is expressed on endothelial 
cell surfaces. TEK encodes for angiopoietin-1 receptor, a tyrosine kinase receptor for 
angiopoietin 1 and 2, both growth factors involved in angiogenesis155. GAPDH was 
used as the housekeeping gene. 
 
Both HUVEC and pHUVEC were encapsulated in HG15 for 4 or 30 days. The 
hydrogels were then degraded with pyridoxal HCl and pyridoxamine 2 HCl (see 
Chapter 4 for more details and the protocol development) followed by cell harvesting, 
RNA isolation and qPCR analysis of the cDNA. To isolate enough RNA was a 
challenge throughout the project, and only results for the 4-day incubation time are 
presented in here since insufficient quantities of RNA were obtained to give reliable 
results for the 30-day incubation. Both cell types were compared to cells grown on 





Figure 3.10: qPCR analysis of endothelial markers in A. HUVEC and B. Primary HUVEC 
cultured in HG15, on TCPS or on a collagen gel. Gene expression relative to GAPDH 
(quantified as 2-(Ct(target gene)-Ct(GAPDH))). (n = 4, ± s.e.m) (****p ≤ 0.0001; ***p ≤ 0.001; **p ≤ 0.01; *p 
≤ 0.05) 
 
For HUVEC in HG15 high expression of vWf factor was observed, while no 
expression was observed on either TCPS or collagen. Similarly, for CDH5 and 
PECAM-1, HUVEC encapsulated in HG15 had significantly higher expression of 
these genes compared to both TCPS and collagen. The expression of KDR was low in 
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HUVEC encapsulated within HG15, but no expression was observed on TCPS or 
collagen. TEK was the only gene where expression down-regulated after 
encapsulation within HG15. For primary HUVEC all genes were downregulated after 
encapsulation within HG15, and expression of the endothelial markers were 
upregulated or similarly expressed on collagen compared to TCPS.  
 
3.8 Mechanical properties of HG15 
 
The mechanical properties of HG15 were analysed by oscillatory rheology. The 
results indicated very low elastic (2.6±0.66 Pa) and viscous (0.6±0.25 Pa) moduli, 
demonstrating the very soft nature of HG15. When increased concentrations of HG15 
were tested (HG15×2, HG15×5, see Figure 3.11 for details) an increase of elastic and 
viscous moduli was observed, indicating an expected increase in mechanical 
properties with increased hydrogel component concentration.  
 
 
Figure 3.11: Elastic (G’) and viscous (G’’) moduli of HG15 (2.4% RGD, 5.4% PEG3000-CL, 1.0% 
(PEG-NH2)4), HG15×2 (4.8% RGD, 10.8% PEG3000-CL and 2% (PEG-NH2)4) and HG15×5 (12% 
RGD, 27% PEG3000-CL and 5% (PEG-NH2)4) as measured by oscillatory rheology (n = 4). 
Average values (±s.e.m) over a frequency sweep from 0.1–10 rad/s (1% strain rate) is shown. 
HG15 had elastic (G’) and viscous (G’’) moduli of 2.6 ± 0.66 Pa and 0.6 ± 0.25 Pa, respectively. 
HG15×2 showed an increase of G’ to 8.7 ± 1.53 Pa and G’’ to 1.0 ± 0.27 Pa, while HG15×5 had 





Due to the very low values of moduli measured for HG15, oscillatory rheology of 
complete Medium 200 was also measured to ensure that the moduli measured were 
due to the hydrogel network structure and not inherently present in the media used 
to make up the hydrogels. The elastic and viscous moduli of Medium 200 was lower 
than that of HG15, indicating that the measured moduli, albeit very low, were due to 
the network in HG15 (Figure 3.12).   
 
Figure 3.12: Rheological properties of HG15 at different concentrations. A. HG15; B. HG15×2; 
C. HG15´5; D. Complete endothelial Medium 200. Frequency sweep at 0.01–10 Hz at fixed 1 




Eight hydrogels were chosen to scale-up to confirm the results from the array screen 
with HUVEC (Chapter 2) based on the number of cells attached per hydrogel feature, 
and their morphology grade, with all having ³ 90 % liquid content. The high water 
content, combined with the dynamic imine cross-linking used for their formation, 
explains the very soft nature of the gels. Furthermore, the main components used for 
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hydrogel formation were both linear (bi-functionalised) and of low molecular weight, 
both contributing to a loosely cross-linked network. For future applications, it would 
be interesting to use multi-branched cross-linkers, such as the (PEG-NH2)4, to 
examine its effect on improving rigidity to the structures. Considering the wide 
variety of commercially available amine-terminated multi-branched PEGs of varied 
molecular weights, and the ease of synthesising these into their aldehyde-equivalents, 
this strategy could easily be adopted to the hydrogel platform developed within this 
thesis.  
 
SEM analysis showed good interactions between the hydrogel structures and cells, 
and DAPI staining (after 24 h) showed formation of cell clusters. Much effort was put 
into optimising the platform in which to perform the scale-up studies. The use of 
silicone gaskets fitted on top of aminoalklysilane-functionalised glass slides worked 
well, but was not without its own limitations. Due to the very soft nature of the 
hydrogels, removal of media for media changes was not possible without disrupting 
the hydrogel network and/or removing cells from the structure. Therefore, a culture 
method analogous to the “hanging drop” methods used for spheroid formation was 
adopted, wherein media was added every 48 h, without any media removal.2 The 
small volume of each hydrogel feature (100 µL) caused evaporation of media from 
the features over 48 h, so that their volume was not constantly increased with the 
media additions. However, not being able to remove old media leads to the build-up 
of metabolites and waste products from the cells. Thus, this is not a suitable 3D cell 
culture platform, and further optimisation of the culture is necessary, but increasing 
the cross-linking concentration to improve the hydrogel mechanical properties would 
be a potential strategy to solve this. Nonetheless, high cell viability of both HUVEC 
and pHUVEC was observed over both 4 and 30 days inside one of the hit hydrogels, 
HG15 (see Figure 3.6).  
 
Protein expression analysis by immunofluorescence of HUVEC and pHUVEC 
encapsulated in HG15 was unsuccessful when staining was attempted in situ, due to 
hydrogel network breakage and removal of cells with multiple staining and washing 
steps. Re-plating the cells on TCPS after encapsulation and then staining them for 
CD31 showed expression of the endothelial cell marker in both HUVEC and 
pHUVEC, but the large number of cells not attaching to the plastic surface, or which 
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detached after media change and washing steps suggests that this is a non-optimal 
method for staining. In addition, 24 h culture on TCPS would alter cell expression 
levels to those observed in the hydrogel. Considering the fact that both cell types 
poorly attached to the TCPS suggest that they had adapted to the more natural in vivo 
environment of the soft 3D hydrogel network. Furthermore, by breaking up the 
hydrogel and releasing the cells, the cell organisation observed within the 3D culture, 
such as clusters, could not be captured. Therefore, IHC on these structures while 
simultaneously allowing for analysis of protein expression was needed.  
 
Protein expression analysis by IHC showed that both HUVEC and pHUVEC 
expressed endothelial markers at 4 and 30 days. Analysis indicated that HUVEC 
incubated in HG15 for 4 days expressed both CD31, a cell adhesion protein found on 
endothelial surfaces,154 and vWf, an important factor for endothelial haemostasis 
maintenance.156 Although the expression of VE-cadherin, responsible for endothelial 
intercellular cohesion and organisation157 was minimal after 4 days it had increased 
after 30 days. Moreover, despite the observation that global CD31 expression in 
HUVEC after 30 days in HG15 was low, it was observed that it was cell specific with 
some cells still expressing CD31. pHUVEC showed good expression of both CD31 
and vWf after 4 days in HG15, which was maintained over 30 days in the hydrogel. 
In a similar manner to the immortalised HUVEC cells, the pHUVEC had very low 
expression of VE-cadherin after 4 days, but an increase in the protein levels was 
observed after 30 days encapsulation. Cell apoptosis levels were low for both HUVEC 
and pHUVEC at day 4, and this increased slightly after 30 days incubation, which 
was expected due to the longer incubation time and build-up of waste products due 
to the limitations of the culture method and media change as discussed above. 
Overall, this demonstrated the capacity of HG15 to maintain the endothelial profile 
of both immortalised and primary endothelial cells, which combined with the high 
proliferation levels and low levels of apoptosis, indicates the promise of HG15 as a 
3D endothelial cell culture platform.  
 
The formation of 3D cell clusters within the gels was also observed during the 
sectioning analysis (Figure 3.8 and 3.9A). These are structures that are not typically 
seen in 2D cell culture, suggesting that the 3D environment of the gel aids in the 
cluster formation.  Although cell clusters were observed for both cell types and 
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incubation times when imaging the full hydrogels by light microscopy (see Figure 
3.6), these were only observed in the IHC sections for HUVEC after 4 days. This could 
be due to sections with cell clusters not being cut from the paraffin blocks of the other 
incubation times, indicating a limitation of the method in that a global picture of 
protein expression is not given since not all parts of the hydrogel will be cut and 
stained.  
 
As for the qPCR and gene expression analysis, results for HUVEC after 4 days in 
HG15 confirmed the results obtained from protein expression analysis. Interestingly, 
vWf was not expressed at all when HUVEC were cultured on TCPS or collagen. 
Considering the importance of vWf for endothelial cell maintenance and function, 
this exemplifies the problem of culturing cell lines on rigid 2D surfaces and its effect 
on cell phenotype. It should be noted that HUVEC used herein had been cultured on 
TCPS for several passages before encapsulation within HG15. Four days inside a 
softer 3D matrix was enough to turn on the gene expression of vWf, and it also led to 
increase in PECAM-1 (CD31) and CDH5 (VE-Cadherin) gene expression compared 
to TCPS. Expression of TEK was higher in HUVEC cultured on TCPS or collagen 
compared to in HG15, and upregulation of TEK has been linked to endothelial cells 
undergoing hypoxia and pro-inflammatory responses.155 Overall, this suggests that 
HUVEC encapsulated in HG15 perform better, or more “naturally”, than when 
cultured on TCPS or collagen.   
 
For pHUVEC, the qPCR data did not match the data seen in the IHC protein 
expression analysis. Several studies have concluded, however, that the correlation 
between mRNA and protein expression levels are poor (ca. 40 %) and that care should 
be taken when equating gene expression with cell phenotype and behaviour.158–162 
Since protein expression of vWf and CD31 was observed of pHUVEC encapsulated 
in HG15 by IHC analysis it is clear that these endothelial markers are present. 
Furthermore, IHC analysis indicated that these and VE-Cadherin were expressed 
after 30-day encapsulation. Taken together, the results from qPCR should be noted, 
but they are not definitive indicators of protein levels, where IHC is the superior 




Finally, the mechanical properties analysis of HG15 demonstrated its very soft nature 
with low elastic and viscous moduli (2.6 ± 0.66 Pa and 0.6 ± 0.25 Pa). Their moduli did 
increase with increased component concentration, which also is seen with Matrigel. 
Low concentration Matrigel (4.4 mg/mL) has a reported elastic moduli of 20 Pa,163 
while Collagen 1 (rat tail, 2 mg/mL) has been measured as 9 Pa.164 As such HG15 is 
of lower stiffness than these commonly used 3D matrices, but that its moduli can be 
tuned via alteration of concentration and the very soft nature of HG15 makes it a 
promising material for studies with cells known to reside within low-moduli in vivo 




A class of dynamic hydrogels were designed as novel 3D cell culture matrices for 
endothelial cell maintenance and proliferation. Successful scale-up of hit hydrogels 
identified from a HTS hydrogel array was achieved, with gels showing cell cluster 
formation. One hydrogel, HG15, was further studied with both immortalised and 
primary HUVEC, with incubation over 4 and 30 days, which showed high cell 
viability for both cell types and immunohistological analysis confirming the 
expression of endothelial marker proteins, and the maintenance of cell proliferation 
with low levels of apoptosis. The confirmation of the array results validates the power 
of the hydrogel array platform for high-throughput screening and the identification 
of 3D cell culture matrices. 
 
3.11 Materials and Methods 
 
3.11.1 Instruments for cell experiments and analysis 
 
HERAcell 150 incubator (Heraeus, Germany) 
 
HERAsafe KS 18 class II biosafety cabinet (Heraeus, Germany) 
 




LightCycler 480 (Roche Holding AG, Switzerland) 
 
3.11.2 Imaging instruments 
 
Axiovert 200m inverted fluorescence microscope with Axiovision 4.8 software (Carl 
Zeiss AG, Germany). Filters: DAPI (λex/em = 300-395/430-505 nm), GPC/FITC (λex/em 
=  447-494/500-554 nm), YPF (λex/em = 490-512/520-554 nm), TRITC/Rhodamine/Cy3 
(λex/em = 527-563/570-650 nm) and Cy5 (λex/em = 620-659/663-725 nm) filters. 
Magnification: x10, x20 and x40  
 
Zeiss Axio Imager Z1 with ZEN imaging software (Carl Zeiss AG, Germany) 
 
Image analysis was carried out in ImageJ 
 
3.11.3 Instruments for characterisation 
 
Carl Zeiss SIMGA HD VP Field Emission Scanning Electron Microscope (Carl Zeiss 
AG, Germany) 
 
Discovery Hybrid Rheometer (DHR-2) fitted with a 25 mm rough parallel aluminium 
plate for oscillatory rheology (TA Instruments, USA) 
 
3.11.4 Cells, media and biological equipment 
 
Primary HUVEC were purchased from ATCC (PCS-100-010™) 
 
HUVEC were donated by Dr Kate Cameron (University of Edinburgh) 
 
Complete Medium 200: Medium 200, Low Serum Growth Supplement (LSGS) kit 






3.11.5 Cell Culture on Tissue Culture Polystyrene  
 
HUVEC and primary HUVEC were cultured in complete Medium 200. Cells were 
grown to 70–80% confluency in T25 flasks (37 °C, 5% CO2) before passaging. 
Immortalised HUVEC were used between passage 5–9 and primary HUVEC from 
passage 1–4. 
 
3.11.6 Scanning Electron Microscopy 
 
The hit hydrogels were printed (n = 3) on a masked aminoalkylsilane glass slide (See 
2.6.15). The slide  was UV sterilised for 1 h, seeded with HUVEC (300 000/slide) in 
complete Medium 200 (5 mL) and incubated (37 °C, 5% CO2) for 24 h. The media was 
removed and the samples were fixed with glutaraldehyde (3% in 0.1 M 
(CH3)2AsO2Na, pH 7.3) for 2 h, and washed with Hank’s buffer (3 × 10 min). The 
samples were post-fixed with OsO4 (1% in 0.1 M (CH3)2AsO2Na). Dehydration in 
graded concentrations of acetone (50%, 70%, 90% and 3 × 100%) for 10 min each was 
followed by critical point drying with liquid CO2. After mounting the slide on 
aluminium stubs with carbon tabs attached, the hydrogels were sputter coated with 
gold/palladium (Au/Pd, 20 nm) and analysed using SEM. The images were analysed 
in ImageJ and false coulouring was done with Gimp software.  
 
3.11.7 DAPI staining of HUVEC encapsulated in hit hydrogels 
 
Components of the eight hit hydrogels (n = 3) in water were added to the wells of a 
16-well ProPlate microarray system (GraceBioLabs) (100 µL) fitted on top of an 
aminoalkylsilane-functionalised glass slide. After drying at 40 °C overnight, the slide 
was sterilised under UV light for 30 min. Each hydrogel was seeded with HUVEC 
(15000 cells in 100 µL complete Medium 200) and incubated for 1 h (37 °C, 5 % CO2) 
before addition of complete Medium 200 (100 µL) to each hydrogel. The hydrogels 
were incubated for 4 days (37 °C, 5 % CO2), with media change every 48 h. The cells 
were fixed with 4 % paraformaldehyde (PFA) (100 µL/hydrogel) for 10 min at room 
temperature followed by washing with Hank’s buffer (1×5 mL). The cells were then 
stained with DAPI (100 µL/hydrogel) for 10 min at room temperature and imaged 
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using a Zeiss AxioVert 200m fluorescence microscope with lasers λex/em = 300-
395/430-505 nm. 
 
3.11.8 CD31 staining of HUVEC and pHUVEC encapsulated in 
HG15 and re-plated onto TCPS 
 
Solutions of HG15 (2.4% RGD, 5.4% PEG3000-CL and 1 % (PEG-NH2)4) were added to 
the wells of a 4-well CultureWell silicone gasket (100 µL/hydrogel, n = 4) 
(GraceBioLabs) followed by dehydration in 110 °C oven for 10 min and 40 °C 
overnight. Before cell seeding, the silicone gasket was removed from the glass slide 
and sterilised with 70 % ethanol. After further sterilisation of the silicone gasket and 
glass slide under UV light for 1 h, the silicone gasket was re-fitted onto the glass slide 
to again give wells for each hydrogel feature. Hydrogel formation and in situ cell 
encapsulation was achieved upon addition of cell media with suspended HUVEC or 
primary HUVEC (40 000 cells in 100 µL complete Medium 200 to each hydrogel) 
followed by incubation (37 °C, 5% CO2). After 24 h, pyridoxal HCl (50 µL of 4.9 mM 
in complete Medium 200) was added to each gel and incubated for 15 min (37 °C, 5 
% CO2) followed by addition of pyridoxamine 2HCl (50 µL of 4.1 mM in complete 
Medium 200) and further incubated for 15 min (37 °C, 5 % CO2). The cells were filtered 
through a cell strainer (40 µm nylon mesh, Fisher Scientific) and each well washed 
with Hank’s buffer (100 µL) before centrifugation (300 g, 10 min). The cells were 
suspended in complete Medium 200, plated into a 48 well plate (1 mL) and incubated 
overnight (37 °C, 5 % CO2). The media was removed, each well washed with Hank’s 
buffer and cells fixed with 4 % PFA for 10 min (200 µL/well) and washed with 
washing buffer (0.05 % Tween20 in Hank’s buffer) (200 µL/well). Blocking 
(ProteinBlocker) was carried out for 30 min at room temperature (200 µL/well), 
followed by incubation with a primary CD31 antibody (200 µL/well, 1:99 dilution, 
AbCam28364 Rabbit primary Ab) at 4 °C overnight. The primary antibody solution 
was removed and cells washed with Hank’s buffer twice (2×200 µL). The cells were 
incubated with a fluorescent secondary antibody (200 µL/well) (AlexaFluor 568, 
AbCam175471 Goat primary Ab to Rabbit IgG) with gentle shaking for 1 h at room 
temperature. The solution was removed and cells washed with Hank’s buffer 
(2×200µL). Nuclei staining with DAPI was done for 10 min at room temperature (200 
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µL/well) followed by washing with Hank’s buffer (200 µL/well). The cells were 
imaged in Hank’s buffer (200 µL/well) using a Zeiss AxioVert 200m fluorescence 
microscope with lasers λex/em = 300-395/430-505 nm for DAPI, λex/em = 527-563/570-
650 nm for AlexaFluor 568. 
 
3.11.9 Cell viability of HUVEC and primary HUVEC encapsulated 
in HG15 
 
HG15 (n = 4) was prepared and sterilised as described above (see 3.11.8). Hydrogel 
formation and in situ cell encapsulation was achieved upon addition of cell media 
with suspended HUVEC or primary HUVEC (50 000 cells in 100 µL complete Medium 
200 to each hydrogel) followed by incubation (37 °C, 5% CO2). 15–20 µL of fresh media 
was added to each hydrogel every 48 h. After incubation for the desired time-point, 
the cells were stained with Calcein AM and PI (488/570 nm, LIVE/DEAD Cell 
Imaging Kit ThermoFisher) according to manufacturer’s protocol and imaged on a 
Zeiss AxioVert 200m fluorescence microscope with lasers λex/em = 447-494/500-554 
nm for Calcein AM, λex/em = 527-563/570-650 nm for PI. 
 
3.11.10 Immunohistochemistry of HUVEC and primary HUVEC 
incubated in HG15 
 
HG15 (n = 4) was prepared and sterilised as described above (see 3.11.8). Hydrogel 
formation and in situ cell encapsulation was achieved upon addition of cell media 
with suspended HUVEC or primary HUVEC (50 000 cells in 100 µL complete Medium 
200 to each hydrogel) followed by incubation (37 °C, 5% CO2) for 4 or 30 days. 15–20 
µL of fresh media was added to each hydrogel every 48 h. After incubation for the 
desired time point cells were fixed in 10 % neutral-buffered formalin (1 mL 
concentrated formalin in 9 mL water buffered to pH 6.8 with NaH2PO4) overnight 
followed by washing with PBS and staining with Eosin Y (1% in H2O) for 30 min at 
room temperature. The hydrogels were immersed in heated agarose (2 % aq., 5 mL, 
liquid) (Type 1, low EEO) and the agarose cooled to form gels. Hydrogel slices were 
cut from the agarose block, dehydrated with industrial methylated spirits (IMS) (70%, 
80%, 90%, 5×100% IMS, 1 hour each), infiltrated with xylene (3×100%, 1 hour each) 
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and finally embedded with paraffin wax (3×1 hour). Following mounting and cooling 
of the sample, sections (5 µm thickness) were cut using a microtome (Leica). The 
sections were then dewaxed and rehydrated using xylene (×3), ethanol (100%, 95%, 
80%, 70%, 20 s each) followed by washing with water. H&E staining of slices was 
carried out according to a standard operating procedure at the University of 
Edinburgh. Immunostaining of slices was done using a Bond Max Automated 
Immunostainer and a Leica Bond Polymer Refine detection kit (DS9800) according to 
manufacturer’s protocol and imaged on a Zeiss Axio Imager Z1. Primary antibodies: 
Ki-67 (Abcam Ab15580, 1:500 dilution), Cleaved Caspase 3 (Cell signalling technology 
9661, 1:100 dilution), CD31 (Abcam, Ab28364, 1:600 dilution), von Willebrand factor 
(Dako A0082, 1:1000 dilution), VE-Cadherin (Chemicon International MAB1989, 
1:100 dilution). Semi-quantitative analysis of protein expression was determined 
using the ImageJ colour deconvolution plug-in, H DAB vector. 
 
3.11.11 qPCR analysis of HUVEC and primary HUVEC incubated 
in HG15 
 
HG15 (n = 4) was made and sterilised as described above (see 6.11.8). HUVEC or 
primary HUVEC were seeded in each hydrogel (50 000 cell in 100 µL complete 
medium 200) and incubated at 37 °C with 5 % CO2 for 4 or 30 days. 20 µL media was 
added to each hydrogel every 48 h. After incubation for the desired time point, the 
cells were harvested by addition of pyridoxal hydrochloride (50 µL, 4.9mM in 
complete Medium 200) to each hydrogel and incubated for 15 minutes (37 °C, 5 % 
CO2). Thereafter pyridoxamine dihydrochloride was added (50 µL, 4.1 mM in 
complete Medium 200) and the gels incubated for another 15 minutes at 37 °C with 5 
% CO2. The resulting solutions were put through a cell strainer (40 µm nylon mesh, 
Fisher Scientific) to remove hydrogel components followed by washing with media. 
The cell suspension was pelleted by centrifugation (300g, 2×10 minutes). From the 
cell pellet RNA was isolated using an RNeasy kit (Qiagen) followed by reverse 
transcription of 1 µg RNA using TaqMan reverse transcription reagents (Applied 
Biosystems) according to manufacturer’s protocol. qPCR was carried out with 
TaqMan® Gene Expression Master Mix and TaqMan® primers (Applied Biosystems). 
Primer details: GAPDH (Hs02758991_g1) KDR (Hs00911700_m1), PECAM1 
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(Hs01065279_m1), CDH5 (Hs00901465_m1), vWf (Hs01109446_m1), TEK 
(Hs00945150_m1). Analysis was carried out using a LightCycler with GAPDH as 
housekeeping gene. Relative gene expression was evaluated using 2-(Ct(target gene)-
Ct(GAPDH)).165 
 
3.11.12 Characterisation of Mechanical Properties  
 
Solutions of HG15 (2.4% RGD, 5.4% PEG3000-CL and 1 % (PEG-NH2)4) and variants 
(HG15×2: 4.8% RGD, 10.8% PEG3000-CL and 2% (PEG-NH2)4); (HG15×5: 12% RGD, 
27% PEG3000-CL and 5% (PEG-NH2)4) were added to the wells of a 2-well CultureWell 
silicone gasket (400 µL/hydrogel, n = 3) (GraceBioLabs) followed by drying at 110 °C 
for 10 min and 40 °C overnight. The hydrogels were formed by rehydrating in 
complete Medium 200 (400 µL/hydrogel). Frequency sweep measurements were 
carried out using the constant strain (1 %) mode on a Discovery Hybrid Rheometer. 
Elastic and viscous moduli were measured over the frequency range 0.1–10 rad/s and 




Chapter 4: Development of an enzyme-free 




The ability to passage (or subculture) cells is a fundamental aspect of cell culture. 
Traditional adherent 2D cell culture requires a method of dislodging cells from the 
substrate when they have grown to confluency, and to separate cells from each other 
to afford a single cell suspension, of which a subset is “passaged” to a new culture 
vessel.6,166 Commonly enzymes, such as trypsin or collagenase, that can cleave the 
proteins between cells and between cells and the growth surface are employed for 
this. The most frequently used enzyme in mammalian cell culture is trypsin, a serine 
protease, that cleaves amide bonds.6 The first reports of using trypsin for in vitro 
tissue/cell culture were by Rous and Jones in 1916, when they reported the use of 
trypsin to digest and generate single cell suspensions from embryos and tumours 
from rat and chicken, as well as from normal rat tissue.167 Once cell culture was 
developed in the 1950’s, trypsinisation became the method of choice as a passaging 
method.6  
 
Although the trypsin method of cell dissociation is routinely used and relatively 
quick (5-10 min incubation at 37 °C), the process does not come without issues. A 
primary concern is that the action of trypsin leads to the cleavage of membrane 
proteins and growth factors from the cell surface, which can lead to cell dysregulation 
and damage.168 In fact, a proteomic study of the effects on MCF-7 cells upon trypsin 
digestion indicated that the expression of 36 proteins were changed compared to non-
trypsinised cells.168 Furthermore, among the down-regulated proteins were ones 
regulating cell growth, metabolism, adhesion and electron transport in the 
mitochondria. Conversely, proteins that control apoptosis were upregulated. 
Another drawback of trypsin is that prolonged cell exposure leads to significant cell 
damage and cell death. Because of this, a so-called deactivation step of the enzyme is 
required after trypsinisation, normally using serum or a serum-free deactivation 




Alternative cell-dissociation reagents to trypsin exist, such as Accutase® (Innovative 
Cell Technologies, Inc.), which is an enzyme mixture with both proteolytic and 
collagenolytic activities and is recommended for use with sensitive cell types such as 
hESCs169 and neuronal SCs170 because it is active at lower concentrations compared to 
trypsin or collagenase and does not require a deactivation step. Physical disruption 
of cell layers and colonies is another method of achieving cell dissociation, whereby 
mechanical forces with either a thin capillary or a cell scraper are used to dislodge the 
cells from the surface. This can be particularly useful for ESC cultures since colonies 
of cells are maintained and not dissociated.171   
 
For cell culture within a 3D biomaterial, passaging comes with the added hurdle of 
releasing the cells from the 3D structure, as opposed to the simple 2D surface of 
traditional methods. For commonly used naturally derived 3D matrices, such as 
Matrigel®, GelTrex®, collagen or laminin, combinations of different proteases are 
used to afford cell dissociation from the material. These combinations are often 
marketed under different names and with proprietary compositions depending on 
the vendor, for example Corning™ Cell Recovery Solution for Matrigel® and 
GelTrex® or collagenase for dissocation of collagen gels. For synthetic 3D matrices, 
trypsin is often the method reported to afford cell dissociation from the scaffold or 
hydrogel, but an enzyme-free protocol would be desired considering the issues 
associated with trypsin digestion. This includes the thermally responsive hydrogels 
developed in the Bradley group that enabled the long-term passaging of hESCs (> 30 
passages) with harvesting by lowering the temperature to 15 °C.45 In another 
example, the degradation of imine cross-linked chitosan:PEG hydrogels was reported 
using aqueous pyridoxal HCl, a derivative of pyridoxal 5’-phosphate (PLP), also 
known as Vitamin B6.80 It was envisioned that a similar strategy could be employed 
for the imine cross-linked hydrogels developed within this thesis.  
 
The aim of this chapter was to develop an enzyme-free protocol that allowed for cell 
culture and passaging within a 3D imine cross-linked hydrogel. By using vitamin B6 
derivatives, a biocompatible protocol was developed that allowed for the gentle and 




4.2 pH and cytotoxicity of Vitamin B6 and its 
derivatives  
 
For hydrogel degradation, three derivatives of vitamin B6 were investigated; PLP,  
pyridoxal hydrochloride (referred to as Pyr HCl) and pyridoxamine dihydrochloride 
(referred to as PyrAm). It was desired to carry out the hydrogel degradation using 
solutions made up in cell media to make the system compatible with cell culture 
reagents. Moreover, because the incubation time reported in literature of using 
PyrHCl was 30 min,80 to use cell media was preferred over buffered solutions such as 
PBS, as cell viability could be affected over this time if the cells were only incubated 
in buffer. Initially optimal concentrations of the vitamin B6 derivatives were 
determined. To develop a passaging protocol, the solutions of all components had to 
be used at physiologically relevant pHs in order not to cause cell damage. PyrHCl 
and PyrAm are sold as the HCl salts and therefore it was expected that at higher 
concentrations the pH would be acidic if unbuffered. Indeed, when dissolved in 
endothelial cell medium the pHs of PyrHCl (49 mM) and PyrAm (41 mM) were 3 and 
4 respectively (Table 4.1). At lower concentrations (£ 9.8 mM for PyrHCl and £ 8.3 
mM for PyrAm), the pH was buffered to 7. Although the buffering capacity of the 
Medium 200 could have been increased by addition of NaHCO3 or HEPES to allow 
the use of the higher concentrations this was not desired as the aim was to develop a 
protocol using standard reagents. The highest concentration tested of PLP was 8.1 













Table 4.1: pH of Vitamin B6 derivatives (Pyridoxal 5’-phosphate, Pyridoxal HCl, 
Pyridoxamine 2HCl) at different concentrations and their corresponding pH’s as measured by 
pH paper. All solutions were made up in endothelial Medium 200 supplemented with low 
serum growth supplement.  
 
 
The luminescent-based assay, CellTiterGlo (Promega) was used to determine HUVEC 
viability by measuring levels of ATP from lysed cells following incubation with 
different concentrations of PyrHCl, PyrAm and PLP for 30 minutes (Figure 4.1). 
PyrHCl and PyrAm were non-toxic at concentrations £ 9.8 mM and £ 8.3 mM 
respectively. High cytotoxicity of PyrHCl and PyrAm was observed at 49 mM and 41 
mM respectively, due to the low pH (~ 2) of the solutions. 8.1 mM PLP caused 50 % 
cytotoxicity and PLP was also more toxic to HUVEC than PyrHCl and PyrAm at 
lower concentrations showing 70 % cell viability at 4 mM, compared to no toxicity 





Figure 4.1: Cell viability assay to determine the cytotoxicity of Vitamin B6 and its derivatives 
to HUVEC. The cell viability was measured using a CellTiter Glo 2.0 assay after 30 min 
incubation with A. Pyridoxal 5’-phophate. B. Pyridoxal HCl. C. Pyridoxamine 2HCl. All 
results are normalised to untreated control.  Mean ± s.e.m shown for all cases (n = 6). 
 
4.3 Developing a passaging protocol 
 
4.3.1 Pyridoxal 5’-phosphate for hydrogel degradation 
 
The first passaging trials were attempted using PLP (4 mM) to degrade the hydrogels. 
HG15 had previously been identified as a hit hydrogel from the HUVEC array screen 
(see Chapter 3) and thus HUVEC were encapsulated in HG15 for 24 h (denoted as 
passage 0, P0), before the hydrogel was degraded with PLP. The released cells were 
collected by centrifugation and counted, with only 53 % of the number of cells 
originally seeded recovered after hydrogel degradation. The released cells were 
encapsulated into fresh HG15 (denoted as P1) and incubated for 24 h. Cell viability of 
the passaged cells was then assessed (FDA/PI staining) (Figure 4.2). Although cell 
viability was found to be high (> 80 % in the cell cluster shown in Figure 4.2), it was 
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decided to abandon further studies with PLP for hydrogel degradation and cell 
passaging, due to low cell release and difficulties in pelleting after centrifugation.  
 
Figure 4.2: Passaging of HUVEC encapsulated in HG15 using pyridoxal 5’-phosphate (PLP). 
HUVEC were encapsulated in HG15 for 24 h (P0), followed by cell release using PLP (4.0 mM) 
and encapsulation into fresh HG15 (P1) and incubaion for 24 h. Cell viability was assessed by 
FDA (live stain) (λex/em = 490/526 nm) and PI (dead stain) (λex/em = 570/602 nm).  A cell cluster 
is shown. Scale bar 20 µm. BF = brightfield.  
 
4.3.2 Pyridoxal HCl and Pyridoxamine 2HCl for hydrogel 
degradation 
 
PyrHCl and PyrAm were used to assess their hydrogel degradation properties, both 
individually and when combined. 30 min incubation at 37 °C was chosen as the 
degradation time since early trials of hydrogels in eppendorfs had found that this was 
the optimal time for complete hydrogel degradation. Solutions of PyrHCl (4.9 mM) 
and PyrAm (4.1 mM) were tested at different combinations for their capacity to allow 












Table 4.2: Methods evaluated to afford hydrogel degradation using pyridoxal HCl (PyrHCl) 
and pyridoxamine 2HCl (PyrAm) with cells seeded, propagated and liberated. PyrHCl (4.9 
mM) and PyrAm (4.1 mM) were dissolved in endothelial cell media (Medium 200). Hydrogels 















A PyrHCl, 30 min 20,000 29,500 148 % 
B PyrAm, 30 min 20,000 26,500 133 % 
C i) PyrHCl, 15 min 
ii) PyrAm, 15 min 
20,0000 39,000 195 % 
D PyrHCl + PyrAm, 
30 min 
20,000 26,000 130 % 
 
All combinations resulted in >100 % cell release compared to the number of cells 
initially seeded (indicating HUVEC proliferation within HG15). It was decided to 
proceed with method C (Pyr HCl, 15 min + PyrAm 15 min) as it resulted in the highest 
number of cells recovered after hydrogel degradation and centrifugation (195 %). For 
the other methods, some cells were found in the supernatant after centrifugation. 
 
During the degradation trials, it was found that some of the hydrogel components 
were released with the cells after degradation. During centrifugation these fragments 
pelleted to the bottom before the cells did, thus limiting the centrifugation efficiency 
for cell collection. Therefore, a “straining step” was added after hydrogel degradation 
wherein the cell suspension was filtered through a cell strainer that allowed the cells 
to pass through, but “trapped” the hydrogel network fragments. Cell collection by 
centrifugation was then found to be more efficient. However, this “cell-hydrogel” 
material could well be an ideal material to allow subsequent passaging with cell 








4.4 3D cell culture and passaging in HG15 
 
4.4.1 Encapsulation and passaging of HUVEC 
Once the method for hydrogel degradation was developed, cell viability after 
passaging within HG15 was investigated. HUVEC were encapsulated in HG15 for 
nine days (P0), followed by passaging into a new set of HG15 (P1). After 6 days 
culture cell viability was analysed by Calcein AM/PI staining (Figure 4.3). High 
viability was observed and cell clusters formed as readily for P1 as they had with P0.  
 
Figure 4.3: Passaging of HUVEC encapsulated in HG15 using pyridoxal HCl (PyrHCl) and 
pyridoxamine 2HCl (PyrAm). HUVEC were encapsulated in HG15 for nine days (P0), 
followed by hydrogel degradation and cell release using PyrHCl (4.9 mM) and PyrAm (4.1 
mM) and encapsulation into another HG15 (P1) and incubation for six days. Cell viability was 
assessed by Calcein AM (live stain) (λex/em = 488/515 nm) and PI (dead stain) (λex/em = 570/602 
nm). BF = brightfield. Merge = merge of Calcein AM (green), PI (red) and BF images. Scale bar 
of full image 100 µm. Scale bar of cut-out 50 µm.  
 
Passaging over several passages was necessary to demonstrate the usefulness of the 
passaging method and thus passaging over 3 passages of HUVEC encapsulated in 
HG15 was attempted (Table 4.3 and Figure 4.4). Both the first (P0 to P1) and second 
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passaging (P1 to P2) resulted in ³100 % of the cells seeded being released, but the 
centrifugation step did not result in all cells being collected, with many still in the 
supernatant (Table 4.3). Cell viability at P2 was analysed by Calcein AM/PI staining 
and although all the cells were alive, the lower cell numbers seeded into the hydrogels 
resulted low levels of cell clustering compared to P0 and P1 (Figure 4.4). The third 
passage (P2 to P3) allowed few cells to be released, and no cell pellet was observed 
after centrifugation, which led to the experiment being stopped.  
 
Table 4.3: Passaging of HUVEC encapsulated in HG15 using pyridoxal HCl (PyrHCl, 4.9 mM) 
and pyridoxamine 2HCl (PyrAm, 4.1 mM) over three passages. Hydrogels (100 µL, n = 8) were 
seeded with HUVEC for each method, and the cells were pooled for cell counting. The number 
of cells released after hydrogel degradation and the number of cells pelleted after 
centrifugation are given. Percentages are based on the numbers of cells seeded (calculated by 




Number of cells 
released 
Number of cells pelleted 
after centrifugation 
P0 à P1 400,000 400,000 (100 %) 350,000 (87 %) 
P1 à P2 350,000 420,000 (120 %) 275,000 (65 %) 











Figure 4.4: Passaging of HUVEC encapsulated in HG15 using pyridoxal HCl (PyrHCl, 4.9 
mM) and pyridoxamine 2HCl (PyrAm, 4.1 mM) after 6 days (P0), and encapsulation into 
another HG15 (P1) and incubation for six days with repeated cell release and passaging (P2). 
After 24 h incubation of P2, cell viability was assessed using Calcein AM (live stain) (λex/em = 
488/515 nm) and PI (dead stain) (λex/em = 570/602 nm). BF = brightfield. Merge = merge of 
Calcein AM (green), PI (red) and BF images. Scale bar 20 µm.  
 
4.4.2 Encapsulation and passaging of HEK293  
The problems with poor cell proliferation, limited release from the hydrogel and the 
low number of cells pelleting after centrifugation as a function of continued passaging 
were investigated by changing the cell type to HEK293. These cells proliferate faster 
compared to HUVEC, and do not require specialist cell media, making their culture 
more time and cost-effective and better suited for problem-shooting experiments. In 
a similar manner to Section 4.4.1, HEK293 cells were encapsulated into HG15 and 
passaged with hydrogel release using PyrHCl and PyrAm. Over four passages, good 
levels of cell release after hydrogel digestion and filtering through a cell strainer was 
achieved (Table 4.4). Cell proliferation as a measure of the cells released was only 
observed for P0 à P1 (125 % cell release compared to the amount seeded). As for the 
number of cells pelleting after centrifugation, the number was around 70 % for both 
P0 à P1 and P1 à P2, but dropped to 40 % for P2 à P3. For passage P3 à P4 no cell 





Table 4.4: Passaging of HEK293 encapsulated in HG15 using pyridoxal HCl (PyrHCl) and 
pyridoxamine 2HCl (PyrAm) over four passages. The percentage of cells released after 
hydrogel degradation and the percentage of cells pelleted after centrifugation based on the 
cells seeded are given. Hydrogels (100 µl) were seeded with HEK293 and the cells were pooled 




Cells released as a 
percentage of cells 
seeded 
Cells pelleted as a 
percentage of cells 
seeded 
P0 à P1 800,000 995,000 (125 %) 703,500 (88 %) 
P1 à P2 579,500 537,500 (93 %) 366,500 (63 %) 
P2 à P3 366,500 340,000 (93 %) 137,000 (38 %) 
P3 à P4 137,000 127,000 (93 %) No pellet 
 
To assess the cell viability following passaging, the supernatant from centrifugation 
of the cells suspension was seeded onto TCPS and incubated overnight to allow for 
cell attachment. Thereafter, the cells were stained with Hoechst and Calcein AM to 
visualise the nuclei and assess the cell viability respectively (Figure 4.5). High cell 





Figure 4.5: Passaging of HEK293 encapsulated in HG15 using pyridoxal HCl (PyrHCl) and 
pyridoxamine 2HCl (PyrAm). HEK293 were encapsulated in HG15 for 6 days (P0), followed 
by cell release using PyrHCl (4.9 mM) and PyrAm (4.1 mM) and encapsulation into another 
HG15 (P1). This procedure was repeated over four passages. The supernatant from cell 
centrifugation after hydrogel degradation still contained cells, and at each passaging point, 
the cell supernatant was plated on TCPS and incubated for 48 h. The cell viability of the cells 
on TCPS was assessed by Calcein AM (live stain) (λex/em = 488/515 nm). The nuclei were 
stained with Hoechst (λex/em = 361/497 nm). BF = brightfield. Merge = merge of Calcein AM 
(green) and Hoechst (blue) images. Scale bar 20 µm.  
 
4.5 Discussion  
 
The use of enzyme digestion for cell passaging is not ideal for cell culture as the 
enzymes commonly used (e.g. trypsin, collagenase) can themselves be harmful to the 
cells, suggesting than an enzyme-free passaging protocol would be beneficial. 
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Moreover, a common hurdle for the advancement of hydrogels and scaffolds for 3D 
cell culture is the ability to afford cell release and/or material degradation to enable 
passaging. To address both these issues, herein was developed a passaging system 
that is both enzyme-free and allows for degradation of a 3D hydrogel with cell release.  
 
The previously reported use of the PyrHCl to degrade imine cross-linked 
PEG:chitosan hydrogels80 did not examine whether the conditions used were 
biocompatible. Herein we examined both PyrHCl and PLP (aldehyde-bearing) and 
PyrAm (amine-bearing) for their capacity to compete with the imine-linkage in the 
hydrogel structures and cause their degradation. After determining the 
biocompatible pH range of each component, cytotoxicity studies were carried out. 
These revealed that treatment with all three compounds would be suitable for 30 min 
incubations when used at  ~ 5 mM.  
 
Cell passaging with PLP over one passage was found to be biocompatible, with good 
cell viability after hydrogel degradation and passaging into another set of HG15. It 
was found, however, that PLP was less efficient at degrading the hydrogels compared 
to PyrHCl and PyrAm, reflected by the number of cell released after hydrogel 
degradation. Therefore, it was decided to use PyrHCl and PyrAm for the passaging 
system, with the protocol possible with either or both components. Based on the 
number of cells released after passaging from HG15, the combination of incubating 
the hydrogel with PyrHCl (4.9 mM) for 15 min and then adding PyrAm (4.1 mM) for 
another 15 min was optimal. There is no obvious reason why this order and not the 
opposite (first adding in PyrAm, then PyrHCl) would cause higher levels of hydrogel 
degradation and thereby cell release. After adding the step of removing hydrogel 
fragments with a cell strainer, followed by centrifugation, the passaging protocol was 
complete.  
 
Passaging over one passage with the PyrHCl+PyrAm system showed good cell 
release and centrifugation and high cell viability of both HUVEC and HEK293 at the 
P0 à P1 stage. Further passaging, however, was not straightforward due to issues 
with cell pelleting after centrifugation, which was evident already at the P1 à P2 
stage. Several attempts to solve this were attempted, such as longer centrifugation 
times (20 min) and at lower speed (120 g), as well as repeated centrifugation steps. 
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None of these improved the results compared to the original method (300g, 2´10 
min). Passaging over four passages with HEK293 did confirm, however, that the cells 
that remained in the supernatant were viable. The use of a cell filter that traps cells 
rather than letting them through could be a future solution to the issue of poor cell 




A straightforward, enzyme-free and mild passaging system was developed. 
Although the total time of passaging of 1 hour (30 min hydrogel digestion and around 
30 min washings and centrifugation) is longer than the typical 5-10 min trypsin 
digestion, it is comparable with other 3D matrix digestions protocols, such as 
collagenase (up to 1 h digestion plus washings and centrifugation). This passaging 
system and component concentrations used are hypothesised to be compatible with 
most imine cross-linked hydrogels, independent of hydrogel concentration and 
rigidity.  
 
4.7 Materials and Methods 
 
4.7.1 Instruments for cell experiments  
 
HERAcell 150 incubator (Heraeus, Germany) 
 
HERAsafe KS 18 class II biosafety cabinet (Heraeus, Germany) 
 
4.7.2 Imaging instruments 
 
Axiovert 200m inverted fluorescence microscope with Axiovision 4.8 software (Carl 
Zeiss AG, Germany). Filters: DAPI (λex/em = 300-395/430-505 nm), GPC/FITC (λex/em 
=  447-494/500-554 nm), YPF (λex/em = 490-512/520-554 nm), TRITC/Rhodamine/Cy3 
(λex/em = 527-563/570-650 nm) and Cy5 (λex/em = 620-659/663-725 nm) filters. 




Image analysis was carried out in ImageJ 
 
4.7.3 Cells, media and biological equipment 
 
Primary HUVEC were purchased from ATCC (PCS-100-010™) 
 
HUVEC were donated by Dr Kate Cameron (University of Edinburgh) 
 
Complete Medium 200: Medium 200, Low Serum Growth Supplement (LSGS) kit 
(Thermo Fisher, USA) 
 
Sterile cell strainer (40 µm nylon mesh) (Thermo Fisher, USA) 
 
4.7.4 Cell Culture on Tissue Culture Polystyrene  
 
HEK293T cells were cultured in complete DMEM. HUVEC and primary HUVEC 
were cultured in complete Medium 200. Cells were grown to 70–80% confluency in 
T25 flasks (37 °C, 5% CO2) before passaging. Immortalised HUVEC were used 
between passage 5–9 and primary HUVEC from passage 1–4. 
 
4.7.5 Cell viability studies and pH measurement of pyridoxal 5’-
phosphate, pyridoxal HCl and pyridoxamine 2HCl 
 
HUVEC were plated in 96-well plates (8000 cells/well, n = 6) in 100 µL Medium 200 
supplemented with LSGS (Complete Medium 200) and incubated (37 °C, 5 % CO2) 
overnight. The media was removed and each well washed with Hank’s buffer (1×100 
µL). Solutions of pyridoxal 5’-phosphate, pyridoxal hydrochloride and pyridoxamine 
dihydrochloride (in complete Medium 200) were added to the wells at the desired 
concentrations (see Figure 4.1) and incubated for 30 min (37 °C, 5 % CO2). The well 
plates were allowed to equilibrate at room temperature for 30 min. CellTiter Glo 2.0 
(Promega) (100 µL/well) was added to each well and the plates were shaken on an 
orbital shaker for 2 min to lyse the cells. The plates were left to equilibrate for 10 min. 
The contents of each well were transferred to a white 96-well plate (Costar 3917) and 
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the luminescence signal measured using a plate reader. For each compound and 
concentration controls with no cells were added. The pH of each concentration was 
measured using pH paper.  
 
4.7.6 Passaging of HUVEC in HG15 with pyridoxal 5’-phosphate 
 
HG15 (n = 3) was prepared and sterilised as described in Chapter 3 (see 3.11.8). 
Hydrogel formation and in situ cell encapsulation was achieved by addition of 
complete Medium 200 (100 µL) with suspended HUVEC (32,000, n = 3) followed by 
incubation (37 °C, 5% CO2) for 48 h. Pyridoxal 5’-phosphate (4 mM, 200 µL) in 
complete Medium 200 was added to each gel and incubated for 30 min (37 °C, 5 % 
CO2). The degraded hydrogels/cell solutions were removed from the wells, and the 
wells were washed with Hank’s buffer (2×100 µL) and the combined solution was 
centrifuged (300 g, 5 min). After removal of the supernatant the cells were counted 
(51 000 cells, 53 % of original amount seeded). The cell pellet was re-suspended in 
complete Medium 200 (300 µL) and seeded into new sets of HG15 (17,000 
HUVEC/HG15, n = 3) and incubated (37 °C, 5 % CO2) for 24 h. Cell viability was 
analysed by staining with Calcein AM and PI (488/570 nm, LIVE/DEAD Cell 
Imaging Kit ThermoFisher) according to manufacturer’s protocol and imaged on a 
Zeiss AxioVert 200m fluorescence microscope. 
 
4.7.7 Developing a passaging protocol with pyridoxal HCl and 
pyridoxamine 2HCl  
 
HG15 (n = 8) was prepared and sterilised as described in above (see 3.11.8). using 8-
well CultureWell silicone gaskets (30 µL/hydrogel). Hydrogel formation and in situ 
cell encapsulation was achieved upon addition of complete Medium 200 (30 µL) with 
suspended HUVEC (10,000, n= 8) followed by incubation (37 °C, 5% CO2) for 24 h. 
Hydrogel degradation was attempted using four different methods (See Table 4.2 for 
methods and cell counting data). Following degradation, and washing with Hank’s 
buffer (1×30 µL) the resulting cell suspension was centrifuged (300 g, 2×10 min), the 
supernatant removed, the cells suspended in 100 µL of complete Medium 200 and the 




4.7.8 Passaging of HUVEC in HG15 with pyridoxal HCl and 
pyridoxamine 2HCl 
 
HG15 (n = 8) was prepared and sterilised as described above (see 3.11.8). Hydrogel 
formation and in situ cell encapsulation was achieved upon addition of complete 
Medium 200 (100 µL) with suspended HUVEC (50,000, n = 8) followed by incubation 
(37 °C, 5% CO2) (P0). After six days, pyridoxal HCl (4.9 mM) in complete Medium 200 
was added to each gel and incubated for 15 min (37 °C, 5 % CO2) followed by addition 
of pyridoxamine 2HCl (4.1 mM) in complete Medium 200) and further incubated for 
15 min (37 °C, 5 % CO2). The degraded hydrogels and cell solutions were removed 
from the wells and filtered through a cell strainer (40 µm nylon mesh, Fisher 
Scientific). Each well was washed with Hanks’s buffer (2×100 µL) and the solution 
was filtered through the cell strainer. The cell number in the combined washings and 
cell solutions was counted and the solution then centrifuged (300 g, 2×10 min). The 
number of cells pelleted were counted (For details on cells seeded, released and 
pelleted see Table 4.3) and suspended in complete Medium 200 and seeded into new 
sets of HG15 as above and incubated (37 °C, 5 % CO2) (P1). The same procedure was 
repeated for subsequent passages. For P2 two out of eight replicates were stained with 
Calcein AM and PI (488/570 nm, LIVE/DEAD Cell Imaging Kit ThermoFisher) 
according to the manufacturer’s protocol and imaged using a Zeiss AxioVert 200m 
fluorescence microscope. The remaining five hydrogels were degraded and the cells 
were used to attempt further passaging (P2 à P3), but no cell pellet was observed 
upon centrifugation. 
 
4.7.9 Passaging of HEK293 in HG15 with pyridoxal HCl and 
pyridoxamine 2HCl 
 
Passaging was carried out at described above (see 4.7.8), but at a higher HUVEC 
density per HG15 (100,000 cells in 100 µL complete Medium 200, n = 8 for P0 à P1, n 
= 4 for all other passage points). For details on cell seeded, released and pelleted see 
Table 4.4. At each passage, the supernatant obtained after centrifugation was seeded 
into 24-well plates and incubated for 72h (37 °C, 5 % CO2). The cells were then stained 
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with 1 mL of combined Hoechst (1 µL of 10 mg/mL stock diluted into 10 mL PBS) 
(λex/em = 361/497 nm) and Calcein AM (4 µL of 500 µM stock diluted into 1 mL 
Hoechst staining solution) (λex/em = 496/596 nm) staining solution by incubation for 
15 min at room temperature. Imaging carried out on a Zeiss AxioVert 200m 
fluorescence microscope.  
‡Initial polymer microarray printing was performed Dr Christian Mangani (University of 
Edinburgh) before the start of the author’s PhD. Dr Mangani also supervised the initial 
microarray screen. All biological experiments were performed by Dr Yoshitaka Murota with 
Assistant Professor Kouichi Tabu and Professor Tetsuya Taga (Tokyo Medical and Dental 
University). Scale-up polyacrylate/acrylamide synthesis, coverslip coating, peptide monomer 
synthesis and peptide-containing polymer microarray printing and scale-up was carried out 
as part of this thesis. 
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Chapter 5: Identifying a defined substrate 
for niche mimicking and trapping of 




In 2012, the world health organisation estimated that 32.6 million people world-wide 
lived with cancer, and that 14.1 million new cancer diagnoses were reported.172 As 
such, cancer is a very important target for researchers to understand and develop 
new treatments for. The term cancer, however, composes a wide range of types, e.g. 
breast, lung, skin or prostate that all differ in their cellular composition and disease 
progression. Even within a single solid cancer tumour, a large amount of cell 
heterogeneity is found.173,174 Between tumour cells differences in, for example, 
proliferation rate, metastatic propensity and cell-cell interaction makes the tumour 
cell population very diverse.173,175  
 
Tumour cell heterogeneity was originally explained by two models, the stochastic 
and the hierarchical models.176,177 In the stochastic model, every tumour cell possesses 
the same probability of being tumorous. Any variation observed within the tumour 
population is attributed to stochastic differences in internal and external influences 
upon the cells. In the past 10-15 years, however, mounting evidence has been found 
for the hierarchical model176,178 (Figure 5.1A), where a small subpopulation of tumour 
cells are capable of initiating and maintaining tumours. This subpopulation is 
commonly referred to as Cancer Stem Cells (CSCs), because of their stem-like 
properties, such as self-renewal.178
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 This subpopulation of tumour cells are able to undergo both symmetric (leading to 
two CSCs or two differentiated cells) and asymmetric cell division (leading to one 
CSC and one differentiated cell)179 and are thereby able to both maintain their own 
population and progress tumour growth. CSCs have been identified in a number of 
cancers including breast,180 brain,181 colon,182,183 prostate,184 leukaemia,185 ovarian,186,187 
and pancreatic cancer,188 and the hierarchical model is an accepted concept for 
tumour progression.178 CSCs have been found to be resistant to many 
chemotherapeutic drugs and their existence can explain the common recurrence of 
tumours despite successful chemotherapies that seemingly eradicated the targeted 
tumour.189,190 This makes CSCs an attractive drug target for anticancer treatments 
with the belief that eradicating them would lead to complete tumour eradication. 
However, despite several discoveries in the field of anti-CSC therapeutics, their 
eradication is not straightforward. One rationale for this is because CSCs reside in a 
so-called “CSC niche” that protects the CSCs and substantial efforts have been made 
to identify the make-up of the niche in different tumours. In the initial hierarchical 
model, it was proposed that CSCs, similarly to normal stem cells, were rare and/or 
mainly existed in a dormant (quiescent) state in these niches (Figure 5.1A). Recent 
findings, however, show that the number of CSCs increase with tumour progression, 
and that their original dependence on their niche decreases with increased tumour 
malignancy (Figure 5.1B).178,191 Moreover, there is evidence that differentiated cells, 
through their plasticity, are able to revert to CSCs. This suggests that only targeting 
the CSCs to eradicate tumours may not be enough since the differentiated progeny 





Figure 5.1: Cancer stem cell (CSC) models. A. Classic CSC model (also known as hierarchical 
model). CSCs make up a small subpopulation of the total tumour environment, with a large 
niche cell presence to guide CSCs. Herein only CSCs are able of self-renewal, while non-CSC 
daughter cells only are capable of differentiation. B. Modified CSC model. CSCs are not rare 
and/or quiescent and with tumour progression CSCs become less dependent of their niche 
cells. Both non-CSC daughter cells and differentiated cancer cells have inherent plasticity, 
capable of reprogramming to CSCs.178 Green arrows indicate niche signalling. Red arrow 
indicates self-renewal. 
 
To be able to further understand tumour progression and the role of CSCs, it is 
necessary to be able to culture CSCs in vitro in a scalable manner. It is vital that such 
culturing conditions maintain the CSC niche, so that the cells maintain their stemness 
and do not differentiate. To this end, a recent publication between the Taga and 
Bradley labs identified a polyurethane (PU10), that bound a series of proteins that 
allowed recapitulation of the glioma CSC niche.126  
 
Pancreatic cancer is a very lethal form of cancer, primarily due to its usually late 
diagnosis with an estimated five-year survival rate of 6.7 %.192 A hallmark of 
pancreatic cancer is its highly invasive nature and it has been suggested that 
pancreatic CSCs are responsible for this and the poor tumour response to current 
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treatments.193–195 The isolation of pancreatic CSCs was first described in 2007 when 
primary human pancreatic adenocarcinomas were implanted in 
immunocompromised mice, followed by the identification of cell surface markers to 
identify the pancreatic CSC subpopulation.188 Cells expressing three markers, CD44, 
CD24 and epithelial-specific antigen (ESA) (0.2-0.8 % of the cell population), were 
identified as pancreatic CSCs since they could self-renew and differentiate. 
Furthermore, injection of 100 pancreatic CSCs into mice was enough to form the same 
type of tumours as they had originated from. Therefore, using fluorescence assisted 
cell sorting (FACS) of CD44+/CD24+/ESA+ cells is a useful way of separating 
pancreatic CSCs from non-CSCs.  
 
The Hoechst 33342 dye exclusion assay is another method for separating CSCs from 
the non-CSCs. This assay was first developed in the Taga lab to isolate rat glioma C6 
CSCs.196 It is based on the principle that CSCs efflux the DNA binding dye Hoechst 
33342 more efficiently than non-CSCs, due to an ATP binding cassette transporter. 
The CSCs are also known as the side population and the non-CSCs as the main 
population.   
 
Another method of separating CSCs from non-CSCs utilises the low activity in CSCs 
of the protein degrading proteasomes.197 CSCs were separated from non-CSCs (in 
both glioma and breast cancer cell lines) based on the low activity of proteasome 26S 
in CSCs.198 Many proteins require ubiquitination to allow initiation of proteasome 
degradation, but the protein ornithine decarboxylase (ODC) can be directly degraded 
by proteasome 26S, avoiding the need for ubiquitination. The recognition site for 
proteasome 26S in ODC, the so-called degron sequence, is a 37-amino acid sequence 
at the carboxyl terminus (known as cODC). Using ZsGreen (a fluorescent reporter), 
fused to the cODC gene a reporter protein (ZsGreen-cODC) was created.199 In non-
CSC cells (with normal activity of proteasome 26S), ZsGreen-cODC was rapidly 
degraded, conversely, in the CSC subpopulation, low proteasome 26S activity 
resulted in accumulation of ZsGreen-cODC and thereby stronger ZsGreen 
fluorescent signal. Using FACS, it was possible to separate the CSC from the non-
CSC populations and this method has subsequently been shown to enable the 
separation of pancreatic CSCs from non-CSCs, and was employed to sort the cells 




The aim of this chapter was to identify polymeric substrates that could support 
pancreatic CSCs over longer periods of incubation (> 48 h, referred to as “niche-
mimicking”), or that were able to selectively bind CSCs over shorter incubation times 
(6-24 h, referred to as “trapping”). Using the established polymer microarray 
techniques of the Bradley group,115,116,200 100’s of different polymers were screened. 
In the first instance a library of polyacrylate/acrylamides and polyurethanes were 
screened, subsequently a novel peptide-incorporating polyacrylate/acrylamide 
library was developed and screened. 
 
5.2 CSC niche mimicking polymer identification  
 
5.2.1 Polymer microarray screening 
To identify pancreatic CSC niche-mimicking substrates, a polymer microarray of 
polyacrylate/acrylamides and polyurethanes of varied structural properties was 
printed using an in-house polymer library.115,116,200 The arrays consisted of 382 
polymers (209 polyacrylates/acrylamides, 173 polyurethanes), all in triplicates (1146 
features per array) (See Appendix Figure A3.1 for array layout and Table A3.1 and 
A3.2 for polymer compositions).  
 
As a pancreatic cancer cell model, KLM1 cells (a human pancreatic adenocarcinoma 
cell line) were used. To allow separation of the subpopulation of CSCs within the cell 
line the genetically engineered version of the cells (KLM1-ZsGreen-cODC) was 
established by fusing the ZsGreen gene to the C-terminal part degron of murine 
cODC198,199. The KLM1-ZsGreen-cODC cells were then isolated by FACS with cells 
with a high ZsGreen intensity (ZsGreen(+)) collected as the CSC fraction, and the rest 
of the cell population was named the non-CSC fraction (ZsGreen(-)) (Figure 5.2). A 
1:1 mixture of the CSC and non-CSC cells were seeded onto the polymer microarrays 
and analysed for the ability to selectively bind CSCs and maintain and propagate 





Figure 5.2: Flow cytometry of CSCs of a ZsGreen-cODC transfected KLM1 cell line. CSC were 
isolated based on their low 26S proteasome activity towards ornithine degradation, and 
consequently high ZsGreen intensity (ZsGreen(+)). Figure produced by Dr Murota.  
 
Two microarray-printed slides were analysed, with the first seeded with a 1:1 ratio of 
CSCs and non-CSCs (1×106 cells/slide) and incubated for 18 h. The ZSGreen 
fluorescence intensity was measured for each polymer spot and the slide was 
incubated for another 30 h. After a total of 48 h incubation the ZsGreen fluorescent 
intensity was measured again, followed by cell fixing, Hoechst staining and 
fluorescence intensity measurement at each polymer spot. The second slide was 
seeded in the same manner, but incubation was stopped after 18 h when ZsGreen 
fluorescence was measured, the cells were fixed, stained with Hoechst and the 
fluorescence intensity was measured. The ZsGreen intensity was used as a measure 
of CSC attachment, while the Hoechst intensity gave the total cell number per spot.  
 
Niche and control polymers for scale-up studies were chosen based on calculated 
values of ‘increasing rate of CSC number’ and ‘CSC specific support’ (see Figure 5.3, 
Equation 1 and 2). Polymers with high values of both (i.e. polymers that selectively 
bound CSCs after 18 h and then underwent self-renewal) were considered as putative 
hit candidates (Figure 5.4). Polymers with low values of ‘increasing rate of CSC 
number’, but similar ‘increasing rates of total cell number’ (see Figure 5.3, Equation 
3 and 4) as the niche polymer candidates, were used as putative negative control 
polymers. Based on this analysis three putative niche-mimicking polymers (PA531, 
PA419, PA514) and four negative control polymers (PA435, PA418, PA108, PA548) 






     (Eqn. 1) 
 
CSC	specific	support = 	 4567889	:9;895:;<	(>?	@) DE8F@5;	:9;895:;<	(>?	@)⁄
4567889	:9;895:;<	(B?	@) DE8F@5;	:9;895:;<	(B?	@)⁄
     (Eqn. 2) 
 
Predicted	Hoechst	intensity	(48	h) = 	 4567889	:9;895:;<	(B?	@)
4567889	:9;895:;<	(B?	@) DE8F@5;	:9;895:;<	(B?	@)⁄
  (Eqn. 3) 
 




CSC	specificity = 	 4567889	:9;895:;<	(B?@)
DE8F@5;	:9;895:;<	(B?	@)
     (Eqn. 5) 
 
Figure 5.3: Equations used to calculate paramters considered for identifying CSC niche-








Figure 5.4: Basis of choosing putative CSC niche-mimicking and CSC-trapping polymers and 
negative controls after polymer microarray seeding. A 1:1 ratio of CSCs (ZsGreen(+)) and  
non-CSCs (ZsGreen(-)) were seeded on the array. On polymer spots considered as niche 
mimicking hits, CSCs bind preferentially over non-CSCs at 18 h, and then preferentially 
undergo self-renewal rather than divide to from non-CSC daughter cells. In contrast, negative 
control polymers are polymer spots where preferential binding of non-CSCs and 
differentiation of CSCs to non-CSCs occur. On polymer spots considered as CSC trapping hits, 
CSCs bind preferentially over non-CSCs at 18 h. In contrast, negative control polymers are 












Figure 5.5: Analysis of a 382-polymer microarray to select niche-mimicking polymer 
candidates for scale-up studies. A. 26 polymers with high values of “Increasing rate of CSC 
Number” (green bars) and “CSC specific support” (red square) were considered as potential 
niche-mimicking substrates subset. Three polymers, PA531, PA419, PA514 (circled in orange) 
were chosen to scale-up as putative niche-mimicking hits. B. 34 polymers with similar cell 
proliferation rates as the chosen niche-mimicking hits, calculated as “Increasing rate of total 
cell number” (blue squares), but with low “Increasing rate of CSC number” were considered 
as potential negative controls. Four polymers, PA435, PA418, PA104 and PA458 were chosen 
to scale-up as putative negative controls. Figure produced by Dr Murota and modified. Mean 





Figure 5.6: Structure of polyacrylates chosen for scale-up for CSC niche-mimicking substrate 
identification.  
 
5.2.2 Polymer screening 
To study the chosen polymers (all polyacrylates/acrylamides) at a larger scale, the 
polymers were resynthesized via AIBN-initiated random free radical polymerisation 
and characterised by GPC (for Mn, Mw and PDI of the scaled-up polymers see Table 
5.1, for GPC traces see Appendix Figure A3.2).  
 
Table 5.1: Mn, Mw and PDI values of scaled-up polyacrylates/acrylamides as putative niche-
mimicking polymers and the negative controls, as determined by GPC.  
Polymer Name Mn (g/mol) Mw (g/mol) PDI 
Hits    
PA531 59,500 183,500 3.08 
PA419 64,100 222,700 3.08 
PA514 43,800 133,900 3.05 
Negative controls    
PA104 42,800 109,200 2.56 
PA435 66,00 210,900 3.20 
PA418 38,700 92,800 2.40 




The resulting polymers were spin-coated as solutions (1 % w/v in THF) onto agarose 
(1 % w/w) coated glass coverslips (32 mm in diameter). A 1:1 ratio of CSCs and non-
CSCs were seeded onto the coverslips (1.25×105 cells/coverslip) and incubated for 48 
or 96 h, followed by cell counting and cell release by trypsinisation for flow cytometry 
analysis of the number of ZsGreen(+) cells. After 48 h, rounded cells were observed 
on both the niche and control polymer candidates, suggesting poor cell attachment. 
After 96 h however, cells started spreading and proliferated well on the polymers. 
Although this was an improvement compared to conventionally used polystyrene 
(PS) dishes (results not shown), there was no significant difference observed between 
the niche and control polymer candidates (Figure 5.7). As such, it was decided to re-
analyse the results from the microarray screen to identify a CSC ‘trapping’ substrate 
rather than a niche-mimicking material.  
 
 
Figure 5.7: Results from the scale-up of the putative hit and control polymer candidates 
chosen as CSC niche-mimicking substrates after the initial polymer microarray screen. 
Culture of a 1:1 ratio of CSCs and non-CSCs for A. 48 h. B. 96 h. No statistically significant 
difference in “Increasing rate of CSC growth” (green bars) or “CSC specific support” (red 







5.3 CSC trapping polymer identification 
 
5.3.1 Polymer microarray screening 
The previously seeded polymer microarray with 18 h incubation was reanalysed to 
assess trapping capacity (see Figure 5.4, labelled “CSC specificity” in Figure 5.8). 
Polymers that bound a high number of cells after 18 h and where the majority were 
CSCs, were considered as CSC trapping hits (see Figure 5.3, Equation 5). Polymers 
that bound a high number of cells, but where the majority were non-CSCs were 
considered as negative controls. Based on these results two putative CSC trapping 
polymers (PA474, PA104) and two putative negative controls (PA450, PA395) were 
chosen for scale-up studies (Figure 5.9).  
 
Figure 5.8: Analysis of members of a 382-polymer microarray to select CSC trapping polymer 
candidates for scale-up studies. 37 polymers with cells showing high hoechst intensity (blue 
bars) were analysed for their “CSC specificity” (red squares) (see Figure 5.3, Equation 5). 
Those with high values of “CSC specificity” were considered as potential CSC trapping 
substrates (on LHS of x-axis). Polymers with low values of “CSC specificity” were considered 
as potential negative control substrates (on RHS of x-axis). Two polymers (PA474 and PA104) 
were chosen as putative CSC trapping polymers and two polymers (PA395 and PA450) were 
chosen as putative negative controls for scale-up studies. Mean (n = 4) with ± SD is shown in 





Figure 5.9: Structure of polyacrylates chosen for scale-up studies as CSC trapping substrate 
identification. 
 
5.3.2 Polymer screening 
The chosen polymers were synthesised and coated onto glass coverslips as described 
in Section 5.2.2 (for Mn, Mw and PDI of the scaled-up polymers see Table 5.2, for GPC 
traces see Appendix Figure A3.2).  
 
Table 5.2 Molecular weight (Mn) and PDI values of scaled-up polyacrylates/acrylamides as 
putative CSC trapping polymers and the negative controls, as determined by GPC.  
Polymer Name Mn (g/mol) Mw (g/mol) PDI 
Hits    
PA474 35,400 71,300 2.01 
PA104 42,800 109,200 2.56 
Negative controls    
PA395 68,300 222,700 3.26 
PA450 47,300 146,500 3.10 
 
A 1:1 ratio of CSCs and non-CSCs (4×105 cells/coverslip) were incubated for 18 h. 
The total number of cells per polymer were counted and the proportion of ZsGreen(+) 
cells determined by flow cytometry. Unfortunately, no significant difference in CSC 
trapping between hit and control polymers was observed using these conditions 
(Figure 5.10). It was hypothesised that the presence of serum in the cell media (10 % 
FBS) during the incubation was sufficient to allow for cell attachment to the polymer 
surface, thereby masking the CSC trapping abilities of the polymers. To investigate 
this, the same experiment was set-up using cell media supplemented with only 1 % 
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FBS. Unfortunately, the results were similar for all polymers, trapping CSC cells 
equally well according to ZsGreen fluorescence analysis by flow cytometry (results 
not shown).  
 
 
Figure 5.10: Results from the scale-up of putative hit and negative control polymers as CSC 
trapping substrates. Following incubation of a 1:1 ratio of CSCs and non-CSCs for 18 h and 
cell release by trypsinisation, the number of ZsGreen(+) cells were analysed by flow 
cytometry. No statistically significant difference in mean ZsGreen intensity was observed 
between the putative hit and control polymers. All intensities were normalised to the 
polystyrene intensity. Figure produced by Dr Murota and modified. Mean (n = 3) with ± SD 
is shown in all cases. 
 
5.4 Screening of a peptide-containing polymer 
microarray  
 
To progress the project, it was decided to develop a novel polymer microarray 
wherein cell-binding peptides were incorporated into the polymers. It was 
hypothesised that this would aid CSC-binding and provide a better niche-mimicking 
or trapping substrate. Three peptides were chosen to be included into the polymers, 
RGD and cyclic RGD (cRGD), both found in fibronectin, as well as a sequence from 
laminin 111. The linear RGD and laminin 111 peptides had the same cell-binding 
structures as the peptides used in the Chapter 2. cRGD is known to have increased 
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integrin affinity compared to its linear version and is potentially more robust.139,201 
The “peptide-containing polymer microarray” was formed by printing monomers, 
cross-linker and initiator onto glass slides, followed by in situ UV polymerisation.  
 
5.4.1 Peptide monomer synthesis 
All peptide monomers were synthesised using SPPS methods. The linear RGD 
(referred to as acrylamide-GRGDS) and laminin 111 (referred to as acrylamide-
YIGSR) monomers were designed to bear a 6-aminohexanoic acid linker at the N-
terminus to which acryloyl chloride was reacted (Figure 5.11A-B). To afford the cRGD 
monomer (referred to as acrylamide-c(RGDfK)), Fmoc-Lys-OH was modified with 
acryloyl chloride to give Fmoc-Lys(acrylamide)-OH. This was used in SPPS to form 
cRGDfK (Figure 5.11C). All peptides were purified by reverse-phase column 
chromatography (Biotage, Isolera) and characterisied by reverse-phase high-
performance liquid chromatography (RP-HPLC) and high resolution mass 





Figure 5.11: Structures and solid phase synthesis of peptide monomers used in peptide-
containing polymer microarray. A. Acrylamide-Ahx-GRGDS-NH2 (referred to in main text as 
Acrylamide-GRGDS) (i) Fmoc-AA-OH, oxyma, DIC, DMF, 1 h. (ii) 20 % piperidine/DMF, 2 × 
10 min. Steps i and ii repeated with required Fmoc-AA-OH. (iii) acryloyl chloride, DIPEA, 
DMF, 1 h. (iv) TFA/TIS/H2O (95:2.5:2.5), 3 h. B. Acrylamide-Ahx-YIGSR-NH2 (referred to in 
main text as Acrylamide-YIGSR), same procedure as for Acrylamide-GRGDS. C. Acrylamide-
c(RGDfK) (i) Thionyl chloride, DMF, N2, 1 h. (ii) Fmoc-phe-OH, DIPEA, DMF, 1h. (iii) MeOH, 
DIPEA, DCM, 1 × 20 min, 1 × 30 min. (iv) 20 % piperidine/DMF, 2 × 10 min. (v) Fmoc-AA-
OH, oxyma, DIC, DMF, 1 h. (vi) 20 % piperidine/DMF, 2 × 10 min. Steps v and vi repeated 
with required Fmoc-AA-OH. (vii) HFIP, DCM, 3 h. (viii) PyBOB, HOBt, DIPEA, DCM, o.n. 




5.4.2 Microarray printing and screening 
The microarray was fabricated using a sciFLEXARRAYER S5 printer and consisted 
of 96 features printed in quadruplicate (384 features in total). 9 monomers divided 
into three groups (monomer 1, 2 and 3) were used in varying combination and ratios 
(Figure 5.12 for monomer structures, also see Appendix Figure A3.3 for array layout 
and Table A3.3 for polymer compositions) with all monomers printed as solutions 
(20 % w/v in NMP) except for the peptide monomers that due to their limited 
solubility were printed at 2 % w/v in NMP. 1-Hydroxycyclohexyl phenol ketone (30 
% w/v in NMP) was used as the photoinitiator and 1,6-diol diacrylate (30 % w/v in 
NMP) as the cross-linker. Following printing onto fluorosilane-masked glass slides, 
the array was polymerised by UV irradiation for 30 minutes (100 mJ/cm2).  
 
 
Figure 5.12: Structures of monomers used for the peptide-containing polymer array, divided 




For the microarray screening, two slides were screened. On each slide a 1:1 ratio CSCs 
and non-CSCs (5×105 cells/slide) were seeded and incubated for 24 h and ZsGreen 
intensity was measured. The first slide was incubated for a further 48 h and the 
ZsGreen intensity measured again followed by cell fixing and staining with hoechst 
and PI, and fluorescence intensities measured. For the second slide the same 
procedure was repeated, but with the final incubation time at 24 h. High 
autofluorescence (particularly in the hoechst channel) of the polymer spots made the 
fluorescence intensity analysis difficult. Therefore, spot by spot analysis of 
microscope images was carried out by eye to select CSC trapping, CSC niche-
mimicking and their corresponding control polymer candidates. The definition of 
each was analogous to those explained in Figure 5.4. CSC trapping polymers were 
selected based on the ratio of ZsGreen(+) cells per PI+ cells (total cell number) after 
24 h. CSC niche mimicking cells were selected based on the amount of ZsGreen(+) 
cells at 48 h and the ratio of ZSGreen(+) cells per PI+ cells at 72 h. From the analysis 
three putative CSC niche mimicking polymers (PP60, PP62 and PP65) and one 
negative control were chosen (PP79) (Figure 5.13). For CSC trapping, four putative 
hit polymers (PP73, PP74, PP77 and PP80) and one negative control polymer (PP61) 
were chosen (Figure 5.14). All polymers were subsequently scaled-up and used for 
further cell studies.  
 
  
Figure 5.13: Structures of peptide-containing polyacrylate/acrylamides chosen for scale-up 





Figure 5.14: Structures of the peptide-containing polyacrylate/acrylamides chosen for scale-
up for CSC trapping substrate identification.  
 
5.4.3 Polymer synthesis  
For scale-up studies the polymers were polymerised in situ on methacrylate-
functionalised glass coverslips (13 mm in diameter) (Figure 5.15). The methacrylate 
group was installed to react with the acrylate/acrylamide monomers to afford 
anchoring of the polymers onto the glass surface. To ensure that the concentration of 
monomers was high enough to afford polymers on the glass surface, ×10 increase of 
monomer concentration was used compared to the array screening. The initiator and 
crosslinker concentrations were kept the same so as to not generate too heavily cross-
linked polymers or very short polymer chains. The pre-polymer solutions of 
monomers, cross-linker and initiator in NMP were dispensed onto a Poly(ethylene 
terephthalate) (PET) film, with a functionalised glass coverslip put on top, before UV 





Figure 5.15: Set-up of in situ coverslip polymerisation. Hydroxyl-functionalised glass 
coverslips were functionalised with 3-(trimethoxysilyl)propyl methacrylate. This was 
followed by UV-initiated polymerisation by depositing a droplet of monomers, crosslinker 
and initiator on a PET film on top of which the methacrylate-functionalised coverslip was 
placed. After polymerisation the coverslip was peeled off from the PET film to obtain the 
polymer-coated coverslip.  
 
5.4.4 Niche-mimicking polymer screening 
The polymer-coated coverslips were incubated with a 1:1 mixture of CSCs and non-
CSCs (100 000 cells/coverslip) and incubated for 24 and 72 h to assess the ability of 
the polymers to maintain the CSC population (i.e. mimic the CSC niche). TCPS was 
used as an additional negative control. Following incubation the cells were released 
by trypsinisation and the number of ZsGreen(+) cells was determined by flow 
cytometry (Figure 5.16). The two hit candidates PP62 and PP65 were found to 
proliferate and maintain the CSC population over time, with 59 % and 49 % CSCs 
respectively after 72 h incubation. This was an improvement compared to the 
negative controls PP79 and TCPS where greater level of differentiation of the CSCs 
was observed (38 % CSCs for both after 72 h incubation). These results were also 
confirmed by fluorescence microscopy of the coverslips, where a larger proportion of 
ZsGreen(+) cells were visible on PP62 and PP65 compared to the negative control 
PP79 (Figure 5.17). To further understand these results, current experiments are 
underway with the niche-mimicking polymers PP62, PP65 and the negative control 






Figure 5.16: Flow cytometry analysis of cells attached to putative niche-mimicking polymers 
and negative controls (including TCPS) after 24 or 72 h incubation with a 1:1 ratio of CSCs 
and non-CSCs. ZsGreen(+) cells are considered as CSCs, shown in the three top boxes of each 
condition. Cells were pooled for flow cytometry analysis (n = 5).  
 
Figure 5.17: Fluorescence and bright-field images of identified niche-mimicking (PP62 and 
PP65) and negative control (PP79) polymers after 24 and 72 h incubation with a 1:1 ratio of 
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CSCs and non-CSCs. The proportion of ZsGreen(+) cells (CSCs) over times was maintained  
better on PP62 and PP65 than on PP79. Scale bar = 200 µm. 
 
5.4.5 CSC trapping polymer screening 
The putative CSC trapping polymers and negative control polymer were coated on 
coverslips and incubated with a 1:1 ratio of CSCs and non-CSCs (100 000 
cells/coverslip) for 6 h. This was to assess the capacity of these polymers to 
preferentially trap CSCs over non-CSCs. Following the incubation and cell release by 
trypsinisation, the number of ZsGreen(+) cells was determined by flow cytometry. 
Over this short incubation time, however, no significant difference in CSC to non-






Figure 5.18: Flow cytometry analysis of cells attached to putative CSC trapping polymers and 
negative controls (including TCPS) after 6 h incubation with a 1:1 ratio of CSCs and non-CSCs. 
ZsGreen(+) cells are considered as CSCs, shown in the top box of each condition. Cells were 




In current culture methods for pancreatic CSCs, the CSCs make up a very small 
percentage of the cell population (0.2-0-8 %).188 Therefore, identifying a substrate that 




Screening of a 382-member polymer microarray composed of 
polyacrylates/acrylamides and polyurethanes enabled the initial identification of 
polymer substrates that were CSC niche-mimicking, in that they could maintain and 
increase the amount of CSCs (ZsGreen(+) cells) over 72 h. It also enabled the 
identification of polymers where preferential attachment, or trapping, of CSCs was 
seen over non-CSCs (ZsGreen(-) cells). The subsequent scale-up of polymers in both 
these cases was unfortunately unable to show any significant difference between hit 
and control polymer candidates. However, for both niche-mimicking and trapping 
purposes, an improvement was observed compared to the conventional PS culture 
conditions.  
 
The inclusion of cell-binding peptides was proposed to improve the cell attachment 
by incorporating acrylamide monomers bearing RGD, a cRGD or a LamIII sequence 
with commercially available monomers. A new microarray design was developed, 
with a library of 96 peptide-containing polymers being screened as both niche-
mimicking and trapping substrates. Scale-up experiments confirmed the niche-
mimicking abilities of two polymers (PP62 and PP65) as they maintained the CSC 
population over 24 to 72 h incubation, compared with the negative control polymer 
(PP79), where CSC differentiation was observed. Current efforts are focusing on 





A high-throughput screening strategy was employed to identify a substrate that 
could either trap or mimic the pancreatic CSC niche. A 382-member 
polyacrylate/acylamide library was initially screened, although confirmation of 
array screening results in scale-up experiments was unsuccessful. A novel peptide-
containing polymer microarray was designed and screened with pancreatic CSCs and 
the subsequent scale-up studies are underway. Looking further ahead, this new 
microarray design can be used as a screening platform to identify novel substrates 
for not just other types of CSCs, but in principle for any cell type where novel culture 
conditions and substrates are desired. Furthermore, the ease of peptide monomer 
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design makes the facile tailoring of the library to contain certain peptides, such as 
motifs known to bind the cells of interest or other ECM-derived sequences from e.g. 
collagen, emphasises the tuneable properties of this platform.  
 
5.7 Materials and Methods 
 
5.7.1 Instruments used for polymer scale-up 
 
Zepto O2 plasma generator (Diener electronic GmbH, Germany) 
 
CL-1000 Ultraviolet crosslinker (UVP LLC, USA) 
 
Spincoater Model P6700 Series (Specialty Coating Systems, USA) 
 
5.7.2 Instruments for characterisation and purification 
 
Agilent 1100 ChemStation analytical RP-HPLC (Agilent, USA) with a Zorbax Eclipse 
C18 reverse phase column (4.6 mm × 100 mm, 3.5 µ) with an evaporative light 
scattering and a multi-wavelength detector eluting with a gradient of water to 
acetonitrile (5 – 95 %), both with 0.1% formic acid with a flow rate of 1 mL/min 
 
Agilent 1100 GPC equipped with a PLgel MIXED-C columns and a RI detector eluting 
with DMF containing 0.1M LiBr at 60 °C at 1 ml/min (Agilent, USA) 
 
Isolera One equipped with a Biotage® SNAP HP-BioSphere C18 10 g column 
detection at 250 nm, eluting with a gradient of water to acetonitrile, both with 0.1 % 
formic acid with a flow rate of 12 ml/min (Biotage, Sweden) 
 
BenchTop Pro with Omnitronics lyophiliser (SP scientific, USA) 
 
1H NMR at 500 MHz Bruker AVA 500 (Bruker, USA) 
 




HRMS on a Bruker 3.0 T Apex II spectrometer (Bruker, USA) 
 
5.7.3 Chemicals  
 
All protected amino acids, aminomethyl polystyrene resin, and the Fmoc-Rink amide 
linker were purchased from GL Biochem Ltd (Shanghai) or NovaBiochem. 
Poly(ethylene oxide), 4-arm, amine terminated ((PEG-NH2)4) (Mn = 10 000 g/mol), 
was purchased from Sigma Aldrich. All other chemicals were from Sigma Aldrich or 
Acros, and used as received. 
 
5.7.4 Polymer synthesis 
 
The polymers used for polymer microarray fabrication were part of an in-house 
library within the Bradley group and their fabrication was according to previously 
published methods using a Quarraymini contact printer (Genetix, UK).115,116,200 
 
For scale-up studies polymers were synthesised using random free-radical 
polymerisation. Acrylate and acrylamide monomers (see Table 5.3 for compositions) 
and AIBN (initiator) were dissolved degassed solvent (DMF or toluene) and heated 
overnight at 60 °C. The resulting polymers were precipitated into cold diethyl ether, 
centrifuged, decanted and dried under vacuum at 60 °C overnight to afford the final 
product. Polymer molecular weight and PDI were determined by GPC (Agilent 1100) 











Table 5.3 Polyacrylates/acrylamide scaled-up as part of Chapter 5. The polymer compositions 
and molecular weight (Mn and Mw) and PDI values as determined by GPC are given.  M1 = 
Monomer 1, M2 = Monomer 2, M3 = Monomer 3. 
Polymer 
Name 





Niche-mimicking      
Hits       
PA531 MEMA (55) DEAEMA (45) - 59,500 183,500 3.08 
PA419 MEMA (60) DEAEA (30) MA (10) 64,100 222,700 3.08 
PA514 MEMA (40) DEAEA (30) MMA (30) 43,800 133,900 3.05 
Negative controls      
PA104 MEMA (50) DEAEA (10) - 42,800 109,200 2.56 
PA435 MEMA (60) DEAEA (10) MEA (30) 66,00 210,900 3.20 
PA418 MEMA (40) DEAEA (30) MA (10) 38,700 92,800 2.40 
PA458 MEMA (40) DEAEA (30) THFFMA (30) 60,200 197,300 3.36 
       
CSC trapping      
Hits       
PA474 MEMA (40) DEAEA (30) HEMA (30) 35,400 71,300 2.01 
PA104 MEMA (50) DEAEA (10) - 42,800 109,200 2.56 
Negative controls      
PA395 EMA (50) DMAEMA (50) - 68,300 222,700 3.26 
PA450 MEMA (40) DEAEA (30) THFFA (30) 47,300 146,500 3.10 
 
5.7.5 Spin-coating of polymers onto functionalised glass 
coverslips 
 
Glass coverslips (32 mm in diameter) were lightly shaken in 1M NaOH overnight 
followed by washing with acetone and water. The coverslips were submerged in 1 % 
(v/v) APTES in acetonitrile for 1 hour, washed with acetone and dried at 100 °C 
overnight. Thereafter the coverslips were dip-coated in agarose (1 % w/v) (Type 1, 
low EEO) in deionised water and dried at room temperature overnight. Polymer 
solutions (1 % w/v in THF) were spin-coated (200 µl/coverslip) at 2000 rpm for 10 
seconds and dried at 40 °C overnight.  The polymer-coated coverslips were then sent 




5.7.6 Synthesis of Fmoc-Lys(acrylamide)-OH203 
 
 
Fmoc-Lys-OH (500 mg, 1.2 mmol, 1 eq.) was dissolved in 1,4-dioxane (5 mL) and 
cooled on ice. Na2CO3 (10 % (w/v), 14 mL) was added dropwise resulting in a white 
slurry. Acryloyl chloride (123 mg, 1.4 mmol, 1.1 eq.) was added drop-wise and the 
reaction mixture was allowed to warm to room temperature and stirred overnight. 
The reaction was concentrated in vacuo, the crude product dissolved in water and 
washed with diethyl ether (3×50 ml). 1M KHSO4 was added to the aqueous layer until 
pH 2-3 and the product was extracted into ethyl acetate (2×50 ml). The organic layer 
was dried (MgSO4), filtered and concentrated in vacuo and dried under vacuum 
overnight to afford the final product (325 mg, 62 %). 1H NMR (600 MHz, Chloroform-
d) δ 7.74 (d, J = 7.6 Hz, 2H, a), 7.59 (t, J = 7.4 Hz, 2H, b), 7.38 (t, 7.5 Hz, 2H, c), 7.32–
7.26 (m, 2H, d), 6.50 (dd, J = 17.3, 1.3 Hz, 1H, o1) , 6.27 (dd, J = 17.0, 1.3 Hz, 1H, o2), 
6.14 (dd, J = 17.3, 10.4 Hz, 1H, m), 5.95 (dd, J =10.5, 1.3 Hz, 1H, n), 5.76–5.71 (m, 1H, 
g), 5.63–5.58 (m, 1H, e), 4.42 – 4.34 (m, 2 H, f) 4.15 – 4.10 (m, 1H, h) 3.39 – 3.25 (m, 2H, 
l), 1.96 – 1.72 (m, 2H, i), 1.62 – 1.53 (m, 2H, j), 1.51 -  1.35 (m, 2H, k). IR (neat) ν (cm-1) 






5.7.7 Synthesis of acrylamide-Ahx-GRDGS-NH2 and acrylamide-
Ahx-YIGSR-NH2 
 
Acrylamide-Ahx-GRGDS-NH2 and acrylamide-Ahx-YIGSR-NH2 were synthesised 
on solid-phase using the Fmoc/tBu route.148 The Fmoc-Rink amide linker was 
coupled to the aminomethyl polystyrene resin (1 g, loading 0.745 mmol/g) prior to 
peptide synthesis. 
 
Coupling of the protected Rink linker and protected amino acids. Fmoc-Rink or 
Fmoc-protected amino acids (3 eq.) and Oxyma (3 eq.) were dissolved in DMF (1 M) 
and stirred for 5 min followed by the addition of DIC (3 eq.) and further stirred for 5 
min. The mixture was added to the resin and shaken at room temperature for 1 hour. 
The resin was washed with DMF, MeOH and DCM. 
Fmoc deprotection. The N-Fmoc protected peptide on the resin was treated twice 
with 20 % piperidine in DMF for 10 minutes. The resin was subsequently washed 
with DMF, MeOH and DCM. 
Coupling of acryloyl chloride. Acryloyl chloride (5 eq.) and DIPEA (10 eq.) were 
dissolved in DMF (0.1 M) and added to the resin and shaken at room temperature for 
1 hour. The resin was washed with DMF, MeOH and DCM.  
Deprotection of the peptide and cleavage off the resin. TFA/H2O (95:5) was added to 
the pre-swollen resin (in DCM) and shaken at room temperature for 3 h. The peptide 
was precipitated from the filtrate by the addition of cold diethyl ether, collected by 
centrifugation and washed twice with ether. The peptides were re-dissolved in H2O 
(10 mL) and purified by RP-HPLC (Biotage Isolera)  (5% to 60 % MeCN/H2O over 20 
min, 60 % to 95 % MeCN/H2O over 5 min) followed by lyophilisation. The peptides 
were characterised by RP-HPLC (> 95 % purity) and HRMS. Acrylamide-Ahx-
GRGDS-NH2 (409 mg, 83 %) m/zcalculated 657.33146 m/zfound 657.333270. Acrylamide-







5.7.8 Synthesis of acrylamide-c(RGDfK) 
 
Acrylamide-c(RGDfK) was synthesised on solid phase as above but using a 
chlorotrityl-linker on a polystyrene resin.  
Resin activation. Thionyl chloride (86 µL, 1.2 mmol, 2.5 eq.) dissolved in anhydrous 
DMF (1.7 mL, 1 mM) was added to the chlorotrityl-linked polystyrene resin (500 mg) 
and slowly stirred under nitrogen for 1 hour. The resin was washed with anhydrous 
DMF and anhydrous DCM.  
Fmoc-phe-OH coupling. Fmoc-phe-OH (564 mg, 15 mmol, 3 eq.) and DIPEA (507 µl, 
15 mmol, 3 eq.) dissolved in anhydrous DMF (5 mL) was added to the resin and 
stirred at room temperature for 1 hour. The resin was washed with anhydrous DMF 
and anhydrous DCM.  
Resin capping. DIPEA (800 µl) was dissolved in anhydrous DCM (4.3 ml) and dry 
MeOH (800 µl), and the solution added to the resin and shaken at room temperature 
for 20 minutes. After removing the reaction solution from the resin by filtration, fresh 
reaction solution was added and the resin shaken for a further 30 minutes. The resin 
was washed with DMF, MeOH and DCM.  
Fmoc deprotection and coupling of protected amino acids. See 6.5.4 
Cleavage off the resin. Hexafluoroisopropanol/DCM (1:4) was added to the resin and 
shaken at room temperature for 3 h. The protected linear peptide H-
K(acrylamide)R(Pbf)GD(OtBu)f-OH was precipitated from the filtrate by the 
addition of cold diethyl ether, collected by centrifugation and washed twice with 
ether. 
Cyclisation and purification. PyBOP (653 mg, 1.2 mmol, 2 eq.), HOBt (166 mg, 1.2 
mmol, 2 eq.) and DIPEA (343 µl, 2.0 mmol, 3.2 eq.) were dissolved in DCM (810 ml). 
Side-chain protected linear H-K(acrylamide)R(Pbf)GD(OtBu)f-OH (605 mg, 0.6 
mmol, 1 eq.) dissolved in DMF (90 mL) was added drop-wise to the reaction solution 
and stirred at room temperature overnight (final reaction concentration 5.6 mM). The 
reaction solution was concentrated in vacuo, the crude product precipitated into cold 
diethyl ether, centrifuged and washed twice with ether. The side-chain protected 
cyclised peptide was dissolved in DCM (3 mL) and TFA (3 mL) and stirred at room 
temperature for three hours. The reaction solution was concentrated in vacuo, the 
crude product precipitated by the addition of cold diethyl ether, collected by 
centrifugation and washed twice with ether.  The peptide was re-dissolved in H2O 
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and purified by RP-HPLC (Isolera One, Biotage) (5% to 60 % MeCN/H2O over 20 
min, 60 % to 95 % MeCN/H2O over 5 min) followed by lyophilisation.. The peptide 
was characterised by RP-HPLC (> 95 % purity) and HRMS (m/zcalculated 658.33101 
m/zfound 658.33110). 
 
5.7.9 Peptide-containing polymer microarray fabrication  
 
Microscope glass slides (76 × 26 mm) (Menzel GmbH Co. KG) were treated with an 
O2 plasma for 10 minutes at 1.5 bar oxygen pressure. 384 features (12 × 32) of aqueous 
sucrose (20 % w/v) were printed onto the slides using a sciFLEXARRAYER S5 
printer. The pitch between adjacent spots was 0.8 × 0.8 mm. After drying at room 
temperature, tridecafluoro-1,1,2,2-tetrahydrooctyl-dimethylchlorosilane (5 µl/slide) 
was dropped onto five different areas of the slides (1 µl/drop) and reacted overnight 
in a sealed Tupperware box followed by washing of the slides with acetone (10 mL) 
and water (10 mL) and drying at 40 °. The dried slides were coated with 3-
(trimethoxysilyl)propylmethacrylate (10 µl/slide) by spreading the solution with a 
pipette tip, and put into a sealed box, reacted overnight and then washed with water 
and ethanol before drying under N2 stream. For printing, solutions of monomers (20 
% w/v in NMP, except for peptide-based monomers, which were 2 % w/v in NMP), 
1-hydroxycyclohexyol phenyl ketone (initiator) and 1,6-hexanediol diacrylate (cross-
linker) (both 30 % w/v in NMP) were prepared. The solutions were printed in 
varying ratios (see Appendix Table A3.4) with 125 drops/spot (~ 300 pl/drop). After 
printing the slide was placed in a UV cross-linker (100 mJ/cm2, 30 min) followed by 
drying at 40 °C under vacuum.  
 
5.7.10 In situ polymerisation onto functionalised glass 
coverslips202 
 
Glass coverslips (13 mm in diameter) were lightly shaken in 1M NaOH overnight 
followed by washing with water (2 × 1 hour) and acetone (1 × 1 hour), then drying at 
40 °C overnight. The coverslips were submerged and shaken gently in a solution of 
3-(trimethoxysilyl)propyl methacrylate (5 % w/v) and triethylamine (0.5 % w/v) in 
acetonitrile for 48 hours. The coverslips were then washed by shaking in acetone (2 × 
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10 min) and allowed to dry at room temperature. Monomers were purified from 
inhibitor by filtering through a cotton-plugged syringe (2 mL) filled with basic 
aluminium oxide (1 mL).  Solutions of monomers (16 % w/v of M1, 16 % w/v of M2, 
11.2 % w/v of M3), 1,6-hexanediol diacrylate (6 % w/v) and 1-hydroxycyclohexyl 
phenyl ketone (2.4 % w/v) of the identified hit and control polymers were prepared 
in NMP. These pre-polymer solutions (5 µL) were spotted onto PET films (666-5697, 
3M) and a glass coverslip with the functionalised surface facing down was added on 
top of the liquid spot. To remove trapped air bubbles, the coverslips were gently 
pushed into the PET. To afford polymerisation, the coverslips on PET films were 
placed in a UV cross-linker (100 mJ/cm2, 30 min) irradiated for 30 min. The coverslips 
(n = 6) were removed from the PET film and dried at 40 °C overnight, washed with 
ethanol (3 × 10 min) and water (24 h) and dried at room temperature under fume 
hood ventilation. The polymer-coated coverslips were then sent to Tokyo Medical 
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A.1 Appendix for Chapter 2  
Figure A1.1: 250-member hydrogel array screen with HeLa cells. HeLa cells were incubated 
on the array for 18 h followed by viability staining with fluorescein diacetate (FDA) (green, 
live stain, (λex/em = 490/514 nm) and propidium iodide (PI) (red, dead stain, λex/em = 570/602 
nm). The merged images of the FDA, PI and BF channels for each replicate are shown. Images 

























































Figure A1.2: 82-member HG “hit array” screen with HUVEC. HUVEC were incubated on the 
array for 18 h followed by viability staining with fluorescein diacetate (FDA) (green, live stain, 
(λex/em = 490/514 nm) and propidium iodide (PI) (red, dead stain, λex/em = 570/602 nm). The 
merged images of the FDA, PI and BF channels for each replicate are shown. Images are not 















Figure A1.3: Analysis of cell encapsulation from an array screen of 250 hydrogels with HeLa cells. A. HG1-125. B. HG126-250. Cells/mm3 (± s.e.m, n=3) 
for each hydrogel feature is given on the left y-axis. On the right y-axis is the morphology grade (0-5, with 5 being the “best morphology”). Gaps with 















Figure A1.4: Analysis of cell encapsulation from the focused array screen of 82 hydrogels with HUVEC. Cells/mm3 (± s.e.m, n=3) for each hydrogel 
feature is given on the left y-axis. On the right y-axis is the morphology grade (0-5, with 5 being the “best morphology”). Gaps with y=0 indicate features 
where there was no hydrogel formation and/or cell attachment observed. See Table A1.2 for hydrogel compositions. 
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Table A1.1: Hydrogel compositions for the 250-member array. The number of drops printed per 
hydrogel feature is given for each component. All components were printed as solutions in water 
(2.5 %), ~ 300 pL/drop. 
Hydrogel RGD LamIII PEG2000-CL PEG3000-CL (PEG-NH2)4 
1 800 0 800 0 0 
2 900 0 700 0 0 
3 1000 0 600 0 0 
4 1100 0 500 0 0 
5 1200 0 400 0 0 
6 1300 0 300 0 0 
7 1400 0 200 0 0 
8 1500 0 100 0 0 
9 700 0 900 0 0 
10 600 0 1000 0 0 
11 500 0 1100 0 0 
12 400 0 1200 0 0 
13 300 0 1300 0 0 
14 200 0 1400 0 0 
15 100 0 1500 0 0 
16 800 0 800 0 200 
17 900 0 700 0 200 
18 1000 0 600 0 200 
19 1100 0 500 0 200 
20 1200 0 400 0 200 
21 1300 0 300 0 200 
22 1400 0 200 0 200 
23 1500 0 100 0 200 
24 700 0 900 0 200 
25 600 0 1000 0 200 
26 500 0 1100 0 200 
27 400 0 1200 0 200 
28 300 0 1300 0 200 
29 200 0 1400 0 200 
30 100 0 1500 0 200 
31 1600 0 0 0 0 
32 0 0 1600 0 0 
33 800 0 0 800 0 
34 900 0 0 700 0 
35 1000 0 0 600 0 
36 1100 0 0 500 0 
37 1200 0 0 400 0 
 
196 
38 1300 0 0 300 0 
39 1400 0 0 200 0 
40 1500 0 0 100 0 
41 700 0 0 900 0 
42 600 0 0 1000 0 
43 500 0 0 1100 0 
44 400 0 0 1200 0 
45 300 0 0 1300 0 
46 200 0 0 1400 0 
47 100 0 0 1500 0 
48 800 0 0 800 200 
49 900 0 0 700 200 
50 1000 0 0 600 200 
51 1100 0 0 500 200 
52 1200 0 0 400 200 
53 1300 0 0 300 200 
54 1400 0 0 200 200 
55 1500 0 0 100 200 
56 700 0 0 900 200 
57 600 0 0 1000 200 
58 500 0 0 1100 200 
59 400 0 0 1200 200 
60 300 0 0 1300 200 
61 200 0 0 1400 200 
62 100 0 0 1500 200 
63 0 800 800 0 0 
64 0 900 700 0 0 
65 0 1000 600 0 0 
66 0 1100 500 0 0 
67 0 1200 400 0 0 
68 0 1300 300 0 0 
69 0 1400 200 0 0 
70 0 1500 100 0 0 
71 0 700 900 0 0 
72 0 600 1000 0 0 
73 0 500 1100 0 0 
74 0 400 1200 0 0 
75 0 300 1300 0 0 
76 0 200 1400 0 0 
77 0 100 1500 0 0 
78 0 800 800 0 200 
79 0 900 700 0 200 
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80 0 1000 600 0 200 
81 0 1100 500 0 200 
82 0 1200 400 0 200 
83 0 1300 300 0 200 
84 0 1400 200 0 200 
85 0 1500 100 0 200 
86 0 700 900 0 200 
87 0 600 1000 0 200 
88 0 500 1100 0 200 
89 0 400 1200 0 200 
90 0 300 1300 0 200 
91 0 200 1400 0 200 
92 0 100 1500 0 200 
93 0 800 0 800 0 
94 0 900 0 700 0 
95 0 1000 0 600 0 
96 0 1100 0 500 0 
97 0 1200 0 400 0 
98 0 1300 0 300 0 
99 0 1400 0 200 0 
100 0 1500 0 100 0 
101 0 700 0 900 0 
102 0 600 0 1000 0 
103 0 500 0 1100 0 
104 0 400 0 1200 0 
105 0 300 0 1300 0 
106 0 200 0 1400 0 
107 0 100 0 1500 0 
108 0 800 0 800 200 
109 0 900 0 700 200 
110 0 1000 0 600 200 
111 0 1100 0 500 200 
112 0 1200 0 400 200 
113 0 1300 0 300 200 
114 0 1400 0 200 200 
115 0 1500 0 100 200 
116 0 700 0 900 200 
117 0 600 0 1000 200 
118 0 500 0 1100 200 
119 0 400 0 1200 200 
120 0 300 0 1300 200 
121 0 200 0 1400 200 
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122 0 100 0 1500 200 
123 200 200 1200 0 0 
124 300 100 1200 0 0 
125 100 300 1200 0 0 
126 400 400 800 0 0 
127 500 300 800 0 0 
128 600 200 800 0 0 
129 700 100 800 0 0 
130 300 500 800 0 0 
131 200 600 800 0 0 
132 100 700 800 0 0 
133 600 600 400 0 0 
134 700 500 400 0 0 
135 800 400 400 0 0 
136 900 300 400 0 0 
137 1000 200 400 0 0 
138 1100 100 400 0 0 
139 500 700 400 0 0 
140 400 800 400 0 0 
141 300 900 400 0 0 
142 200 1000 400 0 0 
143 100 1100 400 0 0 
144 48 52 1500 0 0 
145 100 100 1400 0 0 
146 148 152 1300 0 0 
147 248 252 1100 0 0 
148 300 300 1000 0 0 
149 344 348 900 0 0 
150 448 452 700 0 0 
151 500 500 600 0 0 
152 548 552 500 0 0 
153 648 652 300 0 0 
154 700 700 200 0 0 
155 200 200 0 1200 0 
156 300 100 0 1200 0 
157 100 300 0 1200 0 
158 400 400 0 800 0 
159 500 300 0 800 0 
160 600 200 0 800 0 
161 700 100 0 800 0 
162 300 500 0 800 0 
163 200 600 0 800 0 
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164 100 700 0 800 0 
165 600 600 0 400 0 
166 700 500 0 400 0 
167 800 400 0 400 0 
168 900 300 0 400 0 
169 1000 200 0 400 0 
170 1100 100 0 400 0 
171 500 700 0 400 0 
172 400 800 0 400 0 
173 300 900 0 400 0 
174 200 1000 0 400 0 
175 100 1100 0 400 0 
176 48 52 0 1500 0 
177 100 100 0 1400 0 
178 148 152 0 1300 0 
179 248 252 0 1100 0 
180 300 300 0 1000 0 
181 344 348 0 900 0 
182 448 452 0 700 0 
183 500 500 0 600 0 
184 548 552 0 500 0 
185 648 652 0 300 0 
186 700 700 0 200 0 
187 200 200 1200 0 200 
188 300 100 1200 0 200 
189 100 300 1200 0 200 
190 400 400 800 0 200 
191 500 300 800 0 200 
192 600 200 800 0 200 
193 700 100 800 0 200 
194 300 500 800 0 200 
195 200 600 800 0 200 
196 100 700 800 0 200 
197 600 600 400 0 200 
198 700 500 400 0 200 
199 800 400 400 0 200 
200 900 300 400 0 200 
201 1000 200 400 0 200 
202 1100 100 400 0 200 
203 500 700 400 0 200 
204 400 800 400 0 200 
205 300 900 400 0 200 
 
200 
206 200 1000 400 0 200 
207 100 1100 400 0 200 
208 48 52 1500 0 200 
209 100 100 1400 0 200 
210 148 152 1300 0 200 
211 248 252 1100 0 200 
212 300 300 1000 0 200 
213 344 348 900 0 200 
214 448 452 700 0 200 
215 500 500 600 0 200 
216 548 552 500 0 200 
217 648 652 300 0 200 
218 700 700 200 0 200 
219 200 200 0 1200 200 
220 300 100 0 1200 200 
221 100 300 0 1200 200 
222 400 400 0 800 200 
223 500 300 0 800 200 
224 600 200 0 800 200 
225 700 100 0 800 200 
226 300 500 0 800 200 
227 200 600 0 800 200 
228 100 700 0 800 200 
229 600 600 0 400 200 
230 700 500 0 400 200 
231 800 400 0 400 200 
232 900 300 0 400 200 
233 1000 200 0 400 200 
234 1100 100 0 400 200 
235 500 700 0 400 200 
236 400 800 0 400 200 
237 300 900 0 400 200 
238 200 1000 0 400 200 
239 100 1100 0 400 200 
240 48 52 0 1500 200 
241 100 100 0 1400 200 
242 148 152 0 1300 200 
243 248 252 0 1100 200 
244 300 300 0 1000 200 
245 344 348 0 900 200 
246 448 452 0 700 200 
247 500 500 0 600 200 
 
201 
248 548 552 0 500 200 
249 648 652 0 300 200 






Table A1.2: Hydrogel compositions for the ‘hit array’ screen of HUVEC. The number of drops 
printed per hydrogel feature is given for each component. All components were printed as 
solutions in water (2.5 %), ~ 300 pL/drop. 
 
Hydrogel RGD LamIII PEG2000-CL PEG3000-CL (PEG-NH2)4 
1 700 0 900 0 200 
2 600 0 1000 0 200 
3 500 0 1100 0 200 
4 400 0 1200 0 200 
5 300 0 1300 0 200 
6 500 0 0 1100 0 
7 400 0 0 1200 0 
8 300 0 0 1300 0 
9 200 0 0 1400 0 
10 100 0 0 1500 0 
11 800 0 0 800 200 
12 900 0 0 700 200 
13 700 0 0 900 200 
14 600 0 0 1000 200 
15 500 0 0 1100 200 
16 400 0 0 1200 200 
17 300 0 0 1300 200 
18 200 0 0 1400 200 
19 100 0 0 1500 200 
20 0 500 1100 0 0 
21 0 400 1200 0 0 
22 0 300 1300 0 0 
23 0 200 1400 0 0 
24 0 100 1500 0 0 
25 0 400 1200 0 200 
26 0 300 1300 0 200 
27 0 200 1400 0 200 
28 0 200 0 1400 200 
29 0 100 0 1500 200 
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30 1100 0 500 0 0 
31 200 0 0 1400 0 
32 0 600 0 1000 200 
33 400 400 800 0 0 
34 500 300 800 0 0 
35 600 200 800 0 0 
36 700 100 800 0 0 
37 248 252 1100 0 0 
38 300 300 1000 0 0 
39 344 348 900 0 0 
40 448 452 700 0 0 
41 500 500 600 0 0 
42 100 300 1200 0 200 
43 400 400 800 0 200 
44 500 300 800 0 200 
45 600 200 800 0 200 
46 700 100 800 0 200 
47 300 500 800 0 200 
48 200 600 800 0 200 
49 100 700 800 0 200 
50 148 152 1300 0 200 
51 248 252 1100 0 200 
52 300 300 1000 0 200 
53 344 348 900 0 200 
54 448 452 700 0 200 
55 500 500 600 0 200 
56 500 300 0 800 0 
57 600 200 0 800 0 
58 700 100 0 800 0 
59 300 500 0 800 0 
60 200 600 0 800 0 
61 100 700 0 800 0 
62 148 152 0 1300 0 
63 248 252 0 1100 0 
64 300 300 0 1000 0 
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65 344 348 0 900 0 
66 448 452 0 700 0 
67 500 500 0 600 0 
68 200 200 1200 0 200 
69 300 100 1200 0 200 
70 100 300 1200 0 200 
71 400 400 800 0 200 
72 500 300 800 0 200 
73 600 200 800 0 200 
74 700 100 800 0 200 
75 300 500 800 0 200 
76 200 600 800 0 200 
77 100 700 800 0 200 
78 100 100 1400 0 200 
79 148 152 1300 0 200 
80 248 252 1100 0 200 
81 300 300 1000 0 200 
82 344 348 900 0 200 











Figure A2.1: Negative controls for immunohistological analysis of endothelial (CD31, VE-
cadherin, vWf), proliferation (Ki-67) and apoptosis (cleaved caspase 3) markers in HUVEC 
and after incubation in HG15 (4 or 30 days). Following cell incubation for the desired time 
point and cell fixation, the gels were embedded in agarose, paraffin-embedded, cut into slices, 
permeabilised and stained with secondary antibody only (no primary antibody) and 





A.3 Appendix for Chapter 5 
 
Figure A3.1: Lay-out of polymer microarray as printed.  
PU16 PU61 PU100 PU24 PU89 PU12 PU63 PU1
PU207 PU152 PU192 PU141 PU183 PU95 PU168 PU123
PA403 PU245 PA414 PU215 PU190 PU219 PU77 PU227
PA128 PA485 PA324 PA468 PA519 PA450 PA509 PA462
PA400 PA197 PA412 PA196 PA159 PA175 PA177 PA120
PA119 PA26 PA139 PA112 PA40 PA134 PA50 PA208
PU17 PU41 PU101 PU25 PU69 PU13 PU67 PU2
PU217 PU234 PU172 PU142 PU184 PU132 PU171 PU124
PA423 PU275 PA415 PU271 PA427 PU202 PU214 PU216
PA359 PA493 PA325 PA469 PA520 PA452 PA511 PA449
PA399 PA193 PA398 PA188 PA160 PA172 PA372 PA164
PA27 PA18 PA59 PA132 PA185 PA329 PA3 PA387
PU29 PU46 PU102 PU28 PU92 PU14 PU73 PU3
PA210 PU153 PU105 PU143 PU185 PU134 PU173 PU115
PA426 PU254 PA416 PU256 PU259 PU250 PU178 PU162
PA141 PA496 PA326 PA470 PA522 PA453 PA513 PA475
PA406 PA214 PA413 PA189 PA361 PA180 PA369 PA135
PA11 PA46 PA102 PA198 PA37 PA335 PA25 PA389
PU79 PU48 PU103 PU120 PU93 PU18 PU77 PU4
PU188 PU154 PU196 PU144 PU163 PU135 PU174 PU126
PA428 PU224 PA417 PU253 PU221 PU241 PU204 PU228
PA142 PA497 PA327 PA474 PA523 PA458 PA512 PA499
PA401 PA215 PA222 PA190 PA358 PA181 PA155 PA137
PA43 PA106 PA131 PA210 PA17 PA186 PA58 PA223
PU71 PU99 PU104 PU33 PU94 PU19 PU81 PU5
PU122 PU156 PU197 PU145 PU187 PU137 PU175 PU128
PA429 PU212 PA418 PU244 PU264 PU208 PU203 PU218
PA143 PA500 PA323 PA437 PA531 PA459 PA514 PA442
PA411 PA216 PA207 PA199 PA363 PA182 PA154 PA307
PA55 PA14 PA138 PA179 PA13 PA204 PA105 PA375
PU116 PU69 PU108 PU35 PU96 PU20 PU83 PU7
PU257 PU159 PU199 PU148 PU161 PU138 EMPTY PU129
PA430 PU246 PA419 PU233 PA435 PU242 PU25 PU205
PA162 PA504 PA330 PA476 PA528 PA460 PA515 PA442
PA397 PA178 PA390 PA357 PA336 PA183 PA364 PA306
PA100 PA21 PA117 PA113 PA12 PA316 PA20 PA191
PU117 PU53 PU110 PU27 PU97 PU22 PU85 PU8
PU247 PU164 PU121 PU149 PU189 PU139 PU179 PU130
PA431 PU235 PA420 PU223 PU205 PU220 PU278 PU239
PA163 PA507 PA331 PA477 PA434 PA465 PA517 PA444
PA393 PA194 PA395 PA201 PA337 PA184 PA167 PA309
EMPTY PA60 PA44 PA19 PA22 PA315 PA56 PA136
PU118 PU119 PU112 PU39 PU98 PU23 PU87 PU10
PU236 PU166 PU201 PU151 PU191 PU140 PU181 PU131
PA432 PU225 PA421 PU230 PU269 PU222 PU226 PU229
PA153 PA508 PA332 PA481 PA360 PA467 PA518 PA446
PA394 PA192 PA396 PA187 PA338 PA185 PA168 PA171
PA140 PA218 PA56 PA104 PA23 PA318 PA57 PA133
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Table A3.1: Compositions of polyacrylate/acrylamides used for microarray screening with 
CSC. For monomer abbreviations, see list at end of Appendix. 







PA3 St DEAA - 90 10 - 
PA11 MMA DEAA - 70 30 - 
PA12 MMA DEAA - 50 50 - 
PA13 MMA DMAA - 90 90 - 
PA14 MMA DMAA - 70 30 - 
PA17 MMA PAA - 70 30 - 
PA18 MMA PAA - 50 50 - 
PA19 MEMA DEAA - 90 10 - 
PA20 MEMA DEAA - 70 30 - 
PA21 MEMA DEAA - 50 50 - 
PA22 MEMA DMAA - 90 10 - 
PA23 MEMA DMAA - 70 30 - 
PA25 MEMA PAA - 90 10 - 
PA26 MEMA PAA - 70 30 - 
PA27 MEMA PAA - 50 50 - 
PA40 HEMA DMAA - 90 10 - 
PA43 HEMA PAA - 90 10 - 
PA44 HEMA PAA - 70 30 - 
PA46 HPMA DEAA - 90 10 - 
PA50 HPMA DMAA - 70 30 - 
PA55 HBMA DEAA - 90 10 - 
PA56 HBMA DEAA - 70 30 - 
PA57 HBMA DEAA - 50 50 - 
PA58 HBMA DMAA - 90 10 - 
PA59 HBMA DMAA - 70 30 - 
PA60 HBMA DMAA - 50 50 - 
PA100 MEMA DMAEMA - 70 30 - 
PA102 MEMA DEAEA - 90 10 - 
PA104 MEMA DEAEA - 50 50 - 
PA105 MEMA DMAEA - 90 10 - 
PA106 MEMA DMAEA - 70 30 - 
PA112 MEMA BAEMA - 70 30 - 
PA113 MEMA BAEMA - 50 50 - 
PA117 MEMA BACOEA - 90 10 - 
PA119 MEMA BACOEA - 50 50 - 
PA120 MEMA DMVBA - 90 10 - 
PA128 MEMA VI - 50 50 - 
PA131 MEMA VPNO - 50 50 - 
PA132 MEMA VP-4 - 90 10 - 
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PA133 MEMA VP-4 - 70 30 - 
PA134 MEMA VP-4 - 50 50 - 
PA135 MEMA VP-2 - 90 10 - 
PA136 MEMA VP-2 - 70 30 - 
PA137 MEMA VP-2 - 50 50 - 
PA138 MEMA DAAA - 90 10 - 
PA139 MEMA DAAA - 70 30 - 
PA140 MEMA DAAA - 50 50 - 
PA141 MEMA MNPMA - 90 10 - 
PA142 MEMA MNPMA - 70 30 - 
PA143 MEMA MNPMA - 50 50 - 
PA153 HEMA DMAEMA - 90 10 - 
PA154 HEMA DMAEMA - 70 30 - 
PA155 HEMA DMAEMA - 50 50 - 
PA159 HEMA DMAEA - 90 10 - 
PA160 HEMA DMAEA - 70 30 - 
PA162 HEMA MTEMA - 90 10 - 
PA163 HEMA MTEMA - 70 30 - 
PA164 HEMA MTEMA - 50 50 - 
PA167 HEMA BAEMA - 50 50 - 
PA168 HEMA DMAPMAA - 90 10 - 
PA171 HEMA BACOEA - 90 10 - 
PA172 HEMA BACOEA - 70 30 - 
PA175 HEMA DMVBA - 70 30 - 
PA177 HEMA VAA - 90 10 - 
PA178 HEMA VAA - 70 30 - 
PA179 HEMA VAA - 50 50 - 
PA180 HEMA VI - 90 10 - 
PA181 HEMA VI - 70 30 - 
PA182 HEMA VI - 50 50 - 
PA183 HEMA VPNO - 90 10 - 
PA184 HEMA VPNO - 70 30 - 
PA185 HEMA VPNO - 50 50 - 
PA186 HEMA VP-4 - 90 10 - 
PA187 HEMA VP-4 - 70 30 - 
PA188 HEMA VP-4 - 50 50 - 
PA189 HEMA VP-2 - 90 10 - 
PA190 HEMA VP-2 - 70 30 - 
PA191 HEMA VP-2 - 50 50 - 
PA192 HEMA DAAA - 90 10 - 
PA193 HEMA DAAA - 70 30 - 
PA194 HEMA DAAA - 50 50 - 
PA196 HEMA MNPMA - 70 30 - 
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PA197 HEMA MNPMA - 50 50 - 
PA198 MMA A-H - 90 10 - 
PA199 MMA A-H - 70 30 - 
PA201 MMA AES-H - 90 10 - 
PA204 MMA MA-H - 90 10 - 
PA207 MMA AAG-H - 90 10 - 
PA208 MMA AAG-H - 70 30 - 
PA210 MMA EGMP-H - 90 10 - 
PA214 MEMA A-H - 70 30 - 
PA215 MEMA A-H - 50 50 - 
PA216 MEMA AES-H - 90 10 - 
PA218 MEMA AES-H - 50 50 - 
PA222 MEMA AAG-H - 90 10 - 
PA223 MEMA AAG-H - 70 30 - 
PA245 MEMA A-H DEAEA 70 10 20 
PA306 MMA GMA DnBA 90 10 - 
PA307 MMA GMA DnBA 70 30 - 
PA309 MMA GMA DnHA 90 10 - 
PA315 MMA GMA DBnA 90 10 - 
PA316 MMA GMA DBnA 70 30 - 
PA318 MMA GMA MnHA 90 10 - 
PA323 MMA GMA cHMA 50 50 - 
PA324 MMA GMA BnMA 90 10 - 
PA325 MMA GMA BnMA 70 30 - 
PA326 MMA GMA BnMA 50 50 - 
PA327 MMA GMA MAEPy 90 10 - 
PA329 MMA GMA MAEPy 50 50 - 
PA330 MMA GMA Pyrle 90 10 - 
PA331 MMA GMA Pyrle 70 30 - 
PA332 MMA GMA Pyrle 50 50 - 
PA335 MMA GMA MAPy 50 50 - 
PA336 MMA GMA MAn 90 10 - 
PA337 MMA GMA MAn 70 30 - 
PA338 MMA GMA MAn 50 50 - 
PA357 MMA DMAEMA - 90 10 - 
PA358 MMA DMAEMA - 70 30 - 
PA359 MMA DMAEMA - 50 50 - 
PA360 MMA DEAEA - 90 10 - 
PA361 MMA DEAEA - 70 30 - 
PA363 MMA DMAEA - 90 10 - 
PA364 MMA DMAEA - 70 30 - 
PA369 HPMA DMAEMA - 90 10 - 
PA372 HPMA DEAEA - 90 10 - 
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PA375 HPMA DMAEA - 90 10 - 
PA387 HBMA DMAEA - 90 10 - 
PA389 HBMA DMAEA - 50 50 - 
PA390 EMA DEAEMA - 90 10 - 
PA393 EMA DMAEMA - 90 10 - 
PA394 EMA DMAEMA - 70 30 - 
PA395 EMA DMAEMA - 50 50 - 
PA396 EMA DEAEA - 90 10 - 
PA397 EMA DEAEA - 70 30 - 
PA398 EMA DEAEA - 50 50 - 
PA399 EMA DMAEA - 90 10 - 
PA400 EMA DMAEA - 70 30 - 
PA401 EMA DMAEA - 50 50 - 
PA403 BMA DEAEMA - 70 30 - 
PA406 BMA DMAEMA - 70 30 - 
PA411 BMA DMAEA - 90 10 - 
PA412 BMA DMAEA - 70 30 - 
PA413 BMA DMAEA - 50 50 - 
PA414 MEMA DEAEMA MA 40 30 30 
PA415 MEMA DEAEMA MA 60 10 30 
PA416 MEMA DEAEMA MA 60 30 10 
PA417 MEMA DEAEMA MA 80 10 10 
PA418 MEMA DEAEA MA 40 30 30 
PA419 MEMA DEAEA MA 60 10 30 
PA420 MEMA DEAEA MA 60 30 10 
PA421 MEMA DEAEA MA 80 10 10 
PA423 MEMA DEAEMA BMA 60 10 30 
PA426 MEMA DEAEA BMA 40 30 30 
PA427 MEMA DEAEA BMA 60 10 30 
PA428 MEMA DEAEA BMA 60 30 10 
PA429 MEMA DEAEA BMA 80 10 10 
PA430 MEMA DEAEMA MEA 40 30 30 
PA431 MEMA DEAEMA MEA 60 10 30 
PA432 MEMA DEAEMA MEA 60 30 10 
PA434 MEMA DEAEA MEA 40 30 30 
PA435 MEMA DEAEA MEA 60 10 30 
PA437 MEMA DEAEA MEA 80 10 10 
PA442 MEMA DEAEA DEGMEMA 40 30 30 
PA443 MEMA DEAEA DEGMEMA 60 10 30 
PA444 MEMA DEAEA DEGMEMA 60 30 10 
PA446 MEMA DEAEMA THFFA 40 30 30 
PA449 MEMA DEAEMA THFFA 80 10 10 
PA450 MEMA DEAEA THFFA 40 30 30 
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PA452 MEMA DEAEA THFFA 60 30 10 
PA453 MEMA DEAEA THFFA 80 10 10 
PA458 MEMA DEAEA THFFMA 40 30 30 
PA459 MEMA DEAEA THFFMA 60 10 30 
PA460 MEMA DEAEA THFFMA 60 30 10 
PA462 MEMA DEAEMA HEA 40 30 30 
PA465 MEMA DEAEMA HEA 80 10 10 
PA467 MEMA DEAEA HEA 60 10 30 
PA468 MEMA DEAEA HEA 60 30 10 
PA469 MEMA DEAEA HEA 80 10 10 
PA470 MEMA DEAEMA HEMA 40 30 30 
PA474 MEMA DEAEA HEMA 40 30 30 
PA475 MEMA DEAEA HEMA 60 10 30 
PA476 MEMA DEAEA HEMA 60 30 10 
PA477 MEMA DEAEA HEMA 80 10 10 
PA481 MEMA DEAEMA A-H 80 10 10 
PA485 MEMA DEAEA A-H 80 10 10 
PA493 MEMA DEAEA MA-H 80 10 10 
PA496 MEMA DEAEMA DMAA 60 30 10 
PA497 MEMA DEAEMA DMAA 80 10 10 
PA499 MEMA DEAEA DMAA 60 10 30 
PA500 MEMA DEAEA DMAA 60 30 10 
PA504 MEMA DEAEMA DAAA 60 30 10 
PA507 MEMA DEAEA DAAA 60 10 30 
PA508 MEMA DEAEA DAAA 60 30 10 
PA509 MEMA DEAEA DAAA 80 10 10 
PA511 MEMA DEAEMA MMA 60 10 30 
PA512 MEMA DEAEMA MMA 60 30 10 
PA513 MEMA DEAEMA MMA 80 10 10 
PA514 MEMA DEAEA MMA 40 30 30 
PA515 MEMA DEAEA MMA 60 10 30 
PA517 MEMA DEAEA MMA 80 10 10 
PA518 MEMA DEAEMA St 40 30 30 
PA519 MEMA DEAEMA St 60 10 30 
PA520 MEMA DEAEMA St 60 30 10 
PA522 MEMA DEAEA St 40 30 30 
PA523 MEMA DEAEA St 60 10 30 
PA528 MEMA DEAEMA - 70 30 - 




Table A3.2: Compositions of polyurethanes used for microarray screening with CSCs. For 
monomer abbreviations, see list at end of Appendix. 













PU2 PEG 900 HDI - 48.5 51.5 - 
PU3 PEG 400 HDI - 48.5 51.5 - 
PU4 PPG 2000 HDI - 48.5 51.5 - 
PU5 PTMG 2000 HDI - 48.5 51.5 - 
PU7 PEG 900 BICH - 48.5 51.5 - 
PU8 PEG 400 BICH - 48.5 51.5 - 
PU10 PTMG 2000 BICH - 48.5 51.5 - 
PU12 PEG 900 TDI - 48.5 51.5 - 
PU13 PEG 400 TDI - 48.5 51.5 - 
PU14 PPG 2000 TDI - 48.5 51.5 - 
PU16 PEG 2000 MDI - 48.5 51.5 - 
PU17 PEG 900 MDI - 48.5 51.5 - 
PU18 PEG 400 MDI - 48.5 51.5 - 
PU19 PPG 2000 MDI - 48.5 51.5 - 
PU20 PTMG 2000 MDI - 48.5 51.5 - 
PU22 PEG 900 PDI - 48.5 51.5 - 
PU23 PEG 400 PDI - 48.5 51.5 - 
PU24 PPG 2000 PDI - 48.5 51.5 - 
PU25 PTMG 2000 PDI - 48.5 51.5 - 
PU27 PEG 900 HMDI - 48.5 51.5 - 
PU28 PEG 400 HMDI - 48.5 51.5 - 
PU29 PPG 2000 HMDI - 48.5 51.5 - 
PU33 PEG 900 HDI BD 0.25 0.52 0.23 
PU35 PEG 400 HDI BD 0.25 0.52 0.23 
PU39 PTMG 2000 HDI BD 0.25 0.52 0.23 
PU41 PEG 2000 BICH BD 0.25 0.52 0.23 
PU46 PEG 400 BICH ED 0.25 0.52 0.23 
PU48 PPG 2000 BICH ED 0.25 0.52 0.23 
PU53 PEG 900 TDI BD 0.25 0.52 0.23 
PU61 PEG 2000 MDI BD 0.25 0.52 0.23 
PU63 PEG 900 MDI BD 0.25 0.52 0.23 
PU67 PPG 2000 MDI BD 0.25 0.52 0.23 
PU69 PTMG 2000 MDI BD 0.25 0.52 0.23 
PU71 PEG 2000 PDI BD 0.25 0.52 0.23 
PU73 PEG 900 PDI BD 0.25 0.52 0.23 
PU77 PPG 2000 PDI BD 0.25 0.52 0.23 
PU79 PTMG 2000 PDI BD 0.25 0.52 0.23 
PU81 PEG 2000 HMDI BD 0.25 0.52 0.23 
PU83 PEG 900 HMDI BD 0.25 0.52 0.23 
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PU85 PEG 400 HMDI BD 0.25 0.52 0.23 
PU87 PPG 2000 HMDI BD 0.25 0.52 0.23 
PU89 PTMG 2000 HMDI BD 0.25 0.52 0.23 
PU92 PTMG 1000 HDI BD 0.485 0.515 - 
PU93 PTMG 650 BICH BD 0.485 0.515 - 
PU94 PTMG 1000 BICH BD 0.485 0.515 - 
PU95 PTMG 650 MDI BD 0.485 0.515 - 
PU96 PTMG 1000 MDI BD 0.485 0.515 - 
PU97 PHNGAD 1800 BICH DMAPD 0.25 0.52 0.23 
PU98 PHNGAD 1800 BICH DEAPD 0.25 0.52 0.23 
PU99 PTMG 650 HDI DMAPD 0.25 0.52 0.23 
PU100 PTMG 1000 HDI DMAPD 0.25 0.52 0.23 
PU101 PTMG 650 BICH DMAPD 0.25 0.52 0.23 
PU102 PTMG 1000 BICH DMAPD 0.25 0.52 0.23 
PU103 PHNGAD 1800 MDI DMAPD 0.25 0.52 0.23 
PU104 PHNGAD 1800 MDI DEAPD 0.25 0.52 0.23 
PU105 PHNGAD 1800 HDI DMAPD 0.25 0.52 0.23 
PU108 PTMG 1000 HDI DEAPD 0.25 0.52 0.23 
PU110 PTMG 1000 BICH DEAPD 0.25 0.52 0.23 
PU112 PTMG 1000 MDI DEAPD 0.25 0.52 0.23 
PU115 PPG 1000 HDI BD 0.485 0.515 - 
PU116 PPG 425 BICH BD 0.485 0.515 - 
PU117 PPG 1000 BICH BD 0.485 0.515 - 
PU118 PPG 425 MDI DMAPD 0.25 0.52 0.23 
PU119 PPG 1000 MDI DMAPD 0.25 0.52 0.23 
PU120 PPG 425 BICH DEAPD 0.25 0.52 0.23 
PU121 PPG 1000 BICH DEAPD 0.25 0.52 0.23 
PU122 PPG 2000 BICH DEAPD 0.25 0.52 0.23 
PU123 PPG 2000 MDI DMAPD 0.25 0.52 0.23 
PU124 PPG 2000 TDI DMAPD 0.25 0.52 0.23 
PU126 PPG 425 TDI DMAPD 0.25 0.52 0.23 
PU128 PPG 2000 BICH DMAPD 0.25 0.52 0.23 
PU129 PPG 425 BICH DMAPD 0.25 0.52 0.23 
PU130 PTMG 650 TDI DMAPD 0.25 0.52 0.23 
PU131 PTMG 1000 TDI DMAPD 0.25 0.52 0.23 
PU132 PHNGAD 1800 BICH BD 0.25 0.52 0.23 
PU134 PHNGAD 1800 MDI BD 0.25 0.52 0.23 
PU135 PTMG 250 BICH DMAPD 0.25 0.52 0.23 
PU137 PTMG 250 BICH BD 0.25 0.52 0.23 
PU138 PTMG 250 BICH EG 0.25 0.52 0.23 
PU139 PTMG 650 BICH EG 0.25 0.52 0.23 
PU140 PTMG 1000 BICH EG 0.25 0.52 0.23 
PU141 PTMG 2000 BICH EG 0.25 0.52 0.23 
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PU142 PTMG 250 BICH PG 0.25 0.52 0.23 
PU143 PTMG 650 BICH PG 0.25 0.52 0.23 
PU144 PTMG 1000 BICH PG 0.25 0.52 0.23 
PU145 PTMG 2000 BICH PG 0.25 0.52 0.23 
PU148 PTMG 250 HDI BD 0.25 0.52 0.23 
PU149 PTMG 250 HDI EG 0.25 0.52 0.23 
PU151 PTMG 1000 HDI EG 0.25 0.52 0.23 
PU152 PTMG 2000 HDI EG 0.25 0.52 0.23 
PU153 PTMG 250 HDI PG 0.25 0.52 0.23 
PU154 PTMG 650 HDI PG 0.25 0.52 0.23 
PU156 PTMG 2000 HDI PG 0.25 0.52 0.23 
PU159 PTMG 250 MDI BD 0.25 0.52 0.23 
PU161 PTMG 650 MDI EG 0.25 0.52 0.23 
PU162 PTMG 1000 MDI EG 0.25 0.52 0.23 
PU163 PTMG 2000 MDI EG 0.25 0.52 0.23 
PU164 PTMG 250 MDI PG 0.25 0.52 0.23 
PU166 PTMG 1000 MDI PG 0.25 0.52 0.23 
PU168 PTMG 250 BICH - 48.5 51.5 - 
PU171 PTMG 250 HDI - 48.5 51.5 - 
PU172 PTMG 650 HDI - 48.5 51.5 - 
PU173 PTMG 1000 HDI - 48.5 51.5 - 
PU174 PTMG 250 MDI - 48.5 51.5 - 
PU175 PTMG 650 MDI - 48.5 51.5 - 
PU178 PTMG 1000 HDI NMPD 0.25 0.52 0.23 
PU179 PTMG 2000 HDI NMPD 0.25 0.52 0.23 
PU181 PTMG 2000 BICH NMPD 0.25 0.52 0.23 
PU183 PTMG 1000 MDI NMPD 0.25 0.52 0.23 
PU184 PTMG 2000 MDI NMPD 0.25 0.52 0.23 
PU185 PHNAD 900 MDI OFHD 0.17 0.52 0.33 
PU187 PTMG 1000 BICH OFHD 0.25 0.52 0.23 
PU188 PTMG 2000 BICH OFHD 0.25 0.52 0.23 
PU189 PPG 1000 BICH OFHD 0.17 0.52 0.33 
PU190 PTMG 650 HDI OFHD 0.25 0.52 0.23 
PU191 PTMG 1000 HDI OFHD 0.25 0.52 0.23 
PU192 PTMG 2000 HDI OFHD 0.25 0.52 0.23 
PU196 PTMG 2000 MDI OFHD 0.25 0.52 0.23 
PU197 PTMG 650 BICH DHM 0.25 0.52 0.23 
PU199 PTMG 2000 BICH DHM 0.25 0.52 0.23 
PU201 PTMG 1000 HDI DHM 0.25 0.52 0.23 
PU202 PTMG 2000 HDI DHM 0.25 0.52 0.23 
PU203 PTMG 650 MDI DHM 0.25 0.52 0.23 
PU204 PTMG 1000 MDI DHM 0.25 0.52 0.23 
PU205 PTMG 2000 MDI DHM 0.25 0.52 0.23 
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PU207 PPG 1000 BICH OFHD 0.25 0.52 0.23 
PU208 PPG 1000 MDI OFHD 0.25 0.52 0.23 
PU210 PPG 1000 BICH PG 0.25 0.52 0.23 
PU212 PHNAD 900 HDI PG 0.25 0.52 0.23 
PU214 PHNAD 900 MDI PG 0.25 0.52 0.23 
PU216 PHNAD 900 BICH BD 0.25 0.52 0.23 
PU217 PHNAD 900 MDI BD 0.25 0.52 0.23 
PU218 PHNAD 900 HDI DMAPD 0.25 0.52 0.23 
PU219 PHNAD 900 BICH DMAPD 0.25 0.52 0.23 
PU220 PHNAD 900 MDI DMAPD 0.25 0.52 0.23 
PU221 PHNAD 900 HDI OFHD 0.25 0.52 0.23 
PU222 PHNAD 900 BICH OFHD 0.25 0.52 0.23 
PU223 PHNAD 900 MDI OFHD 0.25 0.52 0.23 
PU224 PHNAD 900 HDI - 48.5 51.5 - 
PU225 PHNAD 900 BICH - 48.5 51.5 - 
PU226 PHNAD 900 MDI - 48.5 51.5 - 
PU227 PPG-PEG 1900 HDI - 48.5 51.5 - 
PU228 PPG-PEG 1900 BICH - 48.5 51.5 - 
PU229 PPG-PEG 1900 MDI - 48.5 51.5 - 
PU230 PPG-PEG 1900 HDI BD 0.25 0.52 0.23 
PU233 PPG-PEG 1900 HDI OFHD 0.25 0.52 0.23 
PU234 PPG-PEG 1900 BICH OFHD 0.25 0.52 0.23 
PU235 PPG-PEG 1900 MDI OFHD 0.25 0.52 0.23 
PU236 PPG-PEG 1900 HDI PG 0.25 0.52 0.23 
PU239 PPG-PEG 1900 HDI DMAPD 0.25 0.52 0.23 
PU241 PPG-PEG 1900 MDI DMAPD 0.25 0.52 0.23 
PU242 PPG-PEG 1900 HDI EG 0.25 0.52 0.23 
PU244 PPG-PEG 1900 MDI EG 0.25 0.52 0.23 
PU246 PHNGAD 1800 BICH OFHD 0.25 0.52 0.23 
PU247 PHNGAD 1800 MDI OFHD 0.25 0.52 0.23 
PU250 PHNGAD 1800 BICH - 48.5 51.5 - 
PU253 PPG-PEG 1900 MDI DMAPD 0.17 0.52 0.33 
PU254 PHNGAD 1800 BICH BD 0.17 0.52 0.33 
PU256 PPG 425 MDI - 48.5 51.5 - 
PU257 PTMG 1000 BICH DMAPD 0.17 0.52 0.33 
PU259 PTMG 2000 BICH DMAPD 0.17 0.52 0.33 
PU264 PTMG 1000 HDI DMAPD 0.17 0.52 0.33 
PU269 PPG  2000 MDI DEAPD 0.25 0.52 0.23 
PU271 PEG 400 MDI DMAPD 0.25 0.52 0.23 
PU275 PEG 400 MDI - 48.5 51.5 - 







































Figure A3.2: GPC traces of scaled-up polymers in Section§ 5.2 and 5.3. Y-axis = Detector 
Response (mV). X-axis = Time (minutes). A. PA531. B. PA419. C. PA514. D. PA104. E. PA435. 
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Figure A3.3: Lay-out of peptide-containing polymer microarray as printed onto microscope 
glass slide. For polymer compositions see Table A3.3.  
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Table A3.3: Compositions of peptide-containing polymers used for microarray screening with 
pancreatic CSCs. For M1 and M2 abbreviation, see Table for polyacrylate/acrylamide library 
Feature* M1 M2 M3 M1 (%)‡ M2 (%)‡ M3 (%)‡ 
PP1 MEMA DEAEA   7.2 7.2 0 
PP2 MEMA DEAEMA   7.2 7.2 0 
PP3 MEMA AH   7.2 7.2 0 
PP4 MEMA DMAAm   7.2 7.2 0 
PP5 MMA DEAEA   7.2 7.2 0 
PP6 MMA DEAEMA   7.2 7.2 0 
PP7 MMA AH   7.2 7.2 0 
PP8 MMA DMAAm   7.2 7.2 0 
PP9 MEMA DEAEA Acrylamide-GRGDS 7.2 7.04 0.016 
PP10 MEMA DEAEMA Acrylamide-GRGDS 7.2 7.04 0.016 
PP11 MEMA AH Acrylamide-GRGDS 7.2 7.04 0.016 
PP12 MEMA DMAAm Acrylamide-GRGDS 7.2 7.04 0.016 
PP13 MMA DEAEA Acrylamide-GRGDS 7.2 7.04 0.016 
PP14 MMA DEAEMA Acrylamide-GRGDS 7.2 7.04 0.016 
PP15 MMA AH Acrylamide-GRGDS 7.2 7.04 0.016 
PP16 MMA DMAAm Acrylamide-GRGDS 7.2 7.04 0.016 
PP17 MEMA DEAEA Acrylamide-YIGSR 7.2 7.04 0.016 
PP18 MEMA DEAEMA Acrylamide-YIGSR 7.2 7.04 0.016 
PP19 MEMA AH Acrylamide-YIGSR 7.2 7.04 0.016 
PP20 MEMA DMAAm Acrylamide-YIGSR 7.2 7.04 0.016 
PP21 MMA DEAEA Acrylamide-YIGSR 7.2 7.04 0.016 
PP22 MMA DEAEMA Acrylamide-YIGSR 7.2 7.04 0.016 
PP23 MMA AH Acrylamide-YIGSR 7.2 7.04 0.016 
PP24 MMA DMAAm Acrylamide-YIGSR 7.2 7.04 0.016 
PP25 MEMA DEAEA Acrylamide-cRGDfK 7.2 7.04 0.016 
PP26 MEMA DEAEMA Acrylamide-cRGDfK 7.2 7.04 0.016 
PP27 MEMA AH Acrylamide-cRGDfK 7.2 7.04 0.016 
PP28 MEMA DMAAm Acrylamide-cRGDfK 7.2 7.04 0.016 
PP29 MMA DEAEA Acrylamide-cRGDfK 7.2 7.04 0.016 
PP30 MMA DEAEMA Acrylamide-cRGDfK 7.2 7.04 0.016 
PP31 MMA AH Acrylamide-cRGDfK 7.2 7.04 0.016 
PP32 MMA DMAAm Acrylamide-cRGDfK 7.2 7.04 0.016 
PP33 MEMA DEAEA Acrylamide-GRGDS 6.4 6.4 0.16 
PP34 MEMA DEAEMA Acrylamide-GRGDS 6.4 6.4 0.16 
PP35 MEMA AH Acrylamide-GRGDS 6.4 6.4 0.16 
PP36 MEMA DMAAm Acrylamide-GRGDS 6.4 6.4 0.16 
PP37 MMA DEAEA Acrylamide-GRGDS 6.4 6.4 0.16 
PP38 MMA DEAEMA Acrylamide-GRGDS 6.4 6.4 0.16 
PP39 MMA AH Acrylamide-GRGDS 6.4 6.4 0.16 
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PP40 MMA DMAAm Acrylamide-GRGDS 6.4 6.4 0.16 
PP41 MEMA DEAEA Acrylamide-YIGSR 6.4 6.4 0.16 
PP42 MEMA DEAEMA Acrylamide-YIGSR 6.4 6.4 0.16 
PP43 MEMA AH Acrylamide-YIGSR 6.4 6.4 0.16 
PP44 MEMA DMAAm Acrylamide-YIGSR 6.4 6.4 0.16 
PP45 MMA DEAEA Acrylamide-YIGSR 6.4 6.4 0.16 
PP46 MMA DEAEMA Acrylamide-YIGSR 6.4 6.4 0.16 
PP47 MMA AH Acrylamide-YIGSR 6.4 6.4 0.16 
PP48 MMA DMAAm Acrylamide-YIGSR 6.4 6.4 0.16 
PP49 MEMA DEAEA Acrylamide-cRGDfK 6.4 6.4 0.16 
PP50 MEMA DEAEMA Acrylamide-cRGDfK 6.4 6.4 0.16 
PP51 MEMA AH Acrylamide-cRGDfK 6.4 6.4 0.16 
PP52 MEMA DMAAm Acrylamide-cRGDfK 6.4 6.4 0.16 
PP53 MMA DEAEA Acrylamide-cRGDfK 6.4 6.4 0.16 
PP54 MMA DEAEMA Acrylamide-cRGDfK 6.4 6.4 0.16 
PP55 MMA AH Acrylamide-cRGDfK 6.4 6.4 0.16 
PP56 MMA DMAAm Acrylamide-cRGDfK 6.4 6.4 0.16 
PP57 MEMA DEAEA Acrylamide-GRGDS 1.6 1.6 1.12 
PP58 MEMA DEAEMA Acrylamide-GRGDS 1.6 1.6 1.12 
PP59 MEMA AH Acrylamide-GRGDS 1.6 1.6 1.12 
PP60 MEMA DMAAm Acrylamide-GRGDS 1.6 1.6 1.12 
PP61 MMA DEAEA Acrylamide-GRGDS 1.6 1.6 1.12 
PP62 MMA DEAEMA Acrylamide-GRGDS 1.6 1.6 1.12 
PP63 MMA AH Acrylamide-GRGDS 1.6 1.6 1.12 
PP64 MMA DMAAm Acrylamide-GRGDS 1.6 1.6 1.12 
PP65 MEMA DEAEA Acrylamide-YIGSR 1.6 1.6 1.12 
PP66 MEMA DEAEMA Acrylamide-YIGSR 1.6 1.6 1.12 
PP67 MEMA AH Acrylamide-YIGSR 1.6 1.6 1.12 
PP68 MEMA DMAAm Acrylamide-YIGSR 1.6 1.6 1.12 
PP69 MMA DEAEA Acrylamide-YIGSR 1.6 1.6 1.12 
PP70 MMA DEAEMA Acrylamide-YIGSR 1.6 1.6 1.12 
PP71 MMA AH Acrylamide-YIGSR 1.6 1.6 1.12 
PP72 MMA DMAAm Acrylamide-YIGSR 1.6 1.6 1.12 
PP73 MEMA DEAEA Acrylamide-cRGDfK 1.6 1.6 1.12 
PP74 MEMA DEAEMA Acrylamide-cRGDfK 1.6 1.6 1.12 
PP75 MEMA AH Acrylamide-cRGDfK 1.6 1.6 1.12 
PP76 MEMA DMAAm Acrylamide-cRGDfK 1.6 1.6 1.12 
PP77 MMA DEAEA Acrylamide-cRGDfK 1.6 1.6 1.12 
PP78 MMA DEAEMA Acrylamide-cRGDfK 1.6 1.6 1.12 
PP79 MMA AH Acrylamide-cRGDfK 1.6 1.6 1.12 
PP80 MMA DMAAm Acrylamide-cRGDfK 1.6 1.6 1.12 
PP81 MEMA   Acrylamide-GRGDS 12.8 0 0.16 
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PP82 MEMA   Acrylamide-YIGSR 12.8 0 0.16 
PP83 MEMA   Acrylamide-cRGDfK 12.8 0 0.16 
PP84 MMA   Acrylamide-GRGDS 12.8 0 0.16 
PP85 MMA   Acrylamide-YIGSR 12.8 0 0.16 
PP86 MMA   Acrylamide-cRGDfK 12.8 0 0.16 
PP87   DEAEA Acrylamide-GRGDS 0 12.8 0.16 
PP88   DEAEA Acrylamide-YIGSR 0 12.8 0.16 
PP89   DEAEA Acrylamide-cRGDfK 0 12.8 0.16 
PP90   DEAEMA Acrylamide-GRGDS 0 12.8 0.16 
PP91   DEAEMA Acrylamide-YIGSR 0 12.8 0.16 
PP92   DEAEMA Acrylamide-cRGDfK 0 12.8 0.16 
PP93   AH Acrylamide-GRGDS 0 12.8 0.16 
PP94   AH Acrylamide-YIGSR 0 12.8 0.16 
PP95   AH Acrylamide-cRGDfK 0 12.8 0.16 
PP96   DMAAm Acrylamide-GRGDS 0 12.8 0.16 
*For all polymers the concentration of 1-Hydroxycyclohexyl phenol ketone (initiator) and 1,6-
diol diacrylate (cross-linker) were 2.4 % (w/v) and 6 % (w/v) respectively, the remaining % 
of each polymer being NMP solvent. ‡All % are given as % (w/v).   
 




A-H Acrylic acid 
AAG-(H) 2-acrylamidoglycolic acid 
AES-H Mono-2-(acryloyloxy)ethyl succinate 
BACOEA 2-[[(butylamino)-carbonyl]oxy]ethylacrylate 
BAEMA 2-(tert-butylamino)ethyl methacrylate 
BMA Butyl methacrylate 
DAAA Diacetone acrylamide 
DEAA Diethylacrylamide 
DEAEA 2-(diethylamino)ethyl acrylate 
DEAEMA 2-(diethylamino)ethyl methacrylate 
DEGMEMA Di(ethylene glycol) methyl ether methacrylate 
DMAA(m) Dimethylacrylamide 
DMAEA 2-(dimethylamino)ethyl acrylate 
DMAEMA 2-(dimethylamino)ethyl methacrylate 
DMAPMAA N,N-dimethylaminopropyl acrylamide 
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DMVBA N,N-dimethylvinylbenzylamine 
EGMP-H Ethylene glycol methacrylate phosphate 
EMA Ethyl methacrylate 
GMA Glycidyl methacrylate 
HBMA Hydroxybutyl methacrylate 
HEA 2-hydroxyethyl acrylate 
HEMA 2-hydroxyethyl methacrylate 
HPMA Hydroxypropyl methacrylate 
MA-(H) Methacrylic acid 
MEA 2-methoxyethylacrylate 
MEMA 2-methoxymethylacrylate 
MMA Methyl methacrylate 
MNPMA 2-methyl-2-nitropropyl methacrylate 
MTEMA 2-(methylthio)ethyl methacrylate 
PAA N-isopropylacrylamide 
St Styrene 
THFFA Tetrahydrofurfuryl acrylate 























PEG Poly(ethylene glycol) 
PHNAD Poly[1,6-hexanediol/neopentyl glycol-alt-adipic acid] diol 
PHNGAD Poly[1,6-hexanediol/neopentyl glycol/diethylene glycol-alt-
adipic acid] diol 
PPG Poly)propylene glycol) 
PPG-PEG Poly)propylene glycol)- Poly(ethylene glycol) 













DHM Diethyl bis(hydroxymethyl)malonate 
DMAPD 3-dimethylamino-1,2-propanediol 
EG Ehtylene glycol 
NMPD 2-nitro-2-methyl-1,3-propanediol 
OFHD 2,2,3,3,4,4,5,5-octafluoro-1,6-hexanediol 
PG Propylene glycol 
 
